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Activating molecule in Beclin1-regulated autophagy1 (Ambra1) protein 
discovered in 2007 is an essential regulator in autophagy; it is also involved in 
the development of the nervous system, regulating normal cell survival, and, 
proliferation. Its role in autophagy has been extensively studied. However; its 
role in cell proliferation is less understood. Ambra1 has been related to 
proliferative disorders like cancer but, the underlying mechanisms by which 
Ambra1 can regulate cell proliferation in normal and pathologic conditions 
remain largely unclear. Melanoma is the most deadly type of skin cancers and, 
there is a continuous need to develop early biomarkers as well as treatments to 
improve the survivability of patients. 
This study explores the role of Ambra1 in different cellular processes including 
cell proliferation with a focus on Melanoma. The research was designed to use 
a systems based “omics” approach to investigate novel roles of Ambra1. An 
interactomic approach was carried on to identify novel Ambra1 protein binding 
partners using yeast two-hybrid assays and Ambra1 differentially expressing 
A375 melanoma cell lines were utilized for cell proliferation assays, proteomics, 
metabolomics and transcriptomics approaches to investigate the impacts of 
Ambra1 overexpression and knockdown on different cellular processes..  
Yeast two-hybrid assays performed in this study identified novel Ambra1 
binding partners. Analyses of these interactors provide evidence for new roles 
for Ambra1 in different cellular processes. Additional analysis, with data from a 
recent large scale interactome screening project suggests that Ambra is a key 
component of a larger network of proteins than previous evidence suggests. 
Results from the cell proliferation assays, proteomic, metabolomic and 
transcriptomic analyses suggest that Ambra1 overexpression in nutrient rich 
media has little additional effect on proliferation or any other pathways. 
Transcriptomic analysis of the knock-down of Ambra1 however, was shown to 
result in significant dysregulation of a significant number of transcripts. This 
appears to have identified a number of novel roles for Ambra 1 in a range of 
cellular pathways; some of these are hallmarks of cancer signaling including, 
cell cycle, angiogenesis, tissue growth factor, axon guidance and Wnt signaling. 
The work shows that the Ambra1 knockdown appears to upregulate metastatic 
genes/proteins and supports previous studies demonstrating that the loss of 
Ambra1 is associated with poor prognosis in melanoma.   
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Chapter 1- Introduction 
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Cancer is the second cause of death globally according to the world health 
organization (WHO) which estimated 9.6 million deaths in 2018 (WHO 2020). In 
UK Melanoma was the fifth most common cancer in 2016. According to cancer 
research UK (Cancer research UK 2020) around 44 people are diagnosed with 
melanoma everyday accounting for around 16,000 new patients every year and 
more than 6 deaths per day.  The melanoma rate in UK has also increased by 
around 50% over the last three decades (Figure1.1). 
 
 
Figure 1.1: Melanoma skin cancer incidence trends over time. Melanoma 
Skin Cancer, European Age-Standardized Incidence Rates, UK, 1993-2015 






Melanoma is the most deadly type of skin cancer (Karimkhani et al., 2017), 
Whilst easily diagnosed at an early stage due to neoplasm being visible through 
the production of melanin pigments, melanoma remains one of the most 
therapy-resistant and aggressive cancers despite efforts to develop different 
therapies (Tsao et al., 2012). Survival rates for 5 years after being diagnosed 
with melanoma are highly dependent on the stage of the disease. In UK survival 
rate after 5 years is 90% of newly diagnosed patients at stage one falling 





Skin is exposed to high levels of ultraviolet (UV) radiation on daily basis. The 
primary purpose of the melanogensis is to reduce the damaging effects of UV-
radiation which is known to be a major cause of DNA damage and cancer 
development (Rastogi et al., 2010) 
Melanogensis is the production of the photo-protective melanin pigment always 
by melanocytes which are dendritic cells of the neuroectoderm, located in the 
basal layer of the epidermis known as the stratum germinativum (Bonaventure 
et al., 2013) (Figure 1.2). The precursor cells of the melanocytes (melanoblasts) 
are unpigmented cells originating from embryonic neural crest cells 
(Sviderskaya et al., 2001) 
 
Figure 1.2: Scheme of the epidermis structure. Melanocyte reside between 
the basal layer cells and through dendritic processes communicates with about 
30-40 keratinocytes in the epidermal melanin unit. Melanocyte synthesizes 
melanins in melanosomes transported into keratinocytes to protect them from 




There are several steps involved in the life cycle of melanocytes and can be 
listed as: migration and proliferation of melanoblasts, differentiation into 
melanocytes, maturation of melanocytes, transport of mature melanosomes 
(which are the melanin producing organelle in the melanocytes) to keratinocytes 
and cell death (Cichorek et al., 2013). There are two major types of melanin 
pheomelanin and eumelanin. The productions of these types depend on the 
availability of substrates and the function of melanogensis enzymes (Figure 
1.3). 
 
Figure 1.3: Simplified scheme of the melanin synthesis in melanocytes 
during melanogensis. Tyrosine under influence of the basic enzymes such as 
tyrosinase (TYR), tyrosine- related protein 1 (TYRP1) and 2 (TYRP2) changes 
into a polymer of melanin, a mixture of pigments named eumelanin (black-




The melanocyte proliferation and differentiation is under the control of the 
receptor tyrosine kinase c-Kit and the basic helix-loop-helix leucine zipper 
transcription factor micropthalmia transcription factor (MITF). C-Kit activation 
leads to the activation of RAS/RAf signaling and post translational modifications 
of MITF which is responsible for activating genes involved in pigment production 
such as TYR, TRP-1 and TRP-2 and melanocyte survival such as Bcl-2 and is 
modified by mitogen-activated protein kinase (MAPK) phosphorylation (Kormos 
et al., 2011) 
After the melanosomes are produced they migrate to the keratinocytes via 
dendritic extensions using protease-activated receptor-1 (PAR2) which is a 
trans-membrane receptor where they primarily function as a defense against 
UV-radiation (Haass and Herlyn, 2005) there are many keratinocyte-to-
melanocyte signaling pathways that can be activated upon the exposure of 
keratinocytes to UV-radiation which leads to increased number of melanosomes 
exported to adjacent keratinocytes (Boissy, 2003).Keratinocytes can also 
respond to UV-radiation by increasing the amount of melanin pigment produced 
from the melanosomes. 
Melanosomes are positioned and located around the nucleus more to the sun 
exposed side where they primarily act to protect DNA against UV-radiation 
exposure by scavenging reactive oxygen species (ROS) (Felix et al., 1978). 
A benign naevus, more commonly known as a mole is formed when hyper-
proliferative atypical melanocytes are clustered together after they escape their 
normal regulation by the surrounding keratinocytes, this is often happens by a 





Evidence currently available on cells of origin of melanoma and mechanisms of 
tumor initiation is conflicting. Melanocytes and stem cells are both reported to 
be the origin of melanoma. Recently a team led by Harvard Medical School 
researchers at Boston Children’s Hospital has, for the first time, visualized the 
origins of melanoma from the first affected cell and watched its spread in a live 
animal. This team has shown that mature pigment-producing melanocytes can 
be taken back into a stem-cell like state after oncogenes activation (Kaufman et 
al., 2016). Another recent study has proved that melanocytes stem cells are not 
the origin of melanoma but mature melanocytes (Köhler et al., 2017). However; 
there are other studies that suggest that stem cells are the origin of melanoma 
(Moon et al., 2017). 
Cutaneous melanoma arises from the malignant transformation of melanocytes 
derived from either previously normal looking skin or from melanocytic naevi 





Figure 1.4: Stages of histopathologic progression in melanocyte 
transformation. (A) Normal skin. Note the even distribution of dendritic 
melanocytes throughout the basal layer. (B) Benign proliferation of 
melanocytes. Nevoid melanocytes are organized into uniform nests in a 
compound nevus. (C) Melanocyte dysplasia. Note the irregular and bridging 
nests consisting of large atypical melanocytes in a dysplastic nevus. (D) In situ 
melanoma, radial growth phase (RGP). Note the single cells in upper layer of 
the epidermis (pagetoid spread). (E) Malignant melanoma, vertical growth 





The American Joint Committee on Cancer (AJCC) clinical staging of melanoma 
is based on thickness of the lesion and evaluation of its spread to lymph nodes 
and different tissues in the body also known as The TNM (Tumor, Node, 
Metastases). It classifies melanoma into stages 0-4 where stage 0 means the 
lesion is in situ in the epidermis and is not spreading to deeper layers whereas 
an invasive lesions that have spread into other body tissues is classified as 
stage 4 (“Stages and types | Melanoma skin cancer | Cancer Research UK,”) 
(Figure1.5). A very recent study has managed to make a paradigm shift in the 
prognostication and stratification of the American Joint Committee on Cancer 
stage I melanomas by defining epidermal Ambra1/Loricrin loss as a biomarker 









Figure 1.5: Melanoma classification according to tumor size from cancer 
research UK. Tis means the melanoma cells are only in the very top layer of 
the skin surface. It is called melanoma in situ. T0 means no melanoma cells can 
be seen where the melanoma started (primary site). T1 means the melanoma is 
1 mm thick or less. It is split into T1a and T1b. T1a means the melanoma is less 
than 0.8 mm thick and the skin over the tumor does not look broken under the 
microscope (not ulcerated). T1b means either: the melanoma is less than 0.8 
mm thick but is ulcerated or the melanoma is between 0.8 mm and 1.0 mm and 
may or may not be ulcerated. T2 means the melanoma is between 1 mm and 2 
mm thick. T3 means the melanoma is between 2 mm and 4 mm thick.T4 means 





Cancer cells show alteration in the balance between cell proliferation and 
apoptosis. Cell proliferation is controlled by multiple complex signaling 
pathways. These pathways control cellular proliferation, differentiation, cell 
growth arrest and apoptosis to maintain tissue homeostasis (Heichman and 
Roberts, 1994). 
Multiple mutations in these signaling pathways lead to the development of 
cancer. Hence; the study of cell proliferation and growth and their respective 
pathway is crucial to understand uncontrolled cell proliferation in cancer.  
12 
 
1.3 Cell signaling pathways 
Eukaryotic cell division involves four sequential phases: G1, S, G2 and M 
(mitosis). The major events of the cell cycle occur in S and M phase. Where; in 
S phase chromosome duplication takes place to produce an identical copy of 
the cell DNA. While in M phase copied chromosomes are distributed into two 
daughter nuclei and cytoplasmic division takes place generating two daughter 
cells (CHAFFEY, 2003). 
The G1 and G2 phases are gap phases between the S and the M phase. They 
are as simple as a gap period between the two main cell cycle phases to allow 
enough time for the cell to grow, and monitor the internal and external 
environment to assure that conditions are suitable for the cell to divide 
(Molecular cell biology, 2008). 
In multicellular organisms differentiated cells usually exit the active cell cycle 
during G1 phase and enter G0 phase, where they remain metabolically active 
for days or years performing their specified functions (Duronio and Xiong, 
2013). 
Unlike unicellular organisms which grow and divide depending on the 
availability of nutrients. Multicellular organisms require an extracellular signal to 
promote cell cycle and cell division. These signals are termed “mitogens”, and 
there are more than 50 proteins that are identified as mitogens. Most of these 
proteins have a broad specificity (Duronio and Xiong, 2013). One of the first to 
be identified was platelet derived growth factor (PDGF) which can stimulate 
different types of cells to divide (Hannink and Donoghue, 1989). On the other 
hand; there are some mitogens that show narrow specificity like erythropoietin 
that stimulates the proliferation of red blood cells precursors (Krantz, 1991). 
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1.3.1 Cyclin dependent kinases (CDKs) 
G1 phase is of a specific importance as it is the restriction point for cell 
proliferation. Restriction point means that the cell will continue to divide after 
this point regardless of the presence or the removal of the external signals that 
promoted cell division from the start (Pardee, 1974). Cyclin-dependent kinases 
(CDKs) are Central components of the cell-cycle control. The activities of these 
kinases rise and fall as the cell progresses through the cycle, leading to cyclical 
changes in the phosphorylation of intracellular proteins that start and regulate 
the major events of the cell cycle (Morgan, 1995) CDKs levels are constant in 
the simple cell cycle. However, their activity is mainly controlled by cyclins 
which are proteins that undergo a cycle of synthesis and degradation in each 
cell cycle. This change in the cyclin protein levels result in the cyclic activation 
of CDKs, which subsequently triggers cell cycle events (Koepp et al., 1999). On 
the other hand; CDK inhibitors (CKIs) like p16, p21 and p27 act as brakes to 
deactivate the kinase activity of CDK/cyclin complexes to stop the cell cycle 
under favorable conditions (Elledge and Harper, 1994). 
CDKs have no protein kinase activity unless they are tightly bound to a cyclin. 
There are four different types of cyclins: G1 cyclins (D), G1/S cyclins (E), S-
cyclins (A) and M-cyclins (B), they are defined by the stage of the cell cycle at 
which they bind CDKs (Molecular cell biology, 2008). D cyclins start 
accumulating at mid-G1, while cyclin E appears later, just prior to the G1/S 
transition. Cyclin A is involved in S-phase and lastly Cyclin B is essential in 
mitosis (Koepp et al., 1999). 
The hallmark of cancer is uncontrolled cell proliferation. Cancer is able to 
interfere with the normal cell cycle signaling pathway by the mutation of several 
genes that are responsible for encoding proteins that activates cell cycle either 
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by over-activating proteins promoting cell proliferation or deactivating proteins 
suppressing it (Sherr, 1996). An example of these mutations is the 
overexpression of cyclin D1 which is common in many human cancers. Specific 
mutations lead to the inactivation of INK4a gene in melanoma which encodes 
p15 (INK4b), p18 (INK4c), and p19 (INK4d) proteins that inhibits CDK4 or CDK6 
(Hall and Peters, 1996). CDKN1A, CDKN2A, and CDKN2B are proposed to be 
mutated in melanoma (Soto et al., 2005) and also CDK2, CDK1, and CDK5 are 





1.3.2 Epidermal growth factor receptor (EGFR) signaling pathway 
EGFR belongs to the ErbB family of receptor tyrosine kinase (RTK). This family 
also includes ErbB-2, ErbB-3 and ErbB-4 proteins. These four proteins are 
trans-membrane receptors that possess an extracellular ligand-binding domain. 
Signals are often transmitted to other family members when an external signal 
hits one of these receptors. Receptors of this family are activated by binding to 
EGF produced from either the same cells possessing the ErbB receptors or 
surrounding cells (Yarden and Sliwkowski, 2001). Growth factors that act on 
ErbB can be classified into three groups. The first group acts specifically on the 
EGFR, it includes EGF, TGF-α and amphiregulin. The second group acts on 
both EGFR and ErbB-4, it includes heparin-binding growth factor and 
betacellulin, lastly the third group acts on either ErbB-4 only or ErbB-3 and 
ErbB-4, it includes neuregulins (Normanno et al., 2006). An indirect activation of 
these receptors can also take place by cytokines like growth hormone and 
prolactin. 
Activation of ErbB receptors induces the formation of receptor homo- or 
heterodimers, and subsequent activation of the intrinsic tyrosine kinase domain 
within these receptors leading to phosphorylation of specific tyrosine residues 
within the cytoplasmic tail of the ErbB (Olayioye et al., 2000). In turn these 
residues activate proteins containing Src homology 2 (SH2) and 
phosphotyrosine binding (PTB) domains which leads to the activation of 
intracellular signaling pathways like activating: Shc, Grb7, Grb2, Crk, Nck, the 
phospholipase Cγ (PLCγ), the intracellular kinases Src and PI3K proteins, 
RAS/RAF/MAPC pathway and the protein tyrosine phosphatases SHP1 and 
SHP2 and the Cbl E3 ubiquitin ligase (Normanno et al., 2006). All these 
activated proteins and pathways promote cell cycle. 
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ErbB receptors are over expressed in the majority of human carcinomas. EGFR 
protein overexpression occurs in different tumor types. In some cases EGFR 
overexpression is independent of EGFR gene mutations. Literature lacks 
enough data to assess the role of EGFR signaling pathway in Melanoma. 
However, few studies suggest that overexpression of this pathway is 
accompanied with worse prognosis (Dimova and Dyson, 2005) and more 
recently an inhibitor of this pathway in combination with an inhibitor of MET 
(hepatocyte growth factor receptor) decreased melanoma cells invasive abilities 




1.3.3 Transforming growth factor beta (TGF-β) signaling pathways 
TGF-β receptor plays an important role in tissue homeostasis. It is also a trans-
membrane receptor and it is a serine/threonine kinase. The function of TGF-β is 
opposite to the EGFR. When this receptor is activated it phosphorylates Smads 
proteins in the cytoplasm which subsequently migrate to the nucleus and turn 
on specific target genes. One of the most important genes that can be activated 
through this pathway is P21 which is a CDK inhibitor. This pathway signaling 
end result is arresting cell cycle and promoting cell entry to G0 (Massagué et 
al., 2000; Uttamsingh et al., 2007). 
The role of TGF-β in cancer is dual. In some types of cancer TGF-β 
components can act as tumor suppressor. Down regulations in this pathway are 
reported in different types of human cancers. However; TGF-β in other cases is 
overexpressed in Cancer cells which deactivate the tumor-suppressive arm of 
the TGF-β pathway. In the last case TGF-β act as a tumor-derived immune-
suppressor, an inducer of tumor mitogens and a promoter of carcinoma 
invasion in other types of cancer including melanoma (Massagué, 2008; Neel et 




1.3.4 WNT signaling pathway 
The WNT is a signaling pathway in metazoan animals. WNT proteins are 
analogue mitogens to EGF. They are involved in the regulation of cell 
proliferation, cell motility, cell polarity, organogenesis, cell fate and stem cells 
renewals (Logan and Nusse, 2004). 
These proteins activation induces intracellular signal pathways either by the 
canonical (WNT/β-catenin) dependent pathway or the non-canonical β-catenin 
independent pathway. The first pathway occurs when WNT proteins bind to 
Frizzled receptors which are cell surface receptors that upon activation they 
interrupt a β-catenin destruction complex. This complex includes Axin, 
adenomatosis polyposis coli (APC), protein phosphatase 2A (PP2A), glycogen 
synthase kinase 3 (GSK3) and casein kinase 1α (CK1α). The resultant elevated 
β-catenin phosphorylates the cyclin D promoter thus promoting cell cycle 
(Komiya and Habas, 2008). 
Downregulation of APC is the most frequent mutation in this pathway in cancer. 
Mutations of the Wnt pathway are observed in melanoma specifically during 
invasion (Kaur et al., 2016). Moreover, therapies targeting the activation of β-




1.3.5 RAS/RAf/MAPK pathway 
Mitogens act on the G1 phase to control the rate of cell division, by activating 
CDKs thus promoting the cell cycle to proceed to S phase. This occurs by 
interacting with cell-surface protein kinase receptors like the epidermal growth 
factor receptor (EGFR) and the platelet-derived growth factor receptor (PDGFR) 
to trigger multiple signaling pathways like small GTPase RAS which is one of 
the major signaling pathways (Duronio and Xiong, 2013). Activating this 
pathway leads to the activation of Mitogen-activated protein kinases (MAPK) 
cascade which subsequently lead to an increase in the production of gene 
regulatory proteins. Like MYC (Kelly et al., 1983). MYC promotes cell cycle 
entry by different mechanisms, one of which is over-expressing genes encoding 
D-cyclins; another is increasing cell growth genes like telomerase reverse 
transcriptase (TERT). The increase of D cyclins promotes the G1-Cdk activity 
which subsequently activates E2F proteins. 
 There is evidence that c-Myc can regulate cellular metabolism. Several lines of 
evidence suggest that oncogenic amplification of c-Myc directly alters glucose 
metabolism and also regulates specialized biosynthetic activities required for 
successful cell division. Oncogenic c-Myc promotes increased aerobic 
glycolysis through the constitutive elevation of LDH-A (Osthus et al., 2000; Shim 
et al., 1997), as well as expression of enzymes involved in nucleotide and 
amino acid metabolism (Gordan et al., 2007). 
Many of the genes that were identified as oncogenes in this pathway are mutant 
versions of the genes that encode components that control the mitogenic 
signaling pathways; For instance a mutation of a single amino acid in RAS 
causes constant stimulation of RAS-dependent signaling pathways by 
permanently over-activating RAS protein (Downward, 2003). Another example 
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is the MYC protein where cells proliferate excessively if the MYC is mutated and 
overexpressed (Beroukhim et al., 2010). 
In human cancer cells RAS is one of the most frequently mutated oncogenes. 
K-RAS which is the frequent mutant of RAS appears in 72-90% of pancreatic 
cancer (Dergham et al., 1997). K-RAS plays a key role in the alteration of this 
pathway by RAS gene amplification or activation of the pathway even when the 
oncogenic mutations are not active.  Other mutations in this pathway include the 
somatic B-RAF which is the most common mutation in malignant melanoma in 
(Davies et al., 2002; Cheng et al., 2018).  
MAPK is rarely activated in the absence of K-RAS or B-RAF and is only seen in 
less than 50% in human low-grade ovarian serous carcinomas (Hsu et al., 
2004). 
MYC is also one of the most highly amplified oncogenes in human cancer 
(Beroukhim et al., 2010; Dang, 2012) its knock-down in cancer cell lines usually 
decreases cancer cells proliferation and sometimes induces apoptosis 
(Cappellen et al., 2007). Not all of the molecular functions of MYC are clear. 
However; its main studied molecular functions indicates that MYC plays an 
important role in cell proliferation, differentiation and tumorigenesis (Conacci-




1.3.6 E2F protein sand the Retinoblastoma protein (pRb) 
E2f proteins are a group of gene regulatory factors that promotes the encoding 
of G1-S cyclins, S-cyclins which regulates the G1/S transition and promotes S-
phase entry this is by far the most studied function of the E2F proteins (Nevins, 
1998).  Other roles of these proteins include the regulation of DNA replication 
during the cell cycle. However, it is still unclear if they exert this effect directly 
on DNA or if it happens only in response to certain conditions like DNA damage, 
recently E2F role in links between cell cycle checkpoint and DNA damage repair 
has been explored (Wang et al., 2018). These proteins are also found to be 
involved in: the regulation of mitosis and apoptosis, DNA repair and finally cell 
differentiation (Dimova and Dyson, 2005). 
Retinoblastoma pathway is the primary control of the restriction point in 
mammalian cells. In the absence of mitogens Retinoblastoma protein (pRB) 
inhibits the E2F-stimulated gene expression thus inhibiting cell proliferation 
(Weinberg, 1995). Active G1-Cdk phosphorylates Rb proteins reducing their 
binding to E2F and promoting cell cycle (Hinds et al., 1992). 
Mutations of Rb pathway occurs in nearly all human cancers (Knudsen and 
Wang, 2010). Studies have shown that the E2F proteins can act as both 
oncogenes and tumor suppressor genes. Although deregulation of E2F proteins 
in cancer has been reported in many studies; there are other studies that 
illustrate that mutations in the E2F genes can result in tumor suppression 
(Massagué, 2008). Literature also suggests that it is not possible to fully 
understand the role of this pathway in cancer unless the cellular functions of this 
pathway in controlling normal cell cycle in are fully studied and understood 
(Chen et al., 2009). 
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1.3.7 The mTOR and the AMPK signaling pathway 
Mammalian target of rapamycin (mTOR) kinase is a conserved serine/threonine 
protein kinase that belongs to the phosphoinositide 3-kinase (PI3K)-related 
protein kinase (PIKK) family. It plays an essential role in regulating cell growth 
and cell cycle progression in response to cellular signals. mTOR assembles into 
two distinct structural and functional complexes: mTORC1 which is 
characterized by its RAPTOR subunit and is sensitive to rapamycin and, 
mTORC2 which is characterized by a RICTOR subunit instead of the RAPTOR 
subunit and it is rapamycin insensitive (Yang et al., 2013). While mTORC1 
regulates cell growth and metabolism, mTORC2 instead controls proliferation 
and survival (Saxton and Sabatini, 2017). 
mTORC1 activity is regulated by 4 different signals: growth factors, energy 
status, oxygen and amino acids. Growth factors include: insulin, insulin like 
growth factor 1 (IGF-1), EGF, TGF, hepatocyte growth factor (HGF), vascular 
endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF), 
growth factors mTORC1 activation is mediated by Phosphatidylinositol 3 kinase 
(PI3K)-Akt pathway. Energy status signals are transmitted to mTOR through 
AMP-activated protein kinase (AMPK), decreased energy activates AMPK 
which can either directly inhibit mTORC1 as it phosphorylates RAPTOR or 
indirectly by the phosphorylation of tuberous sclerosis complex 2 (TSC2) which 
in turn deactivates small RAS-related GTpase Rheb (Ras homolog enriched in 
brain) resulting in the reduction of mTORC1 activity. Hypoxia also triggers the 
AMPK leading to the same effect on mTORC1. Amino acids that can regulate 
mTORC1 include leucine and rag proteins. However; the understanding of this 
particular signaling effect on mTOR remains unclear (Laplante and Sabatini, 
2009; Saxton and Sabatini, 2017). 
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Stress and inflammation can also regulate the activity of the mTORC1. 
Activated mTOR phosphorylates different proteins that promote ribosome 
biogenesis, translation and lipids and nucleotides synthesis and it suppress 
autophagy (Tan et al., 2014) 
There are a large number of tumor suppressor genes and proto oncogenes 
involved in the mTOR pathway. Different types of cancers show mutations in 
this pathway specifically in the two mTOR upstream effectors: PI3K/Akt 
pathway as well as the Ras/Raf/Mek/Erk (MAPK) pathway, in fact mTOR 
pathway controls most hallmarks of cancer like cell cycle, metabolism and 
genomic instability (Tan et al., 2014; Tian et al., 2019), mTOR is hyper activated 




1.3.8 The DNA damage response 
Not only mitogens can control cell proliferation signaling pathway, but also other 
intracellular and extracellular effects. DNA damage is one of the most important 
intracellular influences to arrest cell cycle (Broustas and Lieberman, 2014). 
Activating this pathway indirectly activates the gene regulatory protein p53 by 
initiating a signaling pathway that starts by activating either ATM or ATR protein 
kinases which leads to the phosphorylation of Chk1 and Chk2 kinases and 
subsequent phosphorylation and activation of p53 which stimulates the 
encoding of CKI p21 protein and finally resulting in either cell cycle arrest for the 
damaged DNA to be repaired or apoptosis (El-Deiry et al., 1993; Xiong et al., 
1993, Hafner et al., 2019). Mutations in the genes encoding p53 or the ones 
encoding p53 activating proteins are very common in cancer (Beer et al., 2004; 






1.4 Gene mutations in melanoma 
The understanding of different pathways involved in melanoma is crucial as 
there is a continuous need for identifying new potential therapeutic targets 
especially with metastatic melanoma being resistant to almost all available 
therapies. There are far many mutations observed in Melanoma. However; 
there are few gene mutations that can be considered as driver mutations in this 







Figure 1.6: A schematic representation of driver gene mutations in 
melanoma. Identified driver mutated genes are colored in red. Arrows 
represent activation while dotted arrows represent inhibition of target genes. 
Cell Proliferation, survival and metastasis 
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Mitogen-activated protein kinase (MAPK) pathway is very complex and its 
constitutive activation leads to regulating several genes expression involved in 
cell proliferation and survival by the phosphorylation of ERK1 which results in 
phosphorylating nuclear transcription factors like ETS, ELK-1 and MYC, it also 
regulates apoptosis by regulating the post-transitional phosphorylation of 
molecules like BCL2, MCL1 (Dhillon et al., 2007). This constitutive activation is 
reported in different cancers and particularly in melanomas, where the mutation 
rates for B-RAf is 50-70% and NRAS is 15-30%, MEK is also one of the 
identified mutants in this pathway, moreover, ERK1 mutation has been 
identified recently in therapeutic-resistance reoccurring tumors (Jaiswal et al., 
2018). MAPK pathway can also activate PI3K/AKT pathway which is crucial in 
the development of melanoma. Mutations in this pathway include the tumor 
suppressor PTEN which shows inhibitory effect on this pathway and is mutated 
in 20-30% of melanomas (Kwong and Davies, 2013). The loss of PTEN activity 
in BRAF mutated melanoma results in increased tumor invasiveness and 
metastasis. Mammalian target of rapamycin (mTOR) is one of the downstream 
targets of the PI3K/AKT pathway, mTOR activation leads to increased cell 
proliferation and survival. There is evidence that the mTOR is of specific 
importance in the development of the malignancy of melanoma (Karbowniczek 
et al., 2008); in fact one study suggests that the mutation of the two major 
oncogenes in melanoma BRAF and PTEN while blocking the mTOR can 
prevent cancer cells from progressing to malignancy (Souroullas and Sharpless, 
2015). AKT can also control cellular energy and glucose metabolism by the 
phosphorylation and inhibition protein phosphatase 2A (PP2A) glycogen 
synthase kinase-3 (GSK3), phospho-diesterase-3B, and Raf-1 (Khan et al., 
2013). One of the most deleted lesions or inactivated by mutations in 
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melanomas is the locus encoding the cyclin dependent kinase 2A (CDKN2A) 
inhibitors p16INK4A which promotes cell cycle arrest at the G1-S checkpoint and 
p14ARF which is a positive regulator of the most inactivated tumor suppressor 
gene in all cancers P53 (Paluncic et al., 2016). 
Microphthalmia-associated transcription factor (MITF) is a melanocyte specific 
transcription factor amplified in 20-30% of melanomas and is able to control 
different biological processes like proliferation, differentiation as well as 
apoptosis. It is important to highlight that MITF mutation in melanoma has only 
been found in a small subset of melanomas. However, being a downstream 
target of the MAPK pathway contributes for its activation in most cases. MITF is 
also controlled by the Wnt/β-catenin pathway which role is not fully clear in 
melanoma yet but mutation in this pathway is observed more in non-melanoma 
cancers (Hartman and Czyz, 2015). However, non- canonical Wnt signaling is 
of a specific importance in melanoma as it is involved in melanoma 
invasiveness, this role is mediated by Wnt5A (Kaur et al., 2016) 
Being a target in other types of cancer; there is a growing body of research that 
considers the mTOR as a potential therapeutic target in melanoma, this is 
challenging as the gene mutations of mTOR in melanoma are distributed 





Autophagy is the process of up-taking proteins and organelles into lysosomes 
and/or vacuoles for degradation and it is evolutionary conserved in eukaryotes. 
The word autophagy is the Greek for “automated self-eating” and its role is to 
balance sources of energy and remove mis-folded and aggregated proteins, 
clear damaged cell organelles like mitochondria and finally eliminating 
intracellular pathogens (Glick et al., 2010). 
Autophagy roles are essential for a normal cell survival; it is involved in lifespan 
extension, cellular differentiation and development (Yorimitsu and Klionsky, 
2005). Under physiological conditions, autophagy maintains normal turnover of 
cellular components by signaling network that ensures quality control of cellular 
components and maintains cell homeostasis. Whereas; in pathological settings 
such as DNA damage, hypoxia and starvation autophagy act as a key pro 
survival response and its activation mediates defense against extracellular 
insults and pathogens (Behrends et al., 2010; Rubinsztein et al., 2012). 
Moreover; autophagy and cell growth are mirror images of one another. If cell 
growth is defined as the process of mass accumulation through the net uptake 
and conversion of nutrients into macromolecules, autophagy can be considered 
to act in opposition to these biosynthetic processes through the catabolic 
breakdown of biomolecules. Under normal conditions cells have the ability to 
increase their mass in the presence of permissive factors such as nutrients and 
hormonal signals. This cellular growth requires enormous energy and it takes 
place in embryos and juveniles during development as well as in adults whose 
sizes are in steady states, damaged cells are replaced by the growth of 
differentiated and stem cells. Whereas; in pathological conditions like DNA 
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damage and stress cells start a defensive mechanism to deal with the stress 
and among those mechanisms is autophagy (Neufeld, 2012). 
The current model for the role of autophagy in cancer is that in the early stages 
autophagy suppresses tumor development by limiting oxidative stress and 
genomic insatiability, whereas in advanced stages, tumors may trigger 
autophagy to survive metabolic stress (Galluzzi et al., 2015).  Cytotoxic events 
often induce autophagy; it is unclear if this is an effort for cellular preservation or 
a death mechanism (Mizushima, 2007). It is very challenging to resolve the role 
of autophagy in cancer, as in most cases cancer cells will utilize a defective 
autophagy (Aita et al., 1999; Liang et al., 1999; Mathew et al., 2007). 
Factors controlling autophagy are: the status of cellular energy, nutrients and 
amino acids, and growth factors such as insulin (Behrends et al., 2010).  
Autophagy can be classified into three types (Boya et al., 2013): macro-
autophagy, micro-autophagy, and chaperone-mediated autophagy (Figure 1.7). 
In macro-autophagy; the autophagosome is a double-lipid bilayer that engulfs 
the cytoplasmic proteins, and then fuses with the lysosome where degradation 
occurs (Behrends et al., 2010). Micro-autophagy is different as it involves the 
uptake of the cytoplasmic components directly by the lysosome through 
invagination of the lysosomal membrane (Mizushima, 2007). However, the 
common feature of both mechanisms is that they can engulf large cytoplasmic 
components. In chaperone-mediated autophagy, lysosomal-associated 
membrane protein 2A (LAMP-2A) recognises targeted proteins after the 
association of these proteins with the chaperone proteins facilitating their 





Figure 1.7: The three different types of autophagy. Macro-autophagy where 
an autophagosome is formed, Micro-autophagy where lysosomes directly engulf 
cytoplasmic components and Chaperone-mediated autophagy where a 






Macro-autophagy (which will be subsequently referred as autophagy) is a 
complex process that involves the interaction of various proteins and domains 
and there are around 32 so-called autophagy-related (ATG) genes. The process 
is very complex and can be classified into: initiation and nucleation, elongation 
and completion.  
Initiation and nucleation start with the de novo synthesis of autophagosome 
from a precursor phagophore, the source of this phagophore membrane was 
unclear until one study suggested that endoplasmic reticulum(ER) contributes 
for phagophore formation (Axe et al., 2008). Other studies reported additional 
membrane sources for phagophore formation such as plasma membrane (Nair 
et al., 2011), mitochondria (Hailey et al., 2010), Golgi complex (van der Vaart et 
al., 2010), ER–mitochondria contact sites (Hamasaki et al., 2013), ER exit sites 
(Graef et al., 2013), and recycling endosomes (Puri et al., 2013). This step 
requires the activation of class-III phosphoinositide 3-kinase (PI3K), Vps34 
which is a specific macromolecule complex for autophagy and contains beclin1, 
Atg14 and Vps15 and finally it involves Atg5, Atg12 and Atg16 proteins along 
with focal adhesion kinase (FAK) which is newly identified to be involved in 
autophagy (Hara et al., 2008). 
The second step is autophagosome elongation where the membrane expands 
and it is called a phagophore. This phagophore expands and bends to form a 
spherical autophagosome which starts to surround the target cargo. This step 
involves two ubiquitylation-like reactions where in the first one; Atg5 and Atg12 
are conjugated onto (pre-autophagosomal structures)-assembly sites (PAS) in a 
reaction that requires Atg7 [ubiquitin-activating-enzyme (E1)-like] and Atg10 
[ubiquitin-conjugating-enzyme (E2)-like] and are dissociated after phagosome 
formation, this process is positively regulated by the small GTPase Rab5 
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(Ravikumar et al., 2008) and it depends on Vps34 function and activity. While in 
the second ubiquitylation-like reaction which requires the activities of Atg7 (E1-
like) and Atg3 (E2-like) (Mizushima et al., 2004); the microtubule associated 
protein 1 light chain 3 (MAP1-LC3; also known as Atg8 and LC3) conjugates to 
the lipid phosphatidylethanolamine (PE), where the cleavage of C-terminus of 
LC3 by Atg4 forms cytosolic LC3-I , which conjugates covalently with PE to form 
membrane associated LC3-II, which is the only known protein that associates 
specifically with autophagosomes and not with other vesicular structures 
(Kabeya et al., 2000). It also can remain associated with phagosomes after 
fusion with lysosomes and finally recycled as LC3-I (Scherz-Shouval et al., 
2007).  
The completion step is that the phagophore completely surround its target cargo 
to form a double membrane autophagosome which is finally fused with the 
lysosomes clustered around the Microtubule-organization system (MTOC). The 
fusion of the autophagosomes with the lysosomes product in mammalian cells 
is referred as autolysosome. The contents of the autolysosome are degraded 
and the products are part transported to the cytoplasm. An alternative route in 
mammals is that the autophagosome may fuse to an endosome before the final 
fusion with the lysosome. In this case the fusion product of the autophagosome 










Figure 1.8: Morphology of macroautophagy. Nucleation of the phagophore 
occurs following induction by the ULK1/2 complex. Elongation of the 
phagophore is aided by the ATG12–ATG5-ATG16L1 complex, the class III 
PtdIns3K complex, LC3-II, and ATG9. Eventually, the expanding membrane 
closes around its cargo to form an autophagosome and LC3-II is cleaved from 
the outer membrane of this structure. The outer membrane of the 
autophagosome will then fuse with the lysosomal membrane to form an 
autolysosome. In some instances, the autophagosome may fuse with an 
endosome, forming an amphisome, before fusing with the lysosome. The 
contents of the autolysosome are then degraded and exported back into the 




Autophagosome formation is controlled by two distinct signals; the first is 
mammalian target of rapamycin (mTOR) dependent pathway which has a 
central role in controlling both cell growth and autophagy.  The activation of 
mTOR deactivates autophagy. For example starvation induced autophagy is 
activated due to the inhibition of mTOR in starvation conditions. mTOR can also 
be deactivated by the effect of drugs such as rapamycin (Rubinsztein et al., 
2007). Mammalian Atg13, ULK1 and ULK2 are identified as direct targets of 
mTOR, where Atg13 binds to ULK1 and ULK2 (ULK1/2) and mediates their 
interaction with FIP200. This complex is associated with mTOR under nutrient 
rich conditions, while under starvation conditions mTOR is inhibited and 
dissociated from this complex leading to partial dephosphorylation of Atg13 and 
ULK1/2, which leads to activation of autophagy by phosphorylation of FIP200 by 
ULK1/2 (Hosokawa et al., 2009). Other signaling molecules that regulate mTOR 
pathway include; insulin or insulin-like growth factor, activation of adenosine-
monophosphate-activated protein kinase (AMPK) which inhibits mTOR 
pathway. A commonly mutated gene in human cancer; p53 is reported to have 
a dual opposite effect on autophagy. Studies report that p53 can activate 
autophagy by activating AMPK or up-regulating phosphatase and tensin 
homologue (PTEN) and Tsc1. However, other studies report that the same 
effect can also be achieved by the chemical inhibition of p53 (Levine and 
Abrams, 2008). Finally, recent discoveries in the regulation of starvation 
induced autophagy revealed  many pathways that can deactivate autophagy, 
like the binding of apoptosis-related proteins B-cell lymphoma 2 (Bcl2) or basal-
cell lymphoma-extra-large (Bcl-XL) to beclin 1 (Atg6) (Ravikumar et al., 2009), 
moreover, several other beclin1 binding partners can activate beclin1 such as 
activating molecule in beclin-1-regulated autophagy (Ambra1), Rab5, ultraviolet-
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radiation resistance-associated gene (UVRAG) and beclin-1-associated 
autophagy-related key regulator (BARKOR) (Ravikumar et al., 2009). 
The second autophagy controlling signal is mTOR independent pathway which 
was discovered recently (Sarkar et al., 2005) and it up-regulates autophagy by 
the inhibition of inositol monophosphatase (IMPase), thus reduces free inositol 
and myoinositol-1,4,5-triphosphate (IP3) levels (Sarkar et al., 2005), further 
investigations in this pathway revealed that it is also controlled by intracellular 
calcium ions and cyclic AMP (cAMP) (Williams et al., 2008) , where elevated 
intracellular levels of cAMP inhibit autophagy. 
It is widely agreed that the current model of autophagy in cancer is that in the 
early stages of cancer autophagy tend to protect the cells against cancer 
invasion. Hence; cancer development requires the downregulation of 
autophagy. Conversely, the upregulation of autophagy in a developed cancer is 
favored to the tumor and can help metastasis and therapy resistance (White, 




Figure 1.9: Autophagy role in cancer (A) Healthy cells appear to be protected 
from malignant transformation by proficient autophagic responses. Conversely, 
autophagy promotes tumor progression and therapy resistance in a variety of 
models. Thus, the transition of a healthy cell toward a metastatic and therapy‐
insensitive neoplasm may involve a temporary (but not a stable) loss in 
autophagy competence. The mechanisms underlying the restoration of 
proficient autophagic responses after malignant transformation remain to be 
elucidated. (B, C) In specific settings, oncogenesis and tumor progression may 






The protective role of autophagy against cancer development is clearly related 
to the molecular processes of autophagy discussed before. The downregulation 
of autophagy through one of the autophagy related genes is common in 
different cancer developments and is reported in different studies for example, 
BCLN1 loss is associated with the development of different types of cancer (Qu 
et al., 2003) 
Ambra1 is an essential component of the autophagy machinery and this study 





Ambra1 (activating molecule in beclin1 regulated autophagy) is protein that 
regulates autophagy and development of the nervous system (Fimia et al., 
2007). Since its discovery in 2007 advances have been made to study the 
structure, cellular functions and pathological conditions involved with this 
protein. Here we review recent advances in these discoveries. 
1.6.1 Structure 
Ambra1 is a large protein of 1300 amino acids bearing three WD40 domains at 
its amino terminus, proline-and- serine rich domains and dynein binding 
domains. Its molecular mass is ∼130 kDa, it has no apparent orthologs in lower 
eukaryotes (Fimia et al., 2007). The WD40 repeats in a protein fold into a β-
propeller shape of a seven blades, they are involved in different cellular process 
in which they can act as a platform for the interaction between one protein and 
another or one protein (Xu and Min, 2011). The proline-and-serine rich domains 
are of specific importance in Ambra1 binding partners. However; not all the 
functions of these domains have been identified. 
Being an intrinsically disordered protein (IDP); Ambra1 shows high plasticity 
which makes it an excellent scaffold-molecule candidate that coordinates 
autophagy with several intracellular processes (Mei et al., 2014).  
 IDPs are those proteins that are characterized by regions of presumed intrinsic 
disorder (IDRs) (Uversky and Dunker, 2010) and can undergo a range of 
conformational changes to form different interaction surfaces that complement 
different proteins. It means that IDP is a protein of high protein-protein 
interaction capability and is involved in multiple cellular interactions which is the 
case in Ambra1 protein (Cianfanelli et al., 2015). 
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The gene that encodes Ambra1 is located on chromosome 11 in humans and 
on mouse chromosome 2 and it comprises 18–19 exons, some of which are 
predicted or have been shown to undergo alternative splicing, giving rise to at 
least six transcript variants (Cianfanelli et al., 2015). In zebrafish; Ambra1 gene 
is composed of 19 exons and encodes two paralogues Ambra1a and Ambra1b 
which are both essential and do not compensate for each other during 
development (Benato et al., 2013). The difference in the number and the length 
of exons corresponds to the Ambra1 C-terminal identity while the N-terminal 
identity of Ambra1 is highly conserved 
Ambra1 interactions sites have been identified in previous studies, with some 
interactions occur at the proline-and-serine rich domains and others at the WD 
40 domains (Figure1.10) for example: 
 Beclin1 (BCLN1) binds to Ambra Serine-rich domain (Fimia et al., 2007). 
 Dynein light chain1 (DLC1) also termed DYLL1 binds to Ambra1 at it c-
terminus (AA 1056 to AA 1094) (Di Bartolomeo et al., 2010). 
 Cullin 4 adaptor Damage Specific DNA Binding Protein 1 (DDB1) binds 
to Ambra1 at its WD40 domains resulting in Ambra1 sharp degradation 
(Antonioli et al., 2014). 
  Cullin 5 substrate Elongin B binds to the C-terminal part of Ambra1 
(Antonioli et al., 2014)) 
 Protein phosphatase 2AC (PP2CA) binds to the proline-rich region of 
Ambra1 as well as its C-terminal region (Cianfanelli et al., 2015) 
 TNF receptor-associated factor 6 (TRAF6) binds to Ambra1 at its Serine 
rich region (Nazio et al., 2013). 
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 BCL2 Apoptosis Regulator (BCL2) binds Ambra1 at its C-terminus and 
N-terminus (Strappazzon et al., 2011). 
 LC3-interacting region (LIR) near Ambra1 C-terminus binds LC3 
(Strappazzon et al., 2015). 
 TRIM32 preferentially associates with the C-terminal part of Ambra1 
(Rienzo et al., 2019). 
Ambra1 is cleaved by Caspases and Calpains; an event that is required to 
induce apoptosis, Caspases are responsible for Ambra1 cleavage at D482 site. 





























































































































































































































































































































































































































































































































1.6.2 The role of Ambra1 in Autophagy 
Ambra-1 can bind to beclin1 upon autophagic stimuli; promoting its binding to 
Vps34 to induce autophagy. Conversely, down regulation of Ambra-1 leads to a 
remarkable decrease in rapamycin and starvation-induced autophagy (Kang et 
al., 2011). 
Under normal growth conditions Ambra1 is phosphorylated at ser52 and 
inhibited by mTOR and is bound to the dynein light chains (DLC1 and DLC2) of 
the dynein motor complex together with Beclin-1 and PI3KIII. Upon autophagic 
stimuli the ULK1-mediated phosphorylation releases Ambra1 from the dynein 
complex. Ambra1 is then translocated together with Beclin-1 and PI3KIII to the 
endoplasmic reticulum where the autophagosome formation starts (Di 
Bartolomeo et al., 2010). Ambra1 regulates ULK1 activity and stability 
suggesting that it has a boarder rule in executing autophagy, it was 
demonstrated that Ambra enhances the signaling capacity of ULK1 by 
promoting its self-association by the ubiquitylation of the latter through Lys-63-
linked ubiquitin chains, this action is mediated by E3 ligase TNF receptor 
associated factor 6 (TRAF6) (Nazio et al., 2013). 
There is a growing body to look at Ambra1 role in autophagy; recent studies 
have proposed different Ambra1 interactions that can regulate autophagy. An 
example of these interactions is that between Ambra1 and cullin E3 ubiquitin 
ligases. This interaction is essential for autophagy activation (Antonioli et al., 
2014); on the other hand; there are interactions that are essential to terminate 
autophagy. An example is the ubiquitylation of Ambra1 at lys45 with Lys48-
linked ubiquitin chains by a complex compromising ring finger protein 2 (RNF2) 
(Xia et al., 2014). Another example is the ubiquitylation and degradation of 
Ambra1 by the cullin-4–DDB1 complex (Antonioli et al., 2014) 
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Ambra1 plays an important role in a selective form of autophagy termed 
mitophagy in which the defective mitochondria are selectively degraded by 
autophagy (Ding and Yin, 2012). Early discovery showed one mechanism by 
which Ambra1 regulates mitophagy through the interaction between Ambra1 
and PARKIN (PARKIN mediated mitophagy) (Van Humbeeck et al., 2011). 
However, a recent study has identified another mechanism in which Ambra1 
regulates mitophagy by binding the autophagosome adapter LC3 through a LIR 
(LC3 interacting region) motif (Strappazzon et al., 2015). The later study proved 
that Ambra1 can regulate mitophagy by the later mechanism independent of the 
PARKIN mediated mitophagy indicating that Ambra1 is essential for regulating 




1.6.3 The role of Ambra1 in apoptosis 
Apoptosis is programmed cell death that takes place in normal cell turnover, 
proper development and embryonic development (Elmore, 2007). 
Recent studies suggest that Ambra1 shows an inhibitory effect on the apoptosis 
process and favors autophagic cell survival, Ambra1 must be cleaved during 
apoptosis to prevent pro-survival autophagy (Pagliarini et al., 2012),  therefore it 
can control the conversion between both processes to determine the resulting 
cell survival or death (Fimia et al., 2013; Gu et al., 2014). High number of 




1.6.4 The role of Ambra1 in Development 
Ambra1 appears to have a crucial role in embryogenesis, specifically in the 
development of nervous system. It is highly expressed in the central nervous 
system particularly in the neuroepithelium, spinal cord, dorsal root ganglia, 
neural retina and encephalic vesicles (Fimia et al., 2007; Vázquez et al., 2012). 
Ambra-1 functional deficiency in mouse embryos leads to severe neural tube 
defects associated with autophagy impairment, accumulation of ubiquitinated 
proteins, unbalanced cell proliferation, and excessive apoptotic cell death (Kang 
et al., 2011). In the context of development Ambra1 deficiency leads to 
abnormal skeletal muscle morphology in mice and zebrafish (Skobo et al., 
2014). Most recently Ambra1 has been reported to Control regulatory T-Cell 
differentiation and homeostasis upstream of the FOXO3-FOXP3 axis and its 




1.6.5The role of Ambra1 in cell proliferation 
Ambra1 loss is associated with hyper-proliferative, non-developed cells (Benato 
et al., 2013) it is also associated with higher mRNA levels of cyclins A and B 
(Cianfanelli et al., 2015) the latter study has shown a mechanism by which 
Ambra1 can contribute to the control of cell proliferation which is the facilitation 
of the proto-oncogene c-Myc. degradation by binding to the catalytic subunit of 
the serine/threonine-protein phosphatase 2A (PP2A) resulting in the 
dephosphorylation of c-Myc. (Cianfanelli et al., 2015) the role of Myc. In cell 
proliferation is discussed in section 1.2.5. However; literature lacks any other 
data about the mechanism by which Ambra1 can control cell proliferation 
despite the fact that literature is full of evidence that this particular gene is of a 
great importance in cell proliferation and in cancer.  
To study the role of Ambra1 in cell proliferation it is important to consider the 
mTOR signaling pathway in the context of cell proliferation (1.2.7) mTOR is 
responsible for the phosphorylation of Ambra1 at Ser52 to maintain the latter 




1.6.6 Ambra1 in cancer and other pathologies 
Ambra1 is associated with different pathological conditions like Schizophrenia 
(Rietschel et al., 2011), autism (Dere et al., 2014) and neurodegenerative CNS 
disorders like Alzheimer’s disease (Sepe et al., 2014) and most importantly in 
cancer. The role of Ambra1 in cancer is dynamic and seems to be very 
important during different cancer stages. For instance; in support of Ambra1 
pro-survival role, a very recent study has managed to make a paradigm shift in 
the prognostication and stratification of the American Joint Committee on 
Cancer stage I melanomas by defining epidermal Ambra1/Loricrin loss as a 
biomarker for higher risk melanomas (Ellis et al., 2019).  Furthermore; studies 
have shown the protective role of Ambra1 against cancer cells. Ambra1 
deficient mice show more spontaneous tumorigenesis compared to controls 
and, it is mutated in endometrial, colorectal and urinary tract neoplasms 
(Cianfanelli et al., 2015). The role of Ambra1 in late stage cancer especially 
after metastasis is still under exploring and only few studies reported the role of 
Ambra1 in developed cancers, its role seems to be more of a protective role 
that helps cancer cells survive and even resist therapeutic agents.  A recent 
study has shown that in late stage breast cancer, the higher Ambra1 levels; the 
higher the resistance to epirubicin treatment (Sun et al., 2018).  Another study 
reported Ambra1 to desensitize human prostate cancer cells to cisplatin. This 
role is mediated by the ability of Ambra1 to activate autophagy and cell survival 
(Liu et al., 2019). Finally a study has related the role of Ambra in the cross talk 
between autophagy and apoptosis to its role in cancer cell survival as it 
contributes to shifting the cells towards autophagy rather than apoptosis, this 




1.7 Aims of the study 
It is clear that the unusual nature of intrinsic disordered proteins suggest that 
Ambra1 may play a dynamic role in a whole range of cellular processes. Ambra 
1 is increasingly identified as having a role in an increasing range of 
pathologies. It’s deficiency in early stage melanoma appears to be a strong 
candidate as a biomarker in for example. Understanding the mechanism by 
which this protein acts on the cell may provide leads for identifying potential 
therapeutic targets against proliferative disorders. This study will focus on 
identifying novel functions of Ambra1 using a range of “omics” technologies. 
The specific aims are: 
 To determine if Ambra1 plays a role in regulating cellular proliferation. 
 Identify novel binding partners of Ambra-1 using a Yeast two-Hybrid 
approach. 
 Use a range of “omics” techniques to identify novel roles in cellular 

























2.1.1 Chemicals, reagents and kits 
 
Table 2.1: chemicals, reagents and kits used in the research 
Chemicals, reagents and kits supplier 
Match maker yeast two hybrid system Takara (Clontech) Bio Europe SAS 
(France) 
Easy yeast isolation kit Takara (Clontech) Bio Europe SAS 
(France) 
Universal human normalized mate and 
plate library in Y187 strain 
Takara (Clontech) Bio Europe SAS 
(France) 
T4 DNA ligase Thermo-Fisher (Cramlington, UK) 
Instant sticky-end ligase master mix New England Bio-labs  (Hitchin, UK) 
Electro-ligase New England Bio-labs  (Hitchin, UK) 
In fusion cloning kit Takara (Clontech) Bio Europe SAS 
(France 
Zero blunt topo PCR cloning kit Thermo-Fisher (Cramlington, UK) 
Perfectly blunt cloning kits Novagen 
Superscript III first-strand synthesis 
system fo RT-PCR 
Thermo-Fisher (Cramlington, UK) 
High-capacity cDNA reverse transcription 
kits for 200 reactions (Applied biosystems) 
Thermo-Fisher (Cramlington, UK) 
Gel Extraction Kit (50) Qiagen technologies (Manchester, 
UK) 
plasmid plus midi kit Qiagen technologies (Manchester, 
UK) 
Chemical Competent E-coli DH5-α strain Thermo-Fisher (Cramlington, UK) 
One Shot TOP10  chemically-competent 
Cells 
Thermo-Fisher (Cramlington, UK) 
One Shot TOP10  Electro-competent 
Cells 
Thermo-Fisher (Cramlington, UK) 
MAX Efficiency stbl2 competent cells Thermo-Fisher (Cramlington, UK) 
Stellar chemically competent cells Takara (Clontech) Bio Europe SAS 
(France) 
Immomix master mix Bioline (Nottingham, UK) 
Iproof TM High-fidelity PCR kit Bio-Rad (Perth, UK) 
Q5 DNA polymerase Bioline 
Ampicillin Labtech (Heathfield, UK) 
Kanamycin sulfate Labtech (Heathfield, UK) 
Bio-sera  High or low Dulbecco's Modified 
Eagle Medium (DMEM) 
Thermo-Fisher (Cramlington, UK) 
10% Foetal Bovine serum Gibco/ Thermo-Fisher (Cramlington, 
UK) 
primocin Invivogen UK 
L-glutamine Lab-tech (Heathfield, UK) 
TRIzol reagent (Ambion) Thermo-Fisher (Cramlington,UK) 
RNAse Away (Ambion) Thermo-Fisher (Cramlington,UK) 
RNAsecure (Ambion) Thermo-Fisher (Cramlington,UK) 
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10X Tris Glycine SDS (TGS) buffer Sigma-Aldrich (Poole, UK) 
4X Laemmli Sample Buffer Bio-Rad (Perth,UK) 
2-Mercaptoethanol Bio-Rad (Perth,UK) 
Precision Plus Protein™ All Blue 
Standards 
Bio-Rad (Perth,UK) 
Precision Plus Protein™ unstained 
standards 
Bio-Rad (Perth,UK) 
Mini-PROTAEN® TGX Stain-Free™ gels Bio-Rad (Perth,UK) 
Trans-Blot® Turbo™ PVDF Transfer Pack Bio-Rad (Perth,UK) 
Trans-Blot® Turbo™ LF PVDF Transfer 
pack 
Bio-Rad (Perth,UK) 
Clarity™ Western ECL Blotting Substrate Bio-Rad (Perth,UK) 
GelRed™ Nucleic Acid Stain Thermo-Fisher (Cramlington,UK) 
HyperLadder IKB™ Thermo-Fisher (Cramlington,UK) 
Bradford Reagent Expedion 
BSA protein standard Bio-Rad (Perth,UK) 
3-10 IEF 11cm strips Bio-Rad (Perth,UK) 
3-10 IEF 17cm strips Bio-Rad (Perth,UK) 
5-8 11 cm strips Bio-Rad (Perth,UK) 
5-8 IEF 17cm strips Bio-Rad (Perth,UK) 
Ready prep 2D-clean up kit Bio-Rad (Perth,UK) 
Ready prep 2D starter kit Bio-Rad (Perth,UK) 
Ready prep 2D starter kit 
rehydration/sample buffer 
Bio-Rad (Perth,UK) 
Criterion TGX Stain-Free™ gels Bio-Rad (Perth,UK) 
Trichloroacetic acid Sigma-Aldrich (Poole, UK) 
DDT Thermo-Fisher (Cramlington,UK) 
Iodocetamide Sigma-Aldrich (Poole, UK) 
100% Glycerol Bio-Rad (Perth,UK) 
20% SDS solution Bio-Rad (Perth,UK) 
1.5M Tris Hcl Ph 8.0 Bio-Rad (Perth,UK) 
8M Urea Sigma-Aldrich (Poole, UK) 
Tween 20 Bio-Rad (Perth,UK) 
10X cell lysis buffer Abcam (Cambridge, UK) 
Absolute ethanol Sigma-Aldrich (Poole, UK) 
HPLC-grade methanol Sigma-Aldrich (Poole, UK) 
Isopropanol (2-propanol) Sigma-Aldrich (Poole, UK) 
Glacial acetic acid Sigma-Aldrich (Poole, UK) 
Sodium thiosulphate Sigma-Aldrich (Poole, UK) 
Hydrochloric acid Sigma-Aldrich (Poole, UK) 
Anhydrous sodium acetate Sigma-Aldrich (Poole, UK) 
Silver nitrate Sigma-Aldrich (Poole, UK) 
Anhydrous sodium carbonate Sigma-Aldrich (Poole, UK) 
Formaldehyde Sigma-Aldrich (Poole, UK) 
EDTA-Na2 Sigma-Aldrich (Poole, UK) 
Acetone Sigma-Aldrich (Poole, UK) 
Coomassie brilliant blue G250 Sigma-Aldrich (Poole, UK) 
Ortho-phosphoric acid Sigma-Aldrich (Poole, UK) 
Ammonium sulfate Sigma-Aldrich (Poole, UK) 
SRB stain Sigma-Aldrich (Poole, UK) 
Methoxyhydrochloride Sigma-Aldrich (Poole, UK) 
Pyridine Sigma-Aldrich (Poole, UK) 
MSTFA Sigma-Aldrich (Poole, UK) 
BSTFA Sigma-Aldrich (Poole, UK) 
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2.1.2 Match maker yeast two hybrid system from Clontech Co.  
 0.5 ml solutions of Y2H gold and Y187 yeast strains. 
 pGBKT7 DNA-BD cloning vector. 
 PGADT7 AD cloning vector. 
 pGBKT7-53 Control Vector. 
 pGADT7-T Control Vector. 
 pGBT9 (positive control plasmid). 
 pGBKT7-Lam Control Vector. 
 Cultural media pouches of: YPDA, SD-Trp, SD-Leu, SD-Trp-Leu, SD-
Trp-Leu-His  and SD-Trp-Leu-His-Ade. 
 YPD plus Liquid Medium. 
 50% Polyethylene glycol (PEG) 
 1 M LiAc (10X). 
 10X TE Buffer. 
 X-α-gal. 
 Aeurobasidin A. 
2.1.3 Restriction enzymes 
All restriction enzymes were from Thermo-fisher (Cramlington,UK): 
 BamH I 
 EcoR I 





All primers (table 2.2) were purchased from Integrated DNA Technologies, re-
suspended in sterile TE buffer to give a final concentration of 100 nM solutions 
and were then diluted 100× in TE to make a 100µM stock. 
Table 2.2: Primers used and their sequences 
Primer name sequence 
Ambra1 Fcon 5’- TGC CAC AAT CTC CTG ACC TT -3’ 
Ambra1 Rcon 5’- TCG CTG TGT CTG GTT AAA TT -3’ 
Ambra1 Ffull (full) 5’- CCC CAT ATG AG GTT GTC CCA GAA AAG AAT 
GC -3’ 
Ambra1 Rfull (full) 5’- CCG AAT TCC TAC CTG TTC CGT GGT TCT CCC 
CT -3’ 
AMBRA FullF2 (new) 5’-CCC CAT ATG AAG GTT GTC CCA GAA AAG A -3’ 
AMBRA FullR2 (new) 5’- CCG AAT TCC TAC CTG TTC CGT GGT TCT CC -3’ 
AMBRA LongR (long) 5’- CCG AAT TCC TAC CTG TTC CGT GGT TCT CCC 
C -3’ 
AMBRA LongFnde (long) 5’- CCC CAT ATG AAG GTT GTC CCA GAA AAG AAT 
GCT -3’ 
AMBRA LongFeco (long) 5’ CCC GAA TTC ATG AAG GTT GTC CCA AAG AAT 
GCT -3’ 
AMBRA FusionF 5’- AGG AGG ACC TGC ATA TGA AGG TTG TCC CAG 
AAA AGA ATG CC -3’ 
AMBRA FusionR 5’ GCC TCC ATG GCC ATA CTA CCT GTT CCG TGG 
TTC TCC C-3’ 
PP2CA F 5’- CGC CAT ATG GAC GAG AAG GTG TTC ACC -3’ 
PP2CA R 5’- CGC GAA TTC TTA CAG GAA GTA GTC TGG GGT 
ACG-3’ 
PP2CA F_Eco 5’- CGC GAA TTC ATG GAC GAG AAG GTG TTC ACC 
-3’ 






2.1.5 Cell lines 
Four stably transfected A375 melanoma cell lines were utilized in this study and 
are detailed in section 3.0  
2.1.6 Antibodies 
 
Table 2.3: Western blots antibodies and dilutions 
Primary antibody Supplier Dilution 
Mouse antihuman GAPDH4 Abcam (Cambridge, UK) 1:10,000 
Rabbit anti human Ambra1 
antibody 
SDIX (Oxfordshire, UK) 1:10,000 
Chicken anti-beta-
Galactosidase 
Sigma-aldrich (Poole, UK) 1:5,000 
Mouse monoclonal to VEGF 
receptor 1 (ab9540) 
Abcam (Cambridge, UK) 1:500 
Rabbit monoclonal to Wnt5a-
C-terminal 
Abcam(Cambridge, UK) 1:2,000 
Secondary antibody   
Goat anti rabbit IgG Vector Labs (Peterborough, 
UK) 
1:10,000 
Goat anti mouse IgG Vector Labs (Peterborough, 
UK) 
1:10,000 
Goat anti-chicken IGY 
(ab97135) 
Abcam (Cambridge, UK) 1:10,000 
Goat anti mouse IgG alexa 




Goat anti mouse IgG star 
bright blue 250 







Table 2.4: homemade buffers and their constituents 
Buffer constituents 
TAE (40mM Tris, 20mM acetic acid, 1mM EDTA pH 8.0) 
Tris-buffered saline (TBS) (150mM NaCl, 50mM Tris, pH 7.6) 
TBS-tween (TBST) (TBS, pH 7.6 with 0.05% Tween 20) 
2d equilibration buffer 1 8M Urea, 20%SDS, 14.5M Tris Hcl, Glycerol, 
milliQH2O, DDT 
2d equilibration buffer 2 8M Urea, 20%SDS, 14.5M Tris Hcl, Glycerol, 
milliQH2O, Iodocetamide 
Fixation solution for 2D gels Ethanol (40%  VV-1), glacial acetic acid (10% VV-1) 
and milliQH2O 
Colloidal coomassie staining 
solution 
Coomassie Brilliant Blue G250 (0.1% WV-1), ortho-
phosphoric acid (2% WV-1),  
ammonium sulfate (10% WV-1) and methanol 
Sensitizing solution for silver 
staining of 2D gels 
Ethanol (30% VV-1), sodium thiosulphate (0.01M), 
sodium acetate (0.8M) and milliQH2O 
Silver reaction solution for 2D 
gels 
Silver nitrate (0.015M), milliQH2O 
Developing solution for silver 
staining of 2D gels 
Sodium carbonate (0.25M), Formaldehyde (0.075% 
VV-1) and milliQH2O 
Stopping solution for silver 
staining of 2d gels 






2.2.1 Tissue culture  
Cells were cultured and routinely passaged to be maintained in the exponential 
phase in either high or low Dulbecco's Modified Eagle Medium (DMEM) (Bio-
sera). The media was supplemented with 10% Foetal Bovine serum (Gibco), 
100 µg/ml primocin (Invivogen) and 300 µg/ml L-glutamine (Lab-tech). Cells 
were grown at 37°C in a 5% CO2 humidified atmosphere.  
Transfection maintenance was performed by adding antibiotics to the media. 
The overexpression strains were maintained using G418 at a concentration of 2 
µg ml-1 and the knock-down cell lines were maintained using puromycin at a 
concentration of 2 µg ml-1. Antibiotics were omitted 24 to 72 hours before 




2.2.2 Protein extraction and quantification 
Cell were seeded at a concentration of 5x105 to a 6-well plate and grown at 
37°C, and maintained in the exponential phase. Cells were then washed twice 
with PBS and harvested with 200 µl 1x cell lysis buffer and sonicated for 3x10 
seconds to disrupt cell wall. Lysates were stored at -80°C and used for 
downstream analysis.  
Protein quantification was performed using BSA as a standard and Bradford 
reagent according to the manufacturer’s instructions in a 96-well plate and 




2.2.3 SRB Cell proliferation assays 
Cell proliferation assays were performed using Sulforhodamide B (SRB) to 
monitor the growth of the different cell lines over time. Cells were seeded in a 
concentration of 1500 cell per well at a volume of 200 µl. cells were fixed by 
incubating at 4°C for 1 hour with 50% trichloroacetic acid (TCA) at 24, 48 and 
72 hours intervals. The cells were then stained with 100 µl 0.4% SRB stained 
prepared in 1% acetic acid and incubated for 30 minutes. The plates were 
washed with 1% acetic acid 5 times and incubated at 60°C to dry for 2 hours. 
The stain was solubilized using 100 µl 10mM tris (PH 10.5) and absorbance 
was read at 570nm.  
To plot the data the absorbance reading from a single well was converted to an 
arbitrary value of 100% growth within each cell line from one of the absorbance 
readings at 24 hours. Within each cell line (for example rBgal) the other 
absorbance values were converted to an arbitrary % in order to calculate the 
mean and standard deviation for the growth at each time point. Setting the 
baseline value within each cell line enabled comparisons to be made 
irrespective of the absolute starting number of cells in each well. Statistical 






2.2.4 Western blot analysis 
Proteins were denatured with SDS buffer at 95°C for 5 minutes, and 25µg of 
this lysates were resolved by 12% polyacrylamide gel (Bio-Rad) electrophoresis 
and transferred to polyvinylidene difluoride (PVDF) or low florescence 
polyvinylidene difluoride (LF PVDF) membranes (Bio-Rad). PVDF membranes 
were blocked in Immobilon® Block-Chemiluminescent Blocker (CB) (Merck) for 
1 hour at room temperature, while LF PVDF membranes were blocked by 
incubating over-night at 4°C with TBS containing 5% milk. Membranes were 
then incubated with primary antibodies overnight at 4°C with shaking, washed 
3x10 minutes with TBST and incubated with secondary antibodies for 1 hour at 
room temperature (see table 2.3 for concentrations) followed by another 3x10 
minutes wash, PVDF membranes were then incubated with 2 ml freshly 
prepared (1:1) mixture of peroxide reagent and luminol/enhancer reagent 
supplied from Bio-Rad for chemiluminescent detection of HRP activity of the 
conjugated secondary antibody. However; this step was omitted for LF PVDF 
membranes. The membranes were then analyzed by the ChemiDoc™ Imaging 





Yeast strains were maintained by streaking at least once every 4 weeks on 
fresh YPDA plates, incubated at 30°C for 3 to 5 days then stored at 4°C. Only 
fresh grown colonies were used for transformations. Plates were prepared by 
adding each media pouch content to 500 ml deionized water then autoclaving, 
left to cool to 50°C then X-α-gal and/or antibiotics were added before pouring 
the plates. 
Yeast transformation, positive and negative control experiments were 
performed as stated by Yeast-Two Hybrid System manufacturer (Clontech 
Laboratories).  
All yeast transformations performed are shown in table 2.5. 
Table 2.5: transformed plasmids in different yeast strains 
Y2H gold Y187 strain 












2.2.6 Y2H Control experiments 
Yeast transformation, positive and negative control experiments were 
performed as stated by Yeast-Two Hybrid System manufacturer (Clontech 
Laboratories) a positive control mating was performed by mating Y2H gold 
strain fused with murine p53 and  Y187 yeast strain fused with SV40 large T-
antigen. On the other hand a negative control experiment was performed by 
mating Y2h gold yeast stain fused with lamin and Y187 yeast strain fused with 




2.2.7 cDNA synthesis and PCR amplification: 
Different cDNAs were prepared using oligo and random primers by PCR using 
RNA extracted from U-937 (ATCC® CRL-1593.2™) and A-375 (ATCC® CRL-
1619™) cell lines. An ORF clone with Ambra1 sequence was purchased to be 
used as a PCR template. 
PCR reactions were performed on Bio-Rad T100 thermal cycle. PCR reactions 
were performed using 10 x Immomix master mixes (Bio-Rad), Q5 polymerase 
(Bio-labs), and proof-reading polymerase was later used (Iproof Bio-Rad). 





Table 2.6: PCR protocols 
(A) PCR protocol for the amplification of Ambra1 and PP2CA full lengths 
ORFs a using Immomix and Q5 polymerase 
Temperature 95°C 95°C 64°C 72°C Repeat 72°C 12°C 
Duration 
(minutes) 
3:00  0:30  0:30  1:30 45x 5:00  ∞ 
 
(B) PCR protocol for the amplification of Ambra1 full length using Iproof 
polymerase 
Temperature 98°C 98°C 66.6°C 72°C Repeat 72°C 12°C 
Duration 
(minutes) 
3:00 0:30 0:30 1:30 45x 5:00 ∞ 
 
(C) PCR protocol for the amplification of PP2CA full length using Iproof 
polymerase 
Temperature 95°C 95°C 63°C 72°C Repeat 72°C 12°C 
Duration 
(minutes) 
3:00  0:30  0:30  1:00 45x 5:00  ∞ 
 
Colony PCR was performed by re-suspending a single colony into 100µl sterile 
water and using 1µl as a DNA template for the PCR amplification, all other PCR 
reaction reagents and specifications remains as above. 
All of the PCR products were made ready for gel electrophoresis by adding an 
appropriate amount of 4x loading dye to each reaction mixture, then tested on 
1% Agarose in TAE buffer using gel red as indicator and Hyperladder 1Kb as a 
reference, electrophoresis were made on Bio-rad power Pac basic at 100 volts 
and ran for 45 minutes to 1 hour. 
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2.2.8 Gel excision and DNA extraction 
DNA fragments were extracted from gels using QIAquick® Gel Extraction Kit 
(Qiagen technologies). The DNA fragment was excised from the agarose gel 
with a sterile scalpel, gel slices were weighed in colorless tubes, the protocol 
was performed according to the manufacturer’s instructions  DNA was eluted in 
50µL Buffer EB (10 mM Tris·Cl, pH 8.5). DNA concentrations were quantified on 




2.2.9 DNA digestion, Ligation, Plasmid extraction from E. coli and 
transformation into yeast cells 
Plasmids were transformed to competent E. coli (DH5-α strain) by adding 50 µl 
of E. coli to 100 ng of DNA and left on ice for 30 minutes, the mixture was heat 
shocked at 42°C for 20 seconds, then  transferred back to ice for 5 minutes. 950 
µl of nutrient broth were added and the mixture was shaken at 37° C for 1 hour 
and 200 µls of each sample were plated on Agar plates contained Ampicillin 
(100µgml-1) for the ampicillin resistant vectors and on Agar plates contained 
kanamycin (50µgml-1) for kanamycin resistant vectors. Plasmids were 
transformed into the yeast strains according to the manufacture specifications 
(Clontech). 
E. coli containing plasmids were regrown to facilitate the isolation of the 
plasmids by adding one colony of the grown bacteria of each plasmid to 250 ml 
growth media (15 gm. Tryptophan, 5 g. Yeast, 5 g. NaCl and made up to 1 L 
with water) and 250 µl of antibiotic (either ampicillin or kanamycin) and 
incubated for 5 hours at 37 ̊C then shacked overnight. 
Plasmids were extracted from E. coli using plasmid plus midi kit (QIAGEN 
technologies) according to manufacturer’s instructions. DNA was eluted by 
adding 200 µl of EB buffer and centrifuged for 1 minute. DNA concentration of 
each plasmid was measured on Nano drop light spectrophotometer (Thermo 
Scientific). 
All of the PCR products and plasmids were digested for gel electrophoresis by 
adding 200 ng  DNA to 1 µl of the restriction enzymes, 2 µl 10x fast digest 
buffer and making it up with water to 20 µl. A gel of 0.7% w/v of agarose in TAE 
buffer was prepared and 10 µl of gel green indicator were added. Finally 4 µl of 
6x loading solution were added to each 20 µl digest, mixed and 20 µl of the 
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mixture were loaded on the agarose gel with 5 µl of Hyperladder IKB (Bioline) 
indicator as a reference. 
All ligation reactions were made at a vector to insert ratio of 1:5, the appropriate 





2.2.10 2d Gel electrophoresis 
Total protein was precipitated by either using 2d clean-up kit (Bio-Rad, UK) or 
by adding a 1:1 volume of 100% acetic acid to the protein lysate solution and 
incubated at 4°C for 10 minutes. Proteins were pelleted by centrifugation at 
15000 RPM for 10 minutes, washed twice with ice-cold acetone and the pellets 
were re-suspended in a freshly reconstituted rehydration buffer (Bio-Rad). The 
amount and the final volume of protein used to rehydrate the IEF strips are 
shown in table 2.7. 
Table 2.7: protein concentration and rehydration buffer volume used for 
each IEF strip. 





11cm (3-10 or 5-8) 200 µl 200 µg Coomassie G-250 
11cm (3-10 or 5-8) 200 µl 50 µg Silver stain 
17cm (3-10 or 5-8) 300 µl 300 µg Coomassie G-250 
17cm (3-10 or 5-8) 300 µl 50 µg Silver stain 
 
Strips were covered by mineral oil and left overnight for rehydration. Rehydrated 
strips were then transferred to an IEF focusing tray and loaded to IEF cell. 
Different protocols used are in table 2.8. 
Table 2.8: protocols used for focusing IPG strips 
IEF strip PH 3-
10 or 5-8 
Desalting step 
(2,000 volts for 2 





























After focusing strips were equilibrated for 15 minutes with 5mls equilibration 
buffer1 containing DDT (2% W/V) followed by 5mls equilibration buffer 2 
containing iodocetamide (2.5% W/V). Strips were then loaded onto TGX stain 
free gels (Bio-Rad) and ran on Bio-Rad power Pac at 200V for 1 hour. Gels 
were imaged on a ChemiDoc™ Imaging System (Bio-Rad, UK). Gels were fixed 
by incubation with fixation solution on an orbital shaker for 30 minutes followed 
by overnight incubation with shaking at 4°C. gels were washed with milliQH2O 
for 2x10 minutes. 
All staining steps were performed on an orbital shaker at room temperature. 
2.2.10.1 Colloidal Coomassie G-250 stain 
Gels were stained overnight with a freshly prepared mixture of colloidal 
Coomassie dye stock solution and methanol (80:20% V/V). Gels were finally de-
stained with milliQH2O until background became clear. 
2.2.10.2 Silver stain 
Gels were treated with sensitizing solution for 30 minutes followed by 3x5 
minutes washes with milliQH2O. Gels were then reacted with silver nitrate 
solution and washed 2x 1 minute. For the developing step gels were incubated 
with the developing solution and visually monitored for 2-10 minutes until clear 
brownish protein bands were observed. The reaction was then stopped by 
incubating the gels with EDTA for 10 minutes. Finally the gels were washed 3x5 





Cell were seeded at a concentration of 5x105 to a 6-well plate and grown at 
37°C, and maintained in the exponential phase. Cells were then washed once 
with PBS and harvested with 1 ml HPLC grade methanol, several freeze/thaw 
cycles were applied to the extracts and these extracts were dried on 
LABCONCO CentriVap. Samples were then reacted with 100 µl of methoxy 
hydrochloride in pyridine (20 mg ml-1) and incubated for 2 hours at room 
temperature followed by an overnight reaction with 200 µl of either-N-Methyl-N-
(trimethylsilyl) trifluoroacetamide (MSTFA) or N,O-
bis(trimethylsilyl)trifluoroacetamide (BSTFA) for derivatization. Samples were 




2.2.12 RNA extraction and quality analysis 
Total RNA was extracted from each cell line using Trizol reagent (Thermo-
Fisher, catalogue number 15596026) according to the manufacturer’s 
instructions and the precipitated RNA was re-suspended in 200 µl 1xRNA 
secure reagent (Ambion). 
RNA quality analysis was performed using Experion™ RNA StdSens and 
HighSens Analysis Kits from Bio-Rad following instructions from the 
manufacturer. 
2.2.13 Gene expression analysis by microarray 
The analysis was performed by Source bio-Science. Three biological replicates 
from each cell line at a concentration of 120 Ƞg µl-1 were hybridized on 
GeneChip™ Human Gene 2.0 ST. 
2.2.14 Differential expression data analysis 
The microarray data was normalized and analyzed using Transcriptome 
analysis suite (TAC version 4.0.1) (Thermo-fisher) (Figure 2.1). Ebayes Anova 
method was used and the analysis was set to gene-Level Fold Change < -2 or > 





















































































































2.2.15 Microarray data functional analysis 
Functional analysis of the differentially expressed genes was performed using 
STRING protein-protein interaction tool, KEGG pathways tool and GO biological 
process tool. Fisher’s exact tests were performed and only results of FDR P < 
0.05 were considered. 
A general legend that applies to all string analysis in this research is shown in 
figure 2.2. 
 


















3.1 A375 melanoma cell lines 
Four stably transfected A375 melanoma cell lines were provided by Dr 
Corazzari (University of Piemonte Orientale, Novara) and Prof Lovat (University 
of Newcastle, UK) to be utilized for this study. Overexpression of Ambra1 and 
its matching control, β-galactosidase was performed by retroviral infection 
(Pagliarini et al., 2012). While knockdown of Ambra1 was performed by lentiviral 
infection that expresses a shRNA construct targeted to AMBRA1 and the 
control cell line expressed a scrambled shRNA control (Armstrong et al., 2015). 
Cell lines names used in this study are shown in Table 3.1. 
Table 3.1: modified A375 melanoma cells used and the method of 
modification 










Ambra1 knockdown ShAmb lentivirus infection 
Ambra1 knockdown 
matched control 
ShCon lentivirus infection 
 
3.2 Cell lines growth curves 
Initialy Sulforhodamine B (SRB) assays were performed to study the effect of 
Ambra1 overexpression and knockdown on the proliferation rates of the four cell 
lines; in an attempt to answer one of the main initial hypothesis question “Does 
Ambra1 have a role in cancer cell proliferation?”. SRB assays was the only 
reliable and, inexpenive approach available at the start of the project. Towards 
the end of the project the faculty aquirred a live cell imager, the Incucyte 
(Sartorius), which allows the acquisition of true proliferation rates by live cell 
counting rather than using an indirect measurement. 
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3.2.1 SRB analysis of rAmbra versus rBgal 
The overexpression model was analyzed by SRB to monitor the effect of 
Ambra1 overexpression on the A375 melanoma cell lines proliferation rate. 
Growth curves of rAmbra against the matching control rBgal were generated 
and statistically analyzed (Figures 3.1). A large number of assays (n=10) were 
performed using different passages aiming at generating a conclusion of the 
effect of Ambra1 overexpression on the proliferation rate. Results sometimes 
showed that rAmbra grew faster than rBgal and sometimes; the opposite was 
observed and also some other times; proliferation rates were observed to be 
similar for both cell lines. In conclusion data generated from 10 biological 
replicates was non-reproducible; some of these data are collected to show the 




Figure 3.1: graphical representation of SRB assay comparing the 
proliferation rate of rAmbra to rBgal cell lines over time. Bar chart showing 
the % growth of the two cell lines after 2 and 3 days relative to cells counts at 
24 hours from seeding, error bars represents +/- SD, n=48. Statistical analysis 
was performed by Mann-Whitney U-test, ***p<0.001 comparing the mean value 
of the %growth after 3 days to 1 day for each cell line, blue bars rAmbra, red 










































































































































































































































































































































































































3.2.2 SRB analysis of ShAmb versus ShCon 
The knockdown model was also analyzed by the same technique to assess the 
proliferation rate of ShAmb against its matching control ShCon. SRB assays for 
Ambra1 knockdowns were performed 24 hours after selection antibiotic removal 
(Figure 3.3). Growth curves were generated and statistically analyzed. ShAmb 
proliferation rate was significantly slower than ShCon. SRB assays were 
repeated after extended period of growing both cell lines without antibiotic 
selection. Growth curves were generated and statistically analyzed (Figure 3.4). 
Difference in the proliferation rate between both cell lines was much smaller 
compared to the previous run which indicates that the effect of Ambra1 





Figure 3.3: graphical representation of SRB assay comparing the 
proliferation rate of ShAmb to ShCon cell lines over time. Bar chart 
showing the % growth of the two cell lines after 2 and 3 days relative to cells 
counts at 24 hours from seeding, error bars represents +/- SD, n=48. Statistical 
analysis was performed by Mann-Whitney U-test, ***p<0.001 comparing the 
mean value of the %growth after 3 days to 1 day for each cell line, blue bars 








































Figure 3.4: graphical representation of SRB assay comparing the 
proliferation rate of ShAmb to ShCon cell lines over time after extended 
period of no antibiotic selection. Bar chart showing the % growth of the two 
cell lines after 2 and 3 days relative to cells counts at 24 hours from seeding, 
error bars represents +/- SD, n=48. Statistical analysis was performed by Mann-
Whitney U-test, ***p<0.001 comparing the mean value of the %growth after 3 








































The reproducibility of the SRB assays after running 10 biological replicates was 
very limited, and it did not generate solid data regarding the effect of the change 
in Ambra1 expression on proliferation rates of the cell lines. Data generated 
from comparing rAmbra against rBgal was highly variable. ShAmb proliferation 
rate were mostly consistent to be slower than ShCon. However; a different 
technique to assess the effect of the expression of Ambra1 on the proliferation 
rate was required. 
3.2.3 Incucyte live cell imaging of the four cell lines 
Live cell imaging technique was performed later on to compare the proliferation 
rate of the four cell lines using Incucyte. Cells were seeded at the same 
densities (1500cell/well in 200µl) and, loaded to the Incucyte with or without 
antibiotic selection and, live images to monitor the growth were taken for up to a 
week starting from 24 hours after seeding. Growth curves were generated by 
the Incucyte software (Figure 3.5). Comparing growth curves generated for 
rAmbra and rBgal showed no difference in the proliferation rate for the 
overexpression of Ambra1. On the other hand; growth curves showed a 
distinguishable decrease in the proliferation rate of the ShAmb to all the three 
different cell lines. The proliferation rate of the ShAmb cell lines did not show a 
difference in the presence (Red) or the absence (purple) of the selection 
antibiotic for up to 72 hours. However; after 72 hours an outgrowth of the cells 
without an antibiotic selection was observed. To further demonstrate the effect 
of antibiotic selection on ShAmb proliferation rate; cells were grown for more 
than two weeks without antibiotic selection and proliferation rate was monitored 
(Figure 3.6). The complete removal of the antibiotic selection for extended 
periods of time leads to a no-difference in the proliferation rate of the ShAmb 




Figure 3.5: Incucyte live cell imaging comparing the proliferation rates of 
the different A375 cell lines over time. Growth curves are blotted by Incucyte 
software, phase object confluence percent (Y-Axis) against time in hours (X-
Axis). Cells were seeded at the same densities (1500 cells/well, n= 24), and the 
knockdown model was seeded with and without antibiotic selection. The curves 
show that there is a slower proliferation rate of ShAmb compared to rAmbra, 
rBgal and ShCon. This effect of Ambra1 knockdown on the proliferation rate 
starts and continues to decrease after approximately 72 hours of growth, light 
blue rAmbra, dark blue rBgal, pink ShCon, grey ShCon no antibiotic selection, 




Figure 3.6: Incucyte live cell imaging comparing the proliferation rates of 
the different A375 cell lines over time after extended period of no 
antibiotic selection. Growth curves are blotted by Incucyte software, phase 
object confluence percent (Y-Axis) against time in hours (X-Axis). Curves show 
that there is almost no difference in the proliferation rate of the four cell lines 
when seeded at nearly the same density (n=24) upon the removal of antibiotic 





3.3 Western blot analysis of the cell line models 
Both the overexpression and the knockdown expression of Ambra1 were 
assessed in cell lines to confirm the phenotypic effect of the modifications. 
Western blot (WB) analyses were used to confirm the overexpression and the 
knockdown of Ambra1 in all cell lines. Ambra1 overexpression was confirmed in 
the rAmbra cell lines by WB analysis (Figure3.7). The analysis showed a clear 
band for Ambra1 at~130kD in the rAmbra cell lines and, these bands were very 
faint in the rBgal matching control cells, other bands where observed for rAmbra 
cell lines only at ~150kDa, ~90 KDa, 50 KDa and 30 KDa. A band is observed 
in both cell lines at ~10 kDa, these extra bands are discussed in details (5.3). A 
merged image of the western blot overlaid on a stain free image of the PVDF 
membrane showing total protein is also shown to demonstrate equal loading in 
each lane. The weak band intensities of the Ambra1 in rBgal cell lines indicates 
that endogenous Ambra1 levels are low and hence; its detection is challenging 
 β-galactosidase overexpression was also confirmed by WB (Figure 3.8) and a 
band was observed in the rBgal cells only at~116KDa. The stain free TGX gel 
image merged with the western blot demonstrates slight difference in protein 
loading in each lane. However; this technical error should not affect the results 






Figure 3.7: Western blot analysis of Ambra1 overexpression model. (A) 
Western blot analysis showing Ambra1 overexpression in the transfected 
melanoma cell lines (rAmbra) compared to the matching control overexpressing 
B-Galactosidase (rBgal). Lanes 2 to 4 and lanes 6 to 8 are technical replicates 
of different rAmbra extracts from two different passages. Lanes 9 to 11 and 
lanes 13 to 15 are technical replicates of different rBgal extracts from two 
different passages. Ambra1 is observed at ~130 KDa for rAmbra cell lines as 
well as four bands at ~150, 90, 50 and 37 KDa. A cross reactive protein is 
showing bands at ~10 KDa in both cell lines. Ambra1 band at~130 kDa is also 
observed for rBgal cells. (B)  A merged image of the western blot overlaid on a 
stain free image of the PVDF membrane showing total protein to demonstrate 









Figure 3.8: Western blot analysis of β-galactosidase protein in the 
overexpression model. (A) Lanes 2 to 3 and lanes 4 to 6 are technical 
replicates of rAmbra protein extracts from two different passages. Lanes 8 to 9 
and lanes 10 to 12 are technical replicates of rBgal of protein extracts from two 
different passages. A band for β-galactosidase can be observed at~116KDa for 
rBgal cell lines only. (B) A merged image of the western blot overlaid on a stain 










Ambra1 knockdown was also confirmed by western blot analysis in the knock 
down model (Figure 3.9). However; detecting a band for Ambra1 at such low 
levels of endogenous expression, as well as; even lower levels in the 
knockdown cells was challenging and images generated were not of a good 
quality. A band was observed for Ambra1 at~130KDa in the ShCon cell lines 
and not in the ShAmb cell lines which confirms the knockdown of Ambra1 in the 
ShAmb cell lines. 
ShAmb cells behaved differently to the three other cell lines in terms of 
proliferation rate and morphology; an effect that was gradually diminished upon 
the release of the selection antibiotic. A western blot analysis was performed 
after extended period of no antibiotic selection to monitor the level of Ambra1 in 
the ShAmb (Figure 3.10), under no antibiotic selection ShAmb cells were able 
to compensate for the shRNA mediated knockdown of Ambra1 to levels 
comparable to ShCon. The image for the TGX-stain free gel used shows slight 
difference of total protein loaded in each lane. These differences match with the 






Figure 3.9: Western blot analysis of Ambra1 Knockdown model. (A) 
Western blot analysis showing Ambra1 knockdown in the transfected melanoma 
cell lines ShAmb compared to the matching control ShCon. Lanes (3 and 4), (5 
and 6) and (7 and 8) are technical replicates of biological ShAmb extracts from 
three different passages.  Lanes (10 and 11), (12 and 13) and (14 and 15) are 
technical replicates of biological ShCon extracts from three different passages. 
A band can observed at ~130 KDa for ShCon cell lines and not for the ShAmb. 
(B) Cropped image from A different exposure showing clearer highlighting the 











Figure 3.10: Western blot analysis of Ambra1 Knockdown model after 
extended period of no antibiotic selection. (A) Western blot analysis showing 
Ambra1 re-expression in the ShAmb compared to the matching control ShCon. 
Lanes (2 and 3), (4 and 5) and (6 and 7) are technical replicates of biological 
ShAmb extracts from three different passages.  Lanes (9 and 10), (11 and 12) 
and (13 and 14) are technical replicates of biological ShCon extracts from three 
different passages. A band can observed at ~130 KDa for both cell lines. (B) 








Sulforhodamide B (SRB) assays were developed to measure drug-induced 
cytotoxicity and cell proliferation. Its principle is based on the ability of the 
protein dye Sulforhodamide B to bind electrostatically and pH dependent on 
protein basic amino acid residues of trichloroacetic acid–fixed cells. Under mild 
acidic conditions it binds to and under mild basic conditions it can be extracted 
from cells and solubilized for measurement. Results of the SRB assay were 
linear with cell number and cellular protein measured at cellular densities 
ranging from 1 to 200% of confluence. It performed similarly compared to other 
cytotoxicity assays such as MTT or clonogenic assay. This assay is reliable, 
reproducible and inexpensive approach to study these effects on proliferation 
rate (Orellana and Kasinski, 2016). A different study compared to MTT assays 
to three different cell enumeration assays, one of which was SRB, showed 
superiority of SRB over MTT assays in terms of variability of results (van Tonder 
et al., 2015). Generally speaking there is a limitation in all colorimetric assays 
including SRB, as none of these assays are able to directly count the number of 
viable cells but rather; the viability of the cells based on protein binding ability of 
the dye used. Specific limitations to SRB assays include: complicated 
procedures and, manual handling of the cells especially during repeated 
washing and drying steps which can be a source of technical variance 
(Aslantürk, 2018). 
Using SRB assays to study the proliferation rate of the cell lines was based on 
the reported reliability of this technique. However, data generated from SRB 
was mostly irreproducible (n=10). The difference between rAmbra and rBgal 
was highly variable. In some cases the proliferation rate of rAmbra was 
significantly higher while, in other cases it was significantly lower. Five different 
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cell passages were tried and data was constantly variable. However, the 
reproducibility of SRB assays cannot be judged based on this experiment as the 
variability in the results might be well due to the lack of a direct effect of Ambra1 
overexpression on the proliferation rate of the transfected melanoma cell lines 
rather than the technique used. With all of the colorimetric assays for measuring 
proliferation, such as SRB, the assay is indirect and metabolic differences can 
significantly affect results. Metabolic differences could arise due to different 
passage numbers and variations in initial cell density. These assays do not 
actually measure directly the number of cells. 
These drawbacks of SRB assays were overcame by the use of Incucyte live cell 
imaging which is a semi-automated microscopy based system that captures cell 
growth inside an incubator by the production of time-lapse images. Numbers of 
cells are calculated based by training the software to recognize cells and the 
confluency on the surface of the plastic ware is calculated. Growth rates 
produced are therefore based upon actual cell counts. The use of live cell 
imaging confirmed that there is no discernable difference in the proliferation rate 
of rAmbra1 compared to rBgal when seeded at the same density in a rich media 
(DMEM) with high glucose. 
However, the ShAmb cell line viability was noticeably different to the ShCon 
matching control and to the rAmbra and rBgal cell lines. ShAmb cells tended to 
grow much slower compared to the three other transfected cell lines when 
seeded at the same density. It took almost double the time compared to other 
cell lines to reach a confluency of 70-80%. ShAmb cells also looked different 
and not as healthy under the microscope, the morphology tended to be 
distorted with spiky protrusions at the edge of the cell membrane. These 
differences appeared to diminish gradually after the removal of the selection 
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antibiotic and growth rate began to match that of the other three cell lines. 
Incucyte live cell images showed that there is a distinguishable decrease in the 
proliferation rate of the ShAmb compared to all the three different cell lines; with 
the antibiotic selection and initially after the antibiotic selection removal. SRB 
assays were much more consistent in demonstrating slower proliferation rate 
than ShCon where the effects are more marked. Western blot analysis after an 
extended time of no antibiotic selection showed that ShAmb cells had Ambra1 
expression that had returned to normal levels.  
Unpublished data generated by the Lovat laboratory, Newcastle University 
(Jane Armstrong, pers. Comm.) showed that cell proliferation in primary cells 
can be increased by the transient Ambra1 knockdown (siRNA). However, same 
cells become non-viable upon stable knockdown of Ambra1 by shRNA. In this 
study, it is clear that the knockdown of Ambra1 is highly unfavorable to the cells 
and results in decreased proliferation rates. The effect of Ambra1 knockdown 
on the proliferation rate of the ShAmb cell lines starts to gradually diminish after 
approximately 72 hours of selection antibiotic removal, and that this effect was 
completely lost after around two weeks of no selection. Coupled with the 
western blot data it appears that the cells appear to eject the shAmbra construct 
resulting in an outgrowth of more rapidly dividing “wild type” A375 cells that 
express Ambra1 at normal levels. Often the ShAmb cells could be rescued by 
reapplying the selection where initially 80-90% of cells were killed by selection 
(results not shown) supporting the theory that without selection there is a strong 
biological drive to restore “normal” levels of Ambra1 in the cells. This suggests 
that the complete loss of Ambra1 could be lethal in a full genetic knockout.  
The roles of Myc, mTORC1 and, Ambra1 in cell proliferation have been 
discussed (1.3.5, 1.3.7 and 1.6.5). It is clear that in non-tumor cells mTORC1 
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has the opposite effect to Ambra1 on cell proliferation, mTORC1 is an upstream 
effector of Ambra1 and, signaling between mTORC1 and Ambra1 is not limited 
to cell proliferation, it extends to nearly all Ambra mediated roles as Ambra1 is 
primarily inhibited by mTORC1 under normal conditions (Nazio and Cecconi, 
2013), and upon cellular signals that inhibit mTORC1 like nutrient deprivation 
Ambra1 is activated by dephosphorylation and is released from the dynein 
motor complex (Di Bartolomeo et al., 2010). Ambra1 activation reduces cell 
proliferation by enhancing the activity of the catalytic subunit PP2CA leading to 
the de-phosphorylation and degradation of the proto-oncogene c-Myc 
(Cianfanelli et al., 2015). However, growth curves generated in this study show 
that in the melanoma A375 cell lines and under nutrient rich conditions Ambra1 
overexpression does not inhibit cell proliferation and, Ambra1 knockdown 
dramatically decrease cell proliferation, which is the exact opposite of Ambra1 
reported role in normal cells, Ambra1 levels in late stage metastatic melanomas 
is yet to be explored. However, its loss in stage I melanomas identifies high‐risk 
tumor subsets, this was identified by monitoring Ambra1 levels in epidermis 
overlaying primary melanomas, the same group of researchers demonstrated 
the ability of Ambra1 to regulate keratinocytes differentiation (Ellis et al., 2019). 
In summary, they have demonstrated that Ambra1 levels are decreased in the 
proliferative compartment of the epidermis and elevated in the differentiating 
compartment. 
mTORC1 is a very complex signaling pathways, its role is fundamental in 
coordinating anabolic and catabolic processes, deregulation of mTORC1 is 
reported in a vast majority of human cancers, in melanoma mTORC1 
constitutive activation is essential for metastasis (1.4), unlike normal cells, in 
cancer the activation of mTORC1 does not necessarily lead to autophagy 
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inhibition (Paquette et al., 2018), in fact there are studies that reported 
autophagy over activation in late stage melanomas, to the extent that 
autophagy inhibitors to treat melanoma are in clinical trials (Ndoye and 
Weeraratna, 2016). What is already known about mTORC1 and autophagy in 
melanomas may give an explanation to the effect of Ambra1 differential 
expression on the proliferation rates of the melanoma A375 cell lines, Ambra1 
may be overexpressed in metastatic melanoma to an extend that further 
overexpression of this gene appear to not have an effect on the proliferation 
rate, on the other hand, Ambra1 knockdown appear to decrease the metastatic 
melanoma proliferation rate, whether this effect is mediated by autophagy which 
is essential for cell survivals in the case of metastatic cancers, or a different 
mechanism is a question that require an answer to fully understand this role.   
As the project progressed it was clear that the overexpression of Ambra1 in 
media that is not nutrient limiting did not appear to significantly play a direct role 
in cellular proliferation as a consequence the role of the Ambra1 knockdown 


























The physical interaction between proteins or other molecules determines their 
biological activity (Alberts et al., 2002). The detection of such interactions is of 
an importance in understanding the organization and the function of the 
proteome. The Ambra1 protein contains a number of WD 40 domains 
(Cianfanelli et al., 2015) and, is part of a group of proteins referred to as 
intrinsically disordered proteins (IDPs). IDPs appear to have a very fluid 
structure which appears to increase the number of specific protein-protein 
interactions they can engage in and may make them hubs for protein interaction 
complexes (Csizmok et al., 2016). This makes the study of protein-protein 
interactions with Ambra1 particularly intriguing to identify its potential for 
regulating and connecting different biological processes. Many biochemical 
techniques have been employed to detect protein-protein interaction such as 
co-immunoprecipitation (Co-IP), affinity purification and co-purification; 
however, these methods have limitations, perhaps the most important is that 
these techniques require in-vitro handling of protein, unlike Y2H which 
preserves the native surroundings in which the interaction takes place and is 
monitored. (Brückner et al., 2009). 
In 1989 Stanley Fields and Ok-kyu Song reported a novel technique for in-vivo 
study of protein-protein interactions by using the yeast Saccharomyces 
cerevisiae and they applied this technique to test for protein-protein interaction 
between SNF1 and SNF4 proteins known to interact with each other (Fields and 
Song, 1989). This technique is called “Yeast-two-hybrid” and it utilizes the 
properties of a transcription factor called GAL4. GAL4 binds to a specific 
sequence on DNA known as the upstream activation domain (UAS). GAL4 is 
relatively simple and consists of just two functional domains that are at distinct 
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ends of the protein: The: N-terminal domain which is DNA binding domain 
(DBD) and C-terminal which is transcription activation domain (AD) (Keegan et 
al., 1986). Functional GAL4 activation requires the two domains to be within 
close proximity of each other. The principle of the assay is the two domains are 
split into two individual proteins that have no natural affinity. Fusion proteins 
with the domains are then constructed containing two potential naturally binding 
proteins or domains to reconstitute a functionally active GAL4. Generally, the 
protein of interest is attached to GAL4 DBD which is called the “Bait” and is 
typically assayed against a library of proteins translationally fused to the GAL4 
AD referred to as “Prey” (Figure 4.1A). When bait and prey protein interact, the 
GAL4 activates transcription and by testing for the expressed proteins, 
interaction can be detected (Chien et al., 1991). The Matchmaker Gold Yeast 
Two-Hybrid System (Clontech) was used in this study. It is one of the most 
advanced systems due to a combination of a new yeast strain (Y2H Gold), 
stringent reporters, easy-to-use libraries and, high-level expression vectors. 
This system requires the activation of four reporter genes under the control of 
three distinct Gal4-responsive promoters (Figure 4.1B) to detect protein 
interactions: 
 AUR1-C: A dominant mutant version of the AUR1 gene that encodes the 
enzyme inositol phosphoryl ceramide synthase. AUR1-C is expressed in 
Y2HGold Yeast Strain in response to protein-protein interactions that 
bring the GAL4 transcriptional activation and DNA binding domains into 
close proximity. In Saccharomyces cerevisiae, its expression confers 




 HIS3: Y2HGold is unable to synthesize histidine and is therefore unable 
to grow on media that lack this essential amino acid. When bait and prey 
proteins interact, Gal4-responsive His3 expression permits cells to 
biosynthesize histidine and grow on –His minimal medium. 
 ADE2: Y2HGold is also unable to grow on minimal media that does not 
contain adenine. However, when two proteins interact, Ade2 expression 
is activated, allowing these cells to grow on –Ade minimal medium. 
 MEL: MEL-1 encodes a-galactosidase, an enzyme occurring naturally in 
many yeast strains. As a result of two-hybrid interactions, a-
galactosidase (MEL1) is expressed and secreted by the yeast cells. 
Yeast colonies that express Mel1 turn blue in the presence of the 






Figure 4.1: The yeast Two Hybrid principle. (A) Two proteins are expressed 
separately, one (a bait protein) fused to the Gal4 DNA-binding domain (BD) and 
the other (a prey protein) fused to the Gal4 transcriptional activation domain 
(AD). In Y2HGold Yeast Strain, activation of the reporters (AUR1-C, ADE2, 
HIS3, and MEL1) only occurs in a cell that contains proteins which interact and 
bind to the Gal4-responsive promote. (B) In Y2HGold, the HIS3, ADE2, and 
MEL1/AUR1-C reporter genes are under the control of three completely 
heterologous Gal4-responsive promoter elements—G1, G2, and M1, 
respectively. The protein-binding sites within the promoters are different, 
although each is related to the 17-mer consensus sequence recognized by Gal4 
(Figures adapted from Clontech Laboratories). 
(A) 
Y2H gold (Mating Partner) reporter gene constructs 





The aim of this part of the study was to apply the Y2H assay to investigate 
potential Ambra1 protein-protein interactions using the full length Ambra1 
complementary DNA encoding 1298 amino acids; Uniprot isoform 1 ID: 
Q9C0C7-1 (https://www.uniprot.org/uniprot/Q9C0C7). The use of the Y2H 
assay to screen for binding partners of Ambra1 had been previously reported 
prior to this study commencing. A cDNA encoding the first 667 amino acids of 
the human Ambra1 cDNA ORF was used as bait and screened against a 
human brain cDNA library from this, Ambra1-BECLIN1 interaction was reported 
in this study and confirmed by co-immunoprecipitation (Fimia et al., 2007). Later 
on the same team published the use of the same approach to identify Ambra1 
interaction with PP2CA (Cianfanelli et al., 2015). Another yeast two hybrid 
assay was performed by cloning the C-terminal region (aa 533–1,269) cDNA of 
Ambra1, this study identified the interaction between Ambra1 and DLC1 (Di 
Bartolomeo et al., 2010). However, screening of the full length Ambra1 against 




4.2: Yeast two Hybrid work flow 
The Y2H assay is a multi-step process that can be classified into: 
1. Amplifying the gene of interest by PCR.  
2. Cloning the gene of interest into the DNA binding domain (DNA-BD) 
(pGBKT7). 
3. Transforming the recombinant pGBKT7 into Y2H gold yeast strain. 
4. Testing for the gene of interest (Bait) auto-activation of the reporter 
genes. 
5. Mating transformed Y2H gold strain with a normalized universal mate 
and plate library cloned in Y187 yeast strain. 
6. Positive interactions between the assayed bait and different preys are 
plated on X-α-gal and Aureobasidin highly strict plates (SD/–Ade/–His/–
Leu/–Trp), which allows the growth of selected genuine positive 
interactions only that can activate the four reporter genes (AUR1-C, 
HIS3, ADE2 and, MEL1). 
7. Isolation and rescuing plasmids of positive interactions 
8. Sequencing the picked up preys to identify the interactor proteins of the 
tested bait. 





Figure 4.2: Yeast two-hybrid work flow. (A) General Y2H workflow design for 
this study. (B) Summary of Ambra1 and PP2CA control experimentY2H work 
flow. Arrows represent proceeding to the following step. 
  
Ambra1 was amplified by PCR and initial trials to 
clone it into the desired vector was 
unsuccessful, different approaches were applied 
to address possible issues. 
PP2CA control experiments were performed and 
issues in cloning Ambra1 were identified to be 
mainly the selected restriction enzymes with 
traditional  digestion and sticky end ligation. 
Ambra1 was cloned into the desired vector by 
using fusion cloning technique. 
Both Ambra1 and PP2CA passed auto-activation 
tests and, Yeast two hybrid matings were 
performed. Novel binding partners were 
identified for both Ambra1 and PP2CA. 
PCR Amplification 
Transformation into 
Y2H gold yeast strain 
Test for Bait Auto-activation Confirmation of 
genuine positive 
interactions 
Y2H mating with a 
universal library  
(B) 







4.3.1 Amplifying Ambra1 by PCR 
4.3.1.1 Ambra1 primers design  
The initial step of performing the Y2H was to design the primers to amplify 
Ambra1 by PCR. The DNA-BD vector has the restriction sites: Nde I, Nco I, sfi I, 
EcoR I, Sma I/Xma I, BamH I, Sal I and Pst I (Figure 4.3). The Ambra1 cDNA 
sequence is ~4Kb. An in-silico digest of Ambra1 ORF using NEBcutter showed 
that of the enzymes sites available in the vector that most resulted in cuts within 
the ORF (Figure 4.4). These enzymes include : BamH I, Nco I, Pst I and Sal I 
the primers were therefore designed with the restriction sites:  EcoR I and Nde 
I. An initial set of Ambra1 primers was designed to have Nde I restriction site on 
the forward and EcoR I restriction site on the reverse primers. Primers were 





Figure 4.3: Map of the DNA-binding domain vector pGBKT7. The map 
shows the Fusion cloning region of the vector and the multiple cloning sites are 





Figure 4.4: In-silico digest of the Ambra ORF using NEBcutter tool. The 
image shows the OPEN reading frame with the enzymes that cut the ORF 
shown below in purple. The only available enzymes for cloning that did not cut 











Figure 4.5: PCR primer design to enable the cloning of Ambra1 into the 
vector pGBKT7. Ambra primers were designed as to have Nde I restriction site 
on the forward and EcoR I restriction site on the reverse primers. The design of 
the primers would enable Ambra1 to be cloned as a translational fusion with the 
DNA binding domain Image showing the Nde I and EcoR I unique restriction 
site and sequence of primers designed. 
 
  
Nde I restriction site EcoR I restriction site 
Ambra forward primer with Nde I site        Ambra reverse primer with EcoR I site        
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4.3.1.2 Ambra1 PCR amplification 
For the amplification of Ambra1 using PCR, forward and reverse primers at a 
concentration of 0.2µM, 100 ng cDNA synthesized from RNA extracted from U-
937 (ATCC® CRL-1593.2™) or A-375 (ATCC® CRL-1619™) cell lines were 
used as DNA templates and ImmoMixR (IMMOLASE™ DNA Polymerase from 
Bio-Line) as a DNA polymerase. At this stage the PCR reactions were 
unsuccessful and no bands for Ambra1 were observed (Figure 4.6). 
 
Figure 4.6: unsuccessful Ambra1 PCR reaction. Lanes 1 to 10 are replicates 
of Ambra1 PCR reactions. Lane 12 is Hyperladder 50bp. No bands observed for 







Since Ambra1 amplification was not achievable; a set of control primers were 
designed to amplify an internal sequence of ~500bp. of Ambra1 cDNA 
(Ambra1Fcon: TGC CAC AAT CTC CTG ACC TT. Ambra1Rcon: TCG CTG 
GGT CTG GGT AAA TT). This step was to help identify the presence of 
sufficient DNA template in the cDNA synthesized from the two cell lines 
mentioned above used for the PCR reaction. Amplifying this cDNA sequence 
was successful using cDNA from U-937 cell line and a band was observed 
at~500bp as expected (Figure 4.7) after this step only cDNA from the U-937 cell 
line was used as a template for PCR reactions. 
 
Figure 4.7: Ambra Control primers PCR amplification. Lanes 1 and 2 are 
Ambra control primers using cDNA extracted from U-937 and A375 
respectively. A band can be observed at ~500bp for amplification of Ambra1 
internal sequence. Lanes 3 and 4 are two replicates using Ambra full length 
primers using cDNA from U-937 cell line. Lanes 5 and 6 are replicates using 
Ambra full length primers using cDNA from A375 cell line. No bands at~4Kbp 




Upon identifying the presence of the DNA template in the cDNA library; PCR 
reaction was optimized to amplify the Ambra1 full cDNA sequence. First 
approach was to try optimizing the annealing temperature. A temperature 
gradient was set up at temperatures of 60°C and 64°C as the lowest and the 
highest annealing temperature respectively. . However, amplification was still 
not achieved (Figure 4.8). 
 
Figure 4.8: unsuccessful Ambra1 PCR reaction temperature gradient.  
Lanes 1 to 4 are temperature gradient PCR reactions from 60°C to 64°C for the 
annealing step. Lane 5 is Hyperladder 50bp. No bands can be observed 





Since an internal fragment of Ambra1 cDNA was amplified by control primers; 
the second approach to optimize PCR reactions was to design a new set of full 
length primers. The primers (Ambra1Ffull2 and Ambra1Rfull2) were designed 
with four base pairs less than the original primers (Ambra1Ffull and 
Ambra1Rfull) (2.1.4.). However, mis-amplification was observed upon using 
these primers and no bands were observed for full length Ambra1 (Figure 4.9) 
 
Figure 4.9: unsuccessful Ambra1 amplification using the (Full2) set of 
primers. Lanes 1 to 13 are thirteen PCR replicates performed for the 
amplification of Ambra1 showing no bands near the right size (~4kb). Lane 14 is 
hyper ladder 1kb. 
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Successful amplification of an internal sequence of Ambra1 Using the control 
primers suggested that the cDNA synthesized did not have the full length of 
Ambra1 ORF and therefore, the final step to optimize the PCR reaction was to  
purchase an Ambra1 open reading frame (ORF) clone (ORF plasmid clone 
name: IRATp97OC125D Source Bio-Science). The clone was previously 
sequence verified and this ORF clone was subsequently used as a template for 
all Ambra1 amplifications as well as a new set of primers AMBRA LongR and 
AMBRA LongF (2.1.4). PCR reactions were performed using Immomix master 
mix and 20ng and 100ng concentrations of Ambra1 ORF were tested. A band 
was observed for Ambra1 at ~4kbp upon using 20ng of the DNA template 
(Figure 4.10A).  
A proof reading polymerase was subsequently used (IPROOF, Bio-Rad) to 
ensure fidelity of the amplified product to amplify Ambra1 using the 20 ng 
optimum DNA template concentration (2.2.4), and the annealing temperature for 
Ambra1 was set to 66.6°C after running a temperature gradient PCR between 
65°C and 67°C (Figure 4.10B). Reproducibility of Ambra1 PCR amplification 
was achieved; all PCR products were purified by gel excision technique (Figure 




Figure 4.10: Ambra1 PCR amplification using an ORF clone. (A) PCR 
amplification using Immomix master mix. Lanes 2 and 3 are technical replicates 
of PCR reaction using 20ng of DNA template showing a band at~4Kbp. Lanes 4 
and 5 are technical replicates of PCR reaction using 100ng of DNA template 
showing no amplification. Lanes 6 and 7 are Hyperladder 1Kb (B) PCR 
amplification using a proof reading polymerase (Iproof). Lanes 1 to 4 are 
annealing temperature gradient PCR products of Ambra1 from 65°C to 67°C. A 
band is observed in all 4 lanes at ~4kbp with the highest annealing temperature 






Figure 4.11: Ambra1 PCR amplification and purification. PCR amplification 
was optimized using Iproof reading polymerase and DNA was purified by gel 
excision technique. (A) Electrophoresis of PCR products. Lanes 1 to 4 are four 
technical replicates of Ambra1 PCR products using Iproof polymerase. Bands 
are observed at ~4Kbp in all lanes. Lane 5 is Hyperladder 1kb. (B) 
Electrophoresis of purified PCR bands by gel excision technique. Lanes 2 to 5 
are 4 technical replicates. Bands can be observed at ~4Kbp in all lanes. Lane 6 











4.3.2 Cloning Ambra1 into the DNA-binding domain vector 
4.3.2.1: cloning Ambra1 using sticky end ligation 
Ambra1 PCR products and the DNA-binding domain plasmid (PGBkT7) were 
digested with EcoR I and Nde I, Ligated and transformed to DH5α E-coli 
transformations were selected for on kanamycin-agar plates (2.2.6). Initially no 
colonies were observed at all and after repeating the same step few times; few 
colonies were observed on the selection media plates. testing for inserts were 
either performred by colony PCR (Figure 4.12) or by  isolation of plasmids from 
colonies followed by digestion and analysis on agarose gel (Figure 4.13). In all 
cases no recombinant Ambra1 clones were isolated. 
 
Figure 4.12: colony PCR of transformed bacteria to screen for Ambra1 
inserts. Lanes 1 to 15 are different colony PCR products and no bands for 





Figure 4.13:  Restriction analysis of recombinant plasmids to screen for 
Ambra1 insert in the DNA-BD pGBKT7 using EcoR I and Nde I. Lanes 1, 4, 
7 and 10 are undigested plasmids. Lanes 2, 5, 8 and 11 are single EcoR I 
plasmid digests showing linear plasmids. Lanes 3, 6, 9 and 12 are double EcoR 
I and Nde I plasmid digests showing linear plasmids and no inserts. Lane 13 is 





4.3.2.2: cloning Ambra1 using zero blunt TOPO vector 
Traditional digestion and sticky end ligation approaches appeared not to be a 
viable approach to clone Ambra1. Two possible issues were to address at this 
point. Firstly, the use of Nde I restriction enzyme at the end of a linear ORF 
produced by PCR as it has been reported that Nde I can show weak digestion 
efficiency.  Secondly, cloning a large ~4Kbp ORF fragment into a relatively large 
~7.3kbp plasmid creates a very large construct which can be quite difficult to 
transform. Alternatives to overcome these issues were explored and, control 
experiments as well as different approaches were designed. Attempts to clone a 
control ORF of the gene PP2CA (fragment size ~927 bp); Uniprot isoform 1 ID: 
P67775-1 https://www.uniprot.org/uniprot/P67775 indicated similar issues using 
Nde 1 when digesting linear PCR products; so ways to avoid this were 
essential. One option was to try cloning the insert into a relatively smaller 
general purpose cloning vector and then sub-cloning. Therefore, the first 
approach was switching to blunt end cloning into a Zero blunt TOPO cloning 
vector. TOPO vector is ~3.5 Kbp and it was choose as it offers the ability to 
clone blunt ended PCR products by Topoisomerase I and, without the use of 
restriction enzymes. The use of restriction enzymes to digest Ambra1 cDNA 
from a TOPO circular vector rather than a linear PCR product may have 
enhanced the efficiency of digestion and allow sub-cloning the digested Ambra1 
cDNA into the desired pGBKT7 plasmid. 
In order to perform blunt end cloning using the TOPO vector; the use of 
proofreading polymerase is required to produce blunt-end PCR products. 
Ambra1 cDNA was amplified using Q5® High-Fidelity DNA Polymerase (2.2.4) 
(Figure 4.14), incubated with TOPO vector and transformed to Stbl2 E-coli cells 
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which were recommended by the manufacturer. No cloning was observed upon 
the analysis of the transformed colonies (Figure 4.15).  
 A control experiment was performed simultaneously as recommended by the 
TOPO vector supplier (Thermo-Fisher Scientific), and a PCR fragment of 
800BP was amplified to be used as a control and was successfully transformed 
into the TOPO vector (Figure 4.16). 
 
Figure 4.14: Blunt-end Ambra1 cDNA amplification using Q5 polymerase. 
Lanes 1 to 4 are four technical replicates of Ambra1 PCR products showing 







Figure 4.15: Restriction analysis of recombinant TOPO vector to screen 
for Ambra1 inserts using EcoR I and Nde I showing no inserts. These are 3 
biological replicates. Lanes 1, 5 and 9 are undigested plasmids. Lanes 2, 6 and 
10 are single EcoR I digests. Lanes 3, 7 and 11 are single Nde I digests. Lanes 
4, 8 and 12 are EcoR I and Nde I double digests. No Ambra1 cDNA bands were 






Figure 4.16: TOPO vector control PCR Product and restriction digestion 
analysis for successful cloning of the amplified insert into the TOPO 
vector. (A) Electrophoresis of control inserts PCR amplification. Lanes 1 to 5 
are technical replicates and bands can be observed at~800 bp in all lanes. Lane 
7 is Hyperladder 1Kb. (B) Electrophoresis of isolated and digested TOPO 
plasmid with control insert. Lanes 1 to 4 are four biological replicates of EcoR I 
and Nde I double digests of extracted plasmids. Two bands can be observed 
at~3.5Kbp for the TOPO vector and at~1Kbp for the control insert in lanes 1 and 





4.3.2.3: cloning Ambra1 using Electro-transformation 
The use of a general purpose realtively smaller TOPO vector to overcome the 
issue of cloning Ambra1 did not result in cloning Ambra1 and there was a need 
for a different approach to try and overcome the relatively large pGBKT7-
Ambra1 plasmid. Thinking was then shifted towards questioning the ability of 
traditional chemical-transformations to transform such a relatively large plasmid 
and therefore; Electro- transformation was applied to the  transformation of the 
ligated vector. The electro-transforamtion was just another approach that was 
not sufficient to clone the ORF Ambra1 into pGBKT7. At this point the concern 
for the vector size was minimized as if it was the real challenge then one of the 
two approachs used to overcome the size would have resulted in succesful 
cloning. 
4.3.2.4: Designing a control experiment using PP2CA 
A control experiment was  performed after the unsuccessful cloning of Ambra1 
cDNA using the previously mentioned approaches. Attempting cloning of 
PP2CA, a known binding partner of Ambra1,  was ideal as it could also be a 
useful control for the Y2H screening. A recent study has reported and confirmed 
by the yeast two hybrid assay the interaction of Ambra1 with PP2CA. 
PP2CA primers were designed with Nde I and EcoR I resriction sites similar to 
the Ambra1 primers (PP2CA F, PP2CA R 2.1.4). The same approaches were 
repeated using PP2CA amplified with these primers. PCR amplification of 
PP2CA from cDNA was succesful (Figure 4.17) and the product gel purified. 
However, attempts to clone Nde I/EcoR I digested PP2CA PCR product into 




Figure 4.17: PCR amplification of PP2CA cDNA using Iproof and Q5 DNA 
polymerases. (A) Electrophoresis of Iproof PP2CA PCR products. Lanes 1 to 5 
are technical replicates of PCR reaction. A band is observed in all lanes 
at~1Kbp. Lane 7 is Hyperladder 1Kb. (B) Electrophoresis of Q5 polymerase 
PP2CA PCR products. Lanes 1 and 2 are technical replicates of PCR reaction. 






Figure 4.18: Restriction analysis of recombinant plasmids to screen for 
PP2CA inserts in pGBKT7. Lanes 1, 4, 7 and 10 ae undigested plasmids. 
Lanes 2, 5, 8 and 11 are EcoR I digests showing a linear plasmid at ~8Kbp. 
Lanes 3, 6, 9 and 12 are double EcoR I and Nde I digests showing a linear 





The second PP2CA control experiment was blunt end cloning using zero blunt 
Topo vector rather than sticky end ligation. Unlike Ambra1; PP2CA was 
successfully cloned into the TOPO vector and analysing the recombinant TOPO 
vector released the PP2CA insert at ~1kbp (Figure 4.19). However, sub-cloning 
of Nde I/EcoR I digested PP2CA fragment from the TOPO vector into the Nde 
I/EcoR I digested pGBKT7 was unsuccessful (Figure 4.20). It appeared that the 
digestion of pGBKT7 was not digesting well with Nde I (4.4) since the 
generation of the PP2CA fragment from the TOPO vector meant that a Nde I 
site must be generated at the 5’ end of the PP2CA fragment. 
 
Figure 4.19: Restriction digestion analysis of recombinant Zero blunt 
TOPO cloning vector to screen for PP2CA clones. Lanes 2 and 3 are two 
replicates of EcoR I and Nde I digests PP2CA clones, linear plasmid band is 
observed at ~3.5Kbp. A linear ORF PP2CA can be observed at ~1Kbp. Lane 4 




Figure 4.20: Restriction digestion analysis of recombinant pGBKT7 to 
screen for PP2CA inserts. Lanes 1 to 14 are fourteen biological replicates of 
EcoR I and Nde I double digests of plasmids extracted from transformed DH5α 
after PP2CA was sub-cloned from Zero blunt topo vector into pGBKT7. Linear 
plasmid bands can be observed at~8kbp but no bands are observed for PP2CA 






A greater choice of restriction sites abvaialbale for PP2CA meant that BamH I 
was choose to replace the Nde I site on new PP2CA primers to generate an 
EcoR I / BamH I fragment. The forward primer (PP2CA F_Eco) was designed 
with EcoR I restriction site and the reverse primer (PP2CA R_Bam) was 
designed with BamH I restriction site (2.1.4). Repeating the sticky end ligation of 
PP2CA with pGBKT7 resulted in the succesful cloning of PP2CA (Figure 4.21) 
Recombinant clones were verified by sequencing 
 
Figure 4.21: Restriction digestion analysis of PP2CA clones in the Y2H 
bait vector pGBKT7. (A) Recombinant plasmid. (B) Lanes 1,4 and 6 are  EcoR 
I digests of 3 different PP2CA clones, linear band is observed at ~9Kbp. lane 2 
is a BamH I digest, linear band is observed at ~9Kbp. Lanes 3,5 and 7 are 
double digests using EcoR I and BamH I showing a linear plasmid at ~8Kbp 







4.3.2.5: Ambra1 cloning using EcoR I-EcoR I restriction sites 
Successful cloning of PP2CA into pGBKT7 using EcoR I and BamH I confirmed 
that the real challenge was the use of the Nde I. The available alternative to 
Nde I that can be used on Ambra1 cDNA sequence was EcoR I. a new forward 
primer was designed with the sequence of EcoR I restriction site replacing the 
Nde I site (AMBRA LongFeco 2.1.4), in attempt to clone Ambra1 cDNA with 
EcoR I restriction sites on both ends. PCR amplification was performed and 
cloning procedures into pGBKT7 were repeated, an insert was observed 
at~4Kbp on the restriction analysis (Figure 4.22). However; sequencing this 
insert showed that it is not Ambra1 cDNA. 
 
Figure 4.22: Restriction digestion analysis of recombinant plasmids to 
screen for Ambra1 inserts after using EcoR I alone as a restriction 
enzyme. Lanes 1 to 5 are biological replicates of plasmids digested with EcoR I 
to test for cloning Ambra1 into pGBKT7. Linear plasmid bands at~8Kbp can be 
observed in all lanes. A possible Ambra1 band at ~4Kbp can be observed in 




4.3.2.6: Ambra1 cloning using Fusion technique 
An alternative to traditional sticky end and blunt end ligations was chosen to 
attempt to clone Ambra1. The previous control experiments demonstrated that 
the use of Nde I needed to be avoided.  
In-Fusion HD Cloning can be used for fast, directional cloning of one or more 
fragments of DNA into any vector. The cornerstone of In-Fusion cloning 
technology is an In-Fusion Enzyme, which promotes single cross over 
recombination events between homologous DNA fragments (e.g., PCR-
generated inserts and linearized vectors) with an overlap of only 15-bp. These 
15-bp overlaps can be engineered into the 5’-end of primers used for the 
amplification of the desired sequences (Figure 4.23). 
 
Figure 4.23: A representative diagram of In-Fusion HD cloning technique. 
DNA fragment is colored in green and the yellow and purple colors represent 
the 15 bp overlaps that are ligated to generate a recombinant vector (Image 





New primers were designed to have the 15-bp overhangs that will overlap with 
Nde I/EcoR I digested pGBKT7 (AMBRA FusionF, AMBRA FusionR 2.1.4). The 
digestion of pGBKT7 was performed on two steps where the first step was to 
digest with Nde I and running the digested plasmid on an agarose gel to test for 
the linearity and be sure that Nde I has cut the plasmid, the second step was to 
add EcoR I as it is more efficient in cutting the plasmid (Figure 4.24). 
 
Figure 4.24: Multi-step restriction digestion analysis of pGBKT7 with Nde I 
followed by EcoR I. Lane 1 is a single digest of pGBKT7 using Nde I alone. 
Lane 2 is a double digest of pGBKT7 after adding EcoR I to the Nde I digested 
pGBKT7. Lane 3 is intact plasmid. Linear bands can be observed at ~8Kbp in 




In-fusion HD cloning approach was performed according to manufacturer’s 
specifications and the cloning of the full length Ambra1 gene was successful. 
Cloning was confirmed by restriction analysis of isolated recombinant vector 
(Figure 4.25) and verified by sequencing (~800 bases at each end) using a T7 
sequencing primer (Figure 4.26). 
 
 
Figure 4.25: Restriction digestion analysis of Ambra1 clones in the Y2H 
bait vector pGBKT7. (A) Recombinant plasmid. (B) Lanes 1, 3 and 6 are Eco 
R1 digests of 3 different Ambra1 clones, linear band is observed at ~11Kbp. 
lanes 2, 4 and 6 are double digests using Eco R1 and Nde I. In lane 2 a linear 
plasmid at ~8Kbp and the ORF Ambra1 at ~4Kbp are observed. In the same 
lane a linear single digested plasmid is showing a band at ~11Kbp which 





Figure 4.26: Ambra cloning verification by sequencing using T7 
sequencing primer. (A) Recombinant vector sequence showing Ambra cloned 
in frame. The red nucleotides represent pGBKT7 sequence and black 
nucleotides represent Ambra sequence. (B) Blast nucleotide analysis of the 







4.3.3: Yeast two hybrid mating 
4.3.3.1: yeast strains maintenance 
Yeast strains Y2H gold and Y187 were grown and maintained on YPDA plates 
(Figure 4.27).  
 
 
Figure 4.27: yeast two hybrid strains growth and maintenance. (A) Y2H 





4.3.3.2: yeast-two Hybrid control experiments 
Control experiments were performed as specified by manufacturer. The positive 
control experiment is an interaction between pGBKT7-53 (murine p53 protein 
cloned into pGBKT7) transformed into Y2H gold strain and pGADT7-T (SV40 
large T-antigen cloned into pGADT7) transformed into Y187 strain. While the 
negative control involved a mating between pGBKT7-Lam (lamin protein cloned 
into pGBKT7) transformed to Y2H gold strain and pGADT7-T. for both positive 
and negative controls white colonies should grow on the –Leu-Trp plates but 
only a positive protein-protein interaction should result in blue colonies growing 
on the –Leu-Trp/X/Aba as four reports are required to detect a positive 





Figure 4.28: Yeast Two Hybrid control experiments. (A) –Leu-Trp plate 
showing colonies growing for positive control experiment (B) -Leu –Trp plate 
showing similar growth of the negative control experiment to the positive 
control. (C) blue colonies for positive control experiment on –Leu_Trp/X/Aba 
plates confirming an interaction between the candidate proteins (D) negative 













4.3.3.3: Ambra1 and PP2CA auto-activation tests 
The next step after cloning Ambra1 and PP2CA into pGBKT7 was the 
transformation of these recombinant vectors into the target Y2H gold strain and 
testing the insert for auto-activation of the reporter genes. The Transformations 
were performed according to the manufacturer’s instructions. The auto-
activation tests were performed by plating the transformed yeast on single 
dropout plates (SD-Trp), single dropout plates in the presence of X-α-gal (SD-
Trp/Xα) and single dropout plates in the presence of X-α-gal and Aeurobasidin 
antibiotic (SD-Trp/Xα/Aba). Transformed Y2H gold strain with recombinant 
vector should show growth on the SD-Trp plates as tryptophan is expressed by 
the vector. Colonies should also grow on the SD-Trp/Xα but without activation of 
X-α-gal i.e. no blue colonies should be observed. Finally no colonies should 
grow on SD-Trp/Xα/Aba. If the colonies turn blue on the SD-Trp/Xα or show any 
growth on the SD-Trp/Xα/Aba it means that the tested bait activates the reporter 
genes and is not suitable for pursuing the Y2H mating as the results will be 
mostly false positives. 
Ambra1 clone did not show any auto-activation of the reporter genes (Figure 




Figure 4.29: screening of pGBKT7-Ambra1 for auto-activation test. 
Colonies of Y2H gold yeast strain transformed with Ambra1-pGBKT7 plasmid is 
grown on three different media plates to perform the auto-activation test. (A) 
SD-Trp plate showing colonies growing in the absence of tryptophan. (B) SD-
Trp/Xα plate showing colonies growing in the absence of tryptophan and not 
activating Xα-Gal as the colonies have the same color as plate (A). (C) SD-






Figure 4.30: screening of pGBKT7-PP2CA for auto-activation test. Colonies 
of Y2H gold yeast strain transformed with PP2CA -pGBKT7 plasmid is grown on 
three different media plates to perform the auto-activation test. (A) SD-Trp plate 
showing colonies growing in the absence of tryptophan. (B) SD-Trp/Xα plate 
showing colonies growing in the absence of tryptophan and not activating Xα-
Gal as the colonies have the same color as plate (A). (C) SD-Trp/Xα/Aba plate 








4.3.3.4: yeast-two Hybrid mating 
Since the two tested candidates Ambra1 and PP2CA did not show any toxicity 
and passed auto-activation tests of the reporter genes, the transformed yeast 
gold strains with Ambra1-pGBKT7 vector and PP2CA-pGBKT7 were mated with 
a normalized universal mate and plate libraries according to manufacturer’s 
specifications. Different concentrations of the mated culture were plated on 
SD/–Trp, SD/–Leu and SD/–Leu/–Trp (DDO) to calculate the mating efficiency 
and the number of colonies screened. The rest of the mated cultures were 
plated on DDO/X/A plates. All plates were incubated at 30°C for 3 days. 
Ambra1 mating resulted in distinguishable greenish-blue colonies indicating 
positive Ambra1 interactors (Figure 4.31); and so did PP2CA mating (Figure 
4.32). Mating efficiency is calculated using the limiting partner; which is of the 
lower viability (either the bait or the prey). Ambra1 and PP2CA were the limiting 
partners in each individual mating; and hence; mating efficiencies were 
calculated using the baits.  Number of colonies screened is calculated from the 
DDO plates. Mating efficiencies and number of colonies screened for both 
cDNAs are shown in table 4.1. 
Table 4.1: Mating efficiencies and number of screened clones for Ambra1 




Mating efficiency >2% 20% 4.56% 
Number of 
colonies screened 






Figure 4.31: Yeast-two Hybrid screening of Ambra. Successful mating of 
Y2H gold strain transformed with pGBKT7-Ambra with Y187 strain transformed 
with universal mate and plate library. Greenish-blue colonies on these –Leu-




Figure 4.32: Yeast two hybrid screening of PP2CA. Successful mating of 
Y2H gold strain transformed with pGBKT7-PP2CA with Y187 strain transformed 
with universal mate and plate library. Greenish-blue colonies on these –Leu-












4.3.3.5: Confirmation of genuine positive interactions 
 A final step to eliminate false positive interactions and confirm genuine positive 
interactions after successful Y2H mating was performed by streaking greenish-
blue grown colonies from the DDO plates from Ambra1 and PP2CA matings on 
the highly strict quadrupole drop-out plates (QDO/X-αGal/ABA). Only greenish-
blue colonies grown on the QDO plates are genuine positive interactions and 




4.3.4: protein binding partners identified by Y2H 
The colonies growing on the QDO plates and showing a greenish-blue color are 
mated colonies that contain the “Bait” plasmid tested as well as the unknown 
picked up “Prey”. In order to isolate the prey’s plasmids of interest simply they 
were selected for by extracting the plasmids from the grown yeast according to 
Manufacturer’s specifications, transforming the isolated plasmids into E-coli and 
finally growing the transformed bacteria on Ampicillin plates. This step allows 
the growth of bacteria that is only transformed with plasmids containing preys 
as the preys are on pGADT7-RecAB which contains ampicillin resistance 
sequence (Figure 4.33). 
 
Figure 4.33: pGADt7-Rec map showing ampicillin resistance sequence. 





4.3.4.1: Ambra1 interactor’s analysis 
Preys recombinant vectors from Ambra1 mating were extracted from bacteria 
grown on Ampicillin plates. A sample of isolated vectors was digested using 
BamH I and EcoR I to verify there is a vector with a possible insert (Figure 
4.34).  Recombinant vectors were sequenced using a T7 sequence primer 
(source Bio-Science) and compared to databases (NCBI, ensemble) to identify 
interactor’s cDNA. Nearly all sequenced cDNAs were identified more than once 





Figure 4.34: restriction digestion analysis of recombinant plasmids with 
an insert confirmed to be an Ambra interactor. (A) Lanes 1 to 6 are six 
different plasmids of Ambra interactors digested with BamH I and EcoR I.  Lane 
8 is Hyperladder 1Kb. (B) Lanes 1 and 3 are two different samples digested with 






Table 4.2 Ambra1 binding partners identified by yeast two hybrid mating 













Required for RNA-mediated gene silencing (RNAi). 
Binds to short RNAs such as microRNAs (miRNAs) 
and represses the translation of mRNAs which are 
complementary to them. 
Ankyrin-3 ANK3 (2) May participate in the maintenance/targeting 
of ion channels and cell adhesion molecules 






protein 7 (2) 
 
DSTN Destrin (6) Actin-depolymerizing protein. Severs actin 
filaments (F-actin) and binds to actin monomers (G-














May be involved in protein trafficking from the 
plasma membrane to the early endosome (EE) as 
well as in homotypic fusion of endocytic organelles. 
Mediates the endocytic trafficking from early 





protein 7 (3) 
Potential role in vesicular protein trafficking, mainly 
in the early secretory pathway. Appears to play a 
role in the biosynthesis of secreted cargo including 







These identified proteins were analyzed using STRING protein interactions tool 
to scan for any previously reported Ambra1 binding partners (Figure 4.35). 
 
Figure 4.35: STRING protein analysis for Ambra1 identified binding 
partners. The analysis shows that none of the identified Ambra1 binding 
partners have been reported prior to this study. Colored nodes represent 
proteins, lines represent interactions and, light blue color represents interactions 








String analysis of each individual protein was performed to screen for potential 
pathways that these identified proteins can interact. One of this proteins; AGO3 
is of a specific importance as it interacts MYC directly and indirectly via PTEN 
and TFDP1 (Figure 4.36). 
 
Figure 4.36: String protein network analysis showing the interaction 
between AGO3 and MYC from curated databases. Colored nodes represent 
proteins, lines represent interactions, light blue represents interactions from 
curated databases, yellow represents interactions from text mining, purple 





4.3.4.2: PP2CA interactor’s analysis 
Preys recombinant vectors from PP2CA mating were also extracted from 
bacteria grown on Ampicillin plates and isolated plasmids were analyzed on an 
agarose gel to test for isolated plasmids (Figure 4.37). Recombinant vectors 
were sequenced using a T7 sequence primer (source Bio-Science) and 
compared to databases (NCBI, ensemble) to identify interactor’s cDNA. The 
results of the PP2CA Y2H are novel and new binding partners are identified 




Figure 4.37: analysis of plasmids isolated from PP2CA Y2H mating. Lanes 
1 to 7 are different samples of prey’s plasmids isolated from the mating of 

















-Mitotic spindle assembly checkpoint. 




2 subunit beta 
Regulatory subunit of S-adenosylmethionine 
synthetase 2, an enzyme that catalyses the 
formation of S-adenosylmethionine from methionine 
and ATP. Regulates MAT2A catalytic activity by 
changing its kinetic properties, increasing its affinity 
for L-methionine. 
SHANK2 SH3 and multiple 
ankyrin repeat 
domains protein 2 
Seems to be an adapter protein in the postsynaptic 
density (PSD) of excitatory synapses that 
interconnects receptors of the postsynaptic 
membrane including NMDA-type and metabotropic 





These identified proteins were analyzed using STRING protein interactions tool 
to scan for any previously reported PP2CA binding partners (Figure 4.38). 
 
Figure 4.38: STRING protein analysis for PP2CA identified binding 
partners. The analysis shows that none of the identified PP2CA binding 
partners have been reported prior to this study. Colored nodes represent 





Choosing this specific approach (Y2H) was based on the fact that it is one of 
the most widely used protein-protein interaction techniques; it is simple and 
allows the screening of the candidate protein against a universal library of 
human proteins (Brückner et al., 2009). The initial yeast two hybrid design was 
criticized for too many false positives. However; the progress made to this 
technique and the addition of more reporter genes to be activated for detecting 
a true positive has made this technique the best candidate for our experimental 
design. As the system used requires the activation of four different reporter 
genes which minimizes to a great extent the false positive results. Another 
motive behind this technique is the novelty of applying the Y2H to study the full 
sequence complementary DNA of Ambra1 protein. There is one study reported 
using this technique with Ambra1 DNA encoding only 667 amino acids a bait, 
Ambra1 fragment was cloned in EcoR I and BgL II sites of the pGBKT7 vector, 
the Y2H screen of this study identified the interaction between Ambra1 and 
BECLIN1 (Fimia et al., 2007). The same group of researchers identified the 
interaction of Ambra1 with PP2CA using the same vector (Cianfanelli et al., 
2015). Another study has identified the interaction of Ambra1 with DLC1 by the 
same technique where they cloned a fragment of Ambra towards its C-terminus 
using EcoR I and Sal I into the same vector (Di Bartolomeo et al., 2010). 
Another study has used the same technique to study a protein called RNF2 and 
Ambra1 was one of the preys picked up by RNF2 (Xia et al., 2014). Mostly 
Ambra1 protein interaction studies involved other techniques like co-




The initial step of performing the Y2H was to clone Ambra1 into the carrier 
vector (pGBKT7). The restriction enzymes choice was limited to EcoR I and 
Nde I (4.3.1). Upon designing these primers few bases were added to the Nde I 
restriction site. Adding few bases to the Nde I site end of the PCR product can 
enhance the efficiency of Nde I digestion (Jung et al., 1990). 
Few possibilities were considered to identify the reason of initial un-successful 
cloning of Ambra1. First was the weak efficiency of the restriction enzyme used 
Nde I which is reported to be one of the weakest restriction enzymes used 
(Chang et al., 2005). Second was the size of the plasmid plus the insert which is 
more that 11Kbp. However; this possibility was minimized when cloning was 
unsuccessful upon using Electroporation transformation instead of chemical-
transformation. Electroporation can be used to overcome the relatively large 
size of a recombinant vector (Matsumura, 2015). 
Different approaches were applied to overcome the cloning issues. One of 
which was cloning first into a zero blunt TOPO vector followed by sub-cloning 
into the desired pGBKT7 plasmid. Using the TOPO vector is reported to be 
more efficient in cloning PCR products without the use of restriction enzymes 
(Motohashi, 2019). 
Finally, the successful approach was cloning the full length Ambra1 gene using 
the most recent fusion cloning technique which does not require the use of the 
restriction enzymes on the DNA fragment to be cloned (Kirchmaier et al., 2013).  
This study reports novel Ambra1 binding partners (Table 4.2), that gives more 
insight into the potential role of Ambra1 in different cellular functions. These 
interactions with Ambra1 protein have not been reported in literature (Figure 
4.35).  It is important to highlight that all the reported identified proteins were 
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picked up more than once by our bait Ambra1 except for AGO3. This shows 
that these interactions are more likely to be genuine rather than false positives. 
False positives were also omitted by the use of the highly strict quadrupole 
dropout plates which allows only the growth of genuine interactions. It is notable 
that none of the already known Ambra1 binding partners were picked up in this 
Y2H assay, this can be due to the relatively small number of analyzed positive 
interactors in this study (approximately 50 colonies), it can also be due to the 
normalized transcript library used in this assay, which may have picked up less 
abundant binding partners under physiological conditions, finally in this study 
and for the first time the full length cDNA of Ambra1 ORF was used in a Y2H 
assay, considering that Ambra1 is an IDP, the full length protein will have a 
different conformation compared to just a protein translated by a part of Ambra1 
cDNA which was the case in all previous Ambra1 Y2H studies (4.1). 
To address the potential novel roles of Ambra1 that can be explored by these 
results; it is important to review the binding partners identified in terms of their 
cellular functions and, identify different roles of these proteins that can be 
mediated or affected by Ambra1. 
On top of the list of Ambra1 interactors is Protein argonaute-3 (AGO3). 
Argonaute proteins (Ago) are essential components of the RNA-induced 
silencing complex (RISC); they act as binding modules that are highly 
specialized for small RNA including: microRNAs (miRNAs), small interfering 
RNAs (siRNAs) and Piwi-interacting RNAs (piRNAs). These RISC binds to 
complementary sequence and cleave target mRNA with an end result of gene 
silencing (Ender and Meister, 2010). AGO1, AGO2, AGO3 and AGO4, are the 
members of the human Ago proteins. AGO3 is reported to show positive and 
negative regulation of gene expression and, it is also proposed to interact with 
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MYC (Figure 4.33). Protein Argonaute-3 is essential in regulating stem cell 
proliferation in human embryos; it acts with DICER protein to generate retinoic 
acid riRNAs that are essential to modulate the exit from the proliferative stem 
cell state (Hu et al., 2012). 
Second and third Ambra1 identified protein binding partners are: Ankyrin-3 
(ANK3) and, Ankyrin repeat domain-containing protein 7 (ANKRD7) 
respectively. ANK3 is a member of the Ankyrin proteins family, a ubiquitously 
expressed family of intracellular adaptor proteins; they target proteins to 
specialized membrane domains. ANK3 also termed ANK-G is expressed in 
most cell types in the nervous system, they are also the main ankyrin forms in 
epithelial cells, myocytes, hepatocytes, megakaryocytes, and neurons, its non-
canonical isoforms are also expressed in Golgi and lysosomes. Canonical 
Ankyrins comprise a membrane-binding domain (MBD) of 24 ANK repeats, a 
spectrin-binding domain, a death domain and a C-terminal domain. Alternative 
splicing of the Ankyrins gives rise to different subtypes by the insertion of 
different coils between the spectrin-binding and the death domains. ANK3 also 
contains a 40 KDa glycosylated serine/threonine-rich domain (Mohler et al., 
2002). ANK3 is one of the most consistently repeated and significant 
schizophrenia and, bipolar risk genes; it has been shown that it can regulate 
Wnt signaling in neural progenitor cell proliferation in the developing cortex by 
altering the availability and localization of β-catenin (Durak et al., 2015). It is 
very interesting that ANK3 has been reported to be able to bind to the LIR motif 
on different autophagy related proteins resulting in autophagy inhibition, this 
effect was first reported in neurons. There is a high affinity of interaction of 
ANK3-LIR to GABARAP (mammalian homologue of yeast Atg8), but not to 
LC3s (Popelka and Klionsky, 2018).  
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ANKRD7 is a protein coding gene that contains five ankyrin repeat domains 
which expression has only been reported in testis. Ankyrin repeat domains are 
one of the most common protein-protein interaction motifs in nature and, they 
function exclusively for protein-protein interactions, they consist of 30−34 amino 
acid residues, they have been found in numerous proteins with diverse cellular 
functions. For instance; ankyrin repeat domains can be found in INK4 tumor 
suppressor family. Mutations in these repeats have also been linked to diseases 
like cancer including melanoma (Mosavi et al., 2004). ANKRD7 has also been 
reported to be an effector of the endocytic Rab GTPase RAB32 that is involved 
in autophagy, distribution of mitochondria, trafficking of melanogenic enzymes 
to melanosomes, and RAB38 which transports tyrosinase to immature 
melanosomes (Wandinger-Ness and Zerial, 2014).  
Next comes DSTN which encodes the protein Destrin; It is widely expressed in 
different tissues and is ubiquitously expressed in prostate and esophagus. 
DSTN is an Actin-depolymerizing factor (ADF) which is a component of the 
highly dynamic cellular cytoskeleton scaffold; it enhances the turnover of actin 
by slicing actin filaments and binding to actin monomers during cell locomotion, 
cytokinesis and other forms of cell motility. Destrins are essential for cell viability 
and, Actin is one of the most abundant proteins in eukaryotic cells and is 
involved in cell structure and cell motility (Yeoh et al., 2002).  Autophagy is a 
process that involves a lot of proteins trafficking, and autophagosomes 
transportation to specific cellular locations. Cytoskeleton network plays an 
essential role in autophagy. However; relatively little is known about this role 
(Monastyrska et al., 2009). Destrin is also reported to be down regulated as a 
result of parathyroid hormone mediated autophagy activation in response to 
dexamethasone damage (Zhu et al., 2017). 
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The next gene that interacts with Ambra1 is STX7; it encodes the protein 
Syntaxin-7. Syntaxins also termed as t-SNAREs are key proteins in membrane 
fusion that assemble a core-trans SNARE complex with v-SNARE. This fusion 
is essential for communication between cells as well as; intracellular 
compartments. Unlike v-SNAREs that contains an anchored tail with one 
SNARE motif; t-SNAREs consist of two to three polypeptides, a member of the 
Syntaxins subfamily as the heavy chain and members of the SNAP-25 
subfamily as the light chains. The function of SNAREs is simply catalyzing the 
fusion of the membranes of the transport intermediate (vesicles or containers) 
and the target compartment, v-SNAREs are associated with vesicles while; t-
SNAREs are associated with target compartments (Hong, 2005).  
SNAREs have long been reported to have a key role in autophagy; by acting as 
regulators of the precise autophagic fusion process moreover; recently they 
have been reported to have a role in autophagosome biosynthesis. The role of 
these proteins in autophagy has been extensively reviewed (Wang et al., 2016). 
Homotypic fusion of Atg16L1 depends on different SNARE proteins including 
Syntaxin-7 and, is essential for autophagosome formation. Autophagic 
precursors are unable to mature into autophagosomes in the absence of these 
SNARE proteins (Wang et al., 2016).  STX7 which forms a SNARE complex 
with VTI1B, STX8 and VAMP8 which functions in the homotypic fusion of late 
endosomes; is specifically involved in protein trafficking from plasma membrane 
to the lysosomes passing through early and late endosomes, which is the last 
barrier for autophagosome degradation. Lysosomes are the primary protein 
degradation vesicles for cargos from unrecycled endocytosed proteins, 
phagocytosed material and autophagized proteins (Mullock et al., 2000).  
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To add to the list of identified proteins that exerts different roles in protein 
trafficking; Transmembrane emp24 domain-containing protein 7 (TMED7) is on 
the list of Ambra1 identified interactors, which is involved in vesicular protein 
trafficking. It contains a Golgi dynamics (GOLD) domain; it is a β-strand-rich 
domain found in several proteins involved in Golgi dynamics, as well as 
intracellular protein trafficking. TMED7 has been proven to show an essential 
role in inhibiting the toll-like receptor 4 (TLR4) signaling from the endosome 
(Doyle et al., 2012). TMED7 is also involved in the biosynthesis of secreted 
cargos by processing and post translational modifications.  
Finally we have identified an interaction between Ambra1 and an unnamed 
protein encoded from clone RP4-789D17 on chromosome 1p34.1-34.3.  
After reviewing these proteins and their different roles; we were looking for 
common properties and functions that can relate these different proteins. 
Despite the fact that STRING protein analysis did not show a direct interaction 
between these proteins except for TMED7 that interacts with ANK3, nearly all 
these proteins are related to protein trafficking. TMED7 is a trans-membrane 
protein that is involved in vesicular protein trafficking. Moreover; half of the 
proteins on our list either Bear a SNARE domain or are reported to directly or 
indirectly interact with SNARE domains. As mentioned before STX7 is a t-
SNARE protein, Ankyrin repeat domains have long been reported to form 
complexes with SNARE domains (Daste et al., 2015). Moreover; ANRD7 is a 
direct effector of the well-known Snare domain interactor’s endocytic Rab 
Gtpases (Wandinger-Ness and Zerial, 2014), the actin cytoskeleton which is 




Ambra1 physical interaction with these proteins and pathways give a whole new 
insight about Ambra1 roles. Perhaps the most obvious is that Ambra1 is 
involved extensively in cellular proteins trafficking and, specifically proteins 




















































































































































































































































































































































































































































In the context of protein trafficking; STX7, ANKRD7, DSTN and, TMED7 stand 
out in the list of identified proteins. While most of these proteins are centered on 
autophagy related transport; some of their roles extend to different cellular 
processes. 
The interaction of Ambra1 with STX7 is of a great importance to explore a new 
role of Ambra1 in autophagy, Ambra1 is translocated together with Beclin-1 and 
PI3KIII to the endoplasmic reticulum PAS where the autophagosome formation 
starts; a process that involves a lot of protein trafficking (1.5). The global 
network of phagophore formation is not fully discovered, and a lot of members 
of this process are yet to be identified (Wang et al., 2017). Ambra1 loss results 
in reduction in the rate of autophagosome formation (Antonioli et al., 2014; 
Benato et al., 2013). Different proteins including SNAREs and, SNARE 
complexes roles in the autophagosome maturation and fusion with lysosomes 
journey are very well explained (Zhao and Zhang, 2019). The interaction 
between Ambra1 and Syntaxin7 gives a lead to a possible mechanism by which 
Ambra1 may regulate autophagosome formation. Moreover, this interaction 
suggests a role of Ambra1 in the journey of trafficking proteins from plasma 
membrane all the way to lysosomes for degradation; which is a specific role of 
STX7. 
To highlight the role of Ambra1 with SNAREs, ANKRD7, a known effector of 
RAB32 and RAB38 GTPases is on the list of the identified proteins, Rab 
GTPases and their effectors act upstream of SNAREs to provide the first layer 
of specificity in the recognition of membranes compatible for fusion. In addition, 
they contribute key functions and factors required for SNARE-mediated 
membrane fusion. This study shows that Ambra1 can interact with SNAREs 
protein trafficking by binding the GTPase effector ANKRD7. Moreover; it 
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identifies a second role of Ambra1 in protein trafficking as RAB GTPases and 
their effectors roles are not limited to SNAREs, but extends to contribute to the 
structural and functional identity of intracellular organelles. Identified specific 
roles of ANkRD7 include: autophagy, distribution of mitochondria, trafficking of 
melanogenic enzymes to melanosomes, transporting tyrosinase to immature 
melanosomes (Wandinger-Ness and Zerial, 2014). Studying specific roles of 
ANKRD7 mediated by Ambra1 and vice versa can be of a great importance. 
However, since both proteins are involved in autophagy therefore, it is more 
likely that this interaction will be related to their roles in autophagy. 
The final addition to SNARE interaction on our list is Destrin, an Actin 
cytoskeleton depolymerizing factor. Actin cytoskeleton is a very complex 
network that is required for endocytosis, pinocytosis, phagocytosis, cytokinesis, 
cell motility and membrane fusion (Karunakaran et al., 2012); its interaction with 
SNAREs is just one side of this complex network. However; in the context of 
this study it highlights the role of our protein of interest Ambra1 and, how it can 
directly and indirectly interacts with SNAREs. The interaction between Ambra1 
and Destrin gives a novel insight about the potential role of Ambra1 in different 
cellular processes. Destrins are essential for cell viability and, Actin is one of the 
most abundant proteins in eukaryotic cells. An interaction between such protein 
and Ambra1 broadens the role of Ambra1 in vital and essential cellular functions 
specifically cell motility. Moreover, it adds to novel roles of Ambra1 in autophagy 
reported in this study by highlighting a possible role in the link between 
cytoskeleton and, autophagy. Ambra1 can be of an essential role for protein 
trafficking during autophagy through its interaction with Destrin. 
This study also reports Ambra1 to be a bait for TMED7 which is a 
transmembrane protein involved in vesicular protein trafficking and Golgi 
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dynamics. This finding adds to the identified roles of Ambra1 in protein 
trafficking. It is also interesting that this study shows that Ambra1 upregulation 
and knockdown in A375 melanoma cell lines result in a non-significant and a 
significant upregulation of TLR4 respectively (6.3.2) this suggest a role of 
Ambra1 in TLR4 signaling that might be mediated by TMED7. Further analysis 
to study the binding site of TMED7 and Ambra1 can potentially be a gate to 
identify a novel role of Ambra1 in transportation of cargo molecules from the 
endoplasmic reticulum to the Golgi complex specially, if the binding site is the 
GOLD domain of TMED7.  
The interaction between Ambra1 and ANK3 is novel and of a great importance. 
Ambra1 is known to be involved in the development of the nervous system and 
it has been related to different CNS disorders like schizophrenia and, autism. 
This study shows a great influence of Ambra1 on axon guidance cellular 
process pathway (6.3 and 6.4). ANK3 plays an essential role in the 
development of the nervous system and moreover; it is associated with CNS 
disorders and is of an essential role in establishing neuronal axon initial 
segment (Leterrier et al., 2017). The physical interaction between Ambra1 and 
ANK3 provides a proof of a direct link of these two proteins in the development 
of the nervous system as well as; CNS related disorders. This study have also 
shown a role of Ambra1 in regulating the Wnt signaling pathway by altering the 
expression of Wnt5a (6.5), taking this together with the ability of ANK3 in 
regulating the same pathway in cortex development can contribute to the 
understanding of Ambra1 effect of the development of the nervous system. The 
expression of this gene in lysosomes as well can highlight a potential role of 
ANK3 as a protein adaptor in Ambra1-mediated autophagy. Ambra1 bears LIR 
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motif which can potentially be the region where an interaction between Ambra1 
and ANK3 takes place. 
Protein argonaute-3 which shows positive and negative regulation of gene 
expression comes last on our identified proteins. AGO3 functions are not widely 
explored in literature. However; curated databases from string propose and 
interaction of AGO3 with MYC. The few studies that reported AGO3 roles is so 
important, both AGO3 and Ambra1 are reported to be essential in the 
embryonic development, AGO3 with DICER are essential to generate retinoic 
acid sliced riRNAs which modulate the exit of stem cells active proliferative 
phase during embryonic development, studying if Ambra1 has a role in this 
context with AGO3 will be essential to explore Ambra1’s role in cell proliferation. 
Perhaps the first approach should be monitoring AGO3 slicer activity on 
Ambra1 and whether it can promote or limit the activity of Ambra1 during 
embryogenesis and also if this role is also mediated by MYC or by a different 
pathway. 
Collectively this study reports that Ambra1 interacts with SNARE proteins, Actin 
cytoskeleton proteins, RAB GTPases proteins and transmembrane proteins. 
These proteins are widely involved in protein trafficking at different stages, as 
well as, specific involvement in autophagosome formation, membranes fusion, 
autophagy, cell proliferation, Wnt signaling, CNS development and pathologies, 
cell motility and toll like receptor 4 signaling.  
The yeast two hybrid control experiment performed using PP2CA have also 
identified three novel PP2CA binding partners (Table 4.3). Only a small sample 
of PP2CA was sequenced as it is not the main focus of this study, and it was 
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only used a control experiment. However, a relation between identified novel 














Chapter 5- Development of methods for the proteomic 





“Omics” refers to the collective technologies used to explore the roles, 
relationships, and actions of the various types of molecules that make up the 
cells of an organism. These technologies include: genomics, proteomics, 
metabolomics, transcriptomics, glycomics and lipomics. 
The study of proteome allows the understanding of how the genes are 
translated and allows the detection of pot-translational modifications (PTM) of 
the proteins. 2D-electrophoresis (2D-E) was first introduced in 1970s (O’Farrell, 
1975) and it is an orthogonal approach which is capable of, simultaneous 
fractionation, identification, and quantification of proteins when coupled with 
mass spectrometry (Magdeldin et al., 2014). 2D-E allows the separation of 
proteins by two dimensions, the first is isoelectric point (pI) and the second is 
the protein molecular weight.  2D-E is mostly coupled with mass spectrometry 
(2D-E-MS) this technique is very reproducible and applicable for identifying 
proteins by MS (Rabilloud and Lelong, 2011). Comparing two samples can give 
a visual representation of changes in the proteome between them by staining 
the gels with a chemical stain that will bind to the cysteine groups of the 
analyzed proteins. 2D-E can also be used to study PTMs that causes change in 
a protein pI and/or the MW; for example: phosphorylated proteins can show 
higher molecular weights and different pI to dephosphorylated forums of the 
same protein. The literature is rich with studies using this technique to compare 
different in-vivo and in-vitro samples. For example, one study identified four 
differentially expressed genes in chemo-therapy resistant melanoma patients 
using 2D-E-MS (Sinha et al., 2000). 
Metabolomics is defined as “the systematic study of all chemical processes 
concerning metabolites, providing characteristic chemical fingerprints that 
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specific cellular processes yield, by means of the study of their small-molecule 
metabolite profiles” (Burgess et al., 2014). Mass spectrometry (MS) associated 
metabolomics has emerged as a technique for profiling metabolic features 
associated with clinically relevant aspects of tumor biology (Kaushik and 
DeBerardinis, 2018). The most commonly used application of metabolomics in 
cancer is identifying novel biomarkers for diagnosis or predicting prognosis 
(Gowda et al., 2008).  
In this arm, a proteomics and a metabolomics approaches were applied to the 
two melanoma cell lines rAmbra and rBgal to investigate the change in 










To study the proteome change associated with Ambra1 over-expression, a 
mass spectrometry-based proteomics approach was designed. rAmbra cells 
were utilized to study proteomic change upon the over-expression of Ambra1 
compared to the matched control rBgal. The same cell lines were also used to 
apply a mass spectrometry-based metabolomics to study the effect of Ambra1 
over-expression. 
5.2.1 2D gel electrophoresis 
Protein separation using 2D-E is a multi-step process that needs optimization. It 
involves protein extraction, sonication, purification, quantification, focusing on 
IEF strips and separation by TGX gels. Protein extraction, quantification and 
sonication are detailed in section 2.2.2. Protein purification was initially 
performed using 2D clean-up kit (Bio-Rad, Uk). However protein yield was 
optimum when TCA protein precipitation protocol was used (2.2.10). 
 After optimizing the protein extraction step; the study shifted forward towards 
protein separation by the two dimensions electrophoresis. 
5.2.1.1: E-coli standard 2D electrophoresis 
It was important at the beginning to optimize the 2D-E protocol and hence; a 
standard E-coli protein sample (Bio-Rad, Uk) was focused on different strips 
using different protocols (2.2.10). Initial runs (n=4) showed poor protein 
separation (Figure 5.1). However; an optimum protocol was reached after trying 
different focusing conditions; this protocol involved a “desalting” step in which 
protein samples were focused at 2K volts for 2 hours followed by replacing the 
wicks on each side of the focusing strips. A total of 40K volt-hours were set to 




Figure 5.1 E-coli standard protein sample separation using 2D 
electrophoresis. Each dot on the gel represents a protein. 
. 
 
Figure 5.2: Optimized E-coli standard protein sample separation using 2D 
electrophoresis. Each dot on the gel represents a protein. Gel shows 




5.2.1.2 rAmbra and rBgal 2D electrophoresis 
Different IEF strips were used for focusing rAmbra and rBgal samples (2.2.10). 
The first protein separation was performed using a 5-8 11cm. IEF strip, first 
dimension was overnight separation at 25k volt-hours and the second 
dimension was gel electrophoresis separation on stain free gels (Figure 5.3). 
However; separation was optimum when using 40K volt-hours for protein 
focusing on 11cm IEF strips (Figure 5.4) and 60K volt-hours for 17cm IEF strips 
(Figure 5.5). Reproducibility of protein separation using the two cell lines (n=12) 
was very low, and also the few 2D-E runs that did show protein separation did 
not show any noticeable visual difference between rAmbra and rBgal. Some of 
the gels were stained by either colloidal coomassie or silver stain (2.2.10) to 
decide between which stain will be used to proceed to spots excision and mass 
spectrometry. Despite the fact that silver stains showed much higher sensitivity 
compared to colloidal coomassie, this was not of a great use as reproducibility 
of protein separation was very low and therefore; it was useless to stain the gels 









































































































































































































































































































































































































































































5.2.1.3 rAmbra and rBgal 2D western blots 
Visual difference between the gels was not enough to spot significant change in 
the proteome and further analyze these spots using mass spectrometry. rAmbra 
western blots showed additional bands to the 130KDa band for Ambra1 protein 
that was not observed in the rBgal (Figure 3.1). 2D western blots were 
performed to try and identify spots for Ambra1 itself, ideally these spots were to 
be excised and analyzed by mass spectrometry to confirm if they are genuine 
bands of Ambra and, study the difference between them. To test for Ambra1 
spots separated proteins were transferred to the Trans-Blot® Turbo™ Midi 
PVDF membranes (Bio-Rad, UK) using the Trans-Blot® Turbo™ Blotting 
System (Bio-Rad, UK), according to manufacturer’s instructions. However; 
protein transfer was poor (Figure 5.5). Using the same Ambra1 antibody and 
the same protocol used for the 1D western blots was not successful and no 





Figure 5.5 2D-Electrophoresis and stain free blots of rAmbra and rBgal. 
Proteins from both cell lines were separated by 2d electrophoresis and 
transferred to PVDF membranes. (A) rAmbra protein separation. (B) Stain free 
rAmbra PVDF membrane. (C) rBgal protein separation. (D) Stain free rBgal 




5.2.2 GC-MS metabolomics studies: 
This arm of the study was started by metabolite extraction from rAmbra cell 
lines using methanol followed by metabolites derivatization, separation by GC 
and finally identification by MS (2.2.11) an Initial run was performed as a control 
experiment to validate the protocol using rAmbra cell line metabolites 
derivatised by either BSTFA or MSTFA and a blank derivatised only by BSTFA 
(2.2.11). Total ion chromatograms (TIC) were generated from the mass 
spectrometric analysis (Figure 5.6). The blank analysis shows a distinguishable 
peak at 10.140 for derivatizing agent (BSTFA) itself with little background noise, 
the same peak at 10.265 was observed for rAmbra analysis using the same 
derivatizing agent, and was not observed for rAmbra when a different 
derivatizing agent was used. This means that derivatization and analysis 
worked well as in the blank BSTFA did not derivatise anything else but the 
reagent itself. Also the difference in rAmbra identified metabolites upon using 
two different derivatizing agents (Table 5.1) show that these peaks are genuine 
metabolites from rAmbra and that different metabolites can be identified upon 
using two different derivatizing agents. A representative example of MS 
identification of peaks is included in which a peak from TIC of rAmbra 












Figure 5.6: Total ion chromatograms obtained from rAmbra metabolites 
GC-MS. (A) Blank derivatised by BSTFA (B) rAmbra metabolites derivatised by 
MSTFA (C) rAmbra metabolites derivatised by BSTFA.  Different peaks can be 








Table 5.1: mass spectrometry identified metabolites for rAmbra. (A) Blank. 
(B) rAmbra metabolites using MSTFA. (C) rAmbra metabolites using BSTFA. 
(A) 





Peak Number Metabolite 
11.522 Trimethylsilyl ether of glycerol 
16.208 Nonadecane 
22.919 Glucopyranose, pentakis-O-trimethylsilyl- 
24.871 Glucopyranose, 1,2,3,4,6-pentakis-O-(trimethylsilyl)-, D- 
28.418 Octadecanoic acid, trimethylsilyl ester 
34.173 Hexadecanoic acid, 2,3-bis[(trimethylsilyl)oxy]propyl ester 
41.210 3.alpha.-(Trimethylsiloxy)cholest-5-ene 
46.646 Dodecane, 1-fluoro- 
 
(C) 
Peak Number Metabolite 
10.265 tert-Butyl-[2-(tert-
butyldimethylsilyl)oxyethoxy]dimethylsilane 
13.074 Lactic acid ditbdms 
17.102 tert-Butyl-(2-methoxyethoxy)dimethylsilane 




31.639 4-Hydroxythiophenol, S-trimethylsilyl-, trimethylsilyl 
ether 
33.941 Pentanedioic acid, 3-[(tert-butyldimethylsilyl)oxy]-3-
methyl-, bis(tert-butyldimethylsilyl) ester 
39.552 Cyclopentanecarboxylic acid, trimethylsilyl ester 






Figure 5.7: MS analysis of peaks from TIC representative example. Peak 









The following runs were designed to compare metabolites from rAmbra and 
rBgal using both derivatization agents. TICs generated from using MSTFA 
(Figure 5.8) showed difference between the blank sample used and both 
rAmbra and rBgal. However; both cell lines showed nearly identical TICs. While 
TICs generated from using BSTFA (Figure 5.9) showed nearly no difference 
between the three chromatograms from the blank, rAmbra and rBgal, indicating 
that derivatization did not work very well and that these peaks on the TICs are 
more likely to be for contaminants in the samples rather than genuine 
metabolites from the cell line extractions. To study for the difference between 
rAmbra and rBgal metabolites, MS identification was applied to individual peaks 
of the chromatogram. Peaks from both cell lines derivatised by MSTFA were 
analyzed by MS. Compounds identified from both cell lines were near identical, 








Figure 5.8: MS total ion chromatograms for metabolites extracted and 
derivatised using MSTFA. (A) rAmbra. (B) rBgal. (C) Blank. No difference in 












Figure 5.9: MS total ion chromatograms for metabolites extracted and 
derivatised using BSTFA. (A) rAmbra. (B) rBgal. (C) Blank. No difference can 












These runs were repeated few times (n=3) in attempts to identify more 
metabolites that can allow further comparisons of the cell lines and were not 
successful, reproducibility at this point was very low and samples separation 
was not achieved as before. In an attempt to identify and overcome these 
issues; a technique control experiment was performed using a standard solution 
of 20 amino acids at three different concentrations and a blank. The GC 
separation and the MS identification were performed. TIC from a blank and 
three different dilutions were generated (Figure 5.10). The blank sample 
showed more than one peak indicating contamination. And the identified 
metabolites in the amino acid standard used did not relate to all amino acids of 

























































































































































The application of proteomics in cancer studies is widely established and is an 
effective way to identify the change in protein expression between two 
specimens (Cai et al., 2004). Applications of proteomics in melanoma studies 
have been a primary method to look for biomarkers (Sabel et al., 2011). 
Ambra1 PTMs plays an essential role in the activity of this protein and other 
proteins during autophagy, Ambra1 is found in an in-active form by its 
phosphorylation at Ser52 by mTORC1. Upon nutrient starvation mTORC1 is 
inhibited and Ambra1 is dephosphorylated (Nazio et al., 2013), Ambra1 
activation enhances ULK1 kinase activity which phosphorylates essential 
autophagic components including Ambra1 itself at sites that are yet to be 
identified (Botti-Millet et al., 2016). There are more than 20 Ambra1 
phosphorylation sites that are reported and yet to be characterized to 
understand the dynamic role of Ambra1 PTM by phosphorylation (Cianfanelli et 
al., 2015).  A recent study has characterized the phosphorylation of Ambra1 at 
Ser1014 by HUWE1 an E3 ubiquitin ligase which enhances Ambra1- LC3B 
binding during mitophagy (Di Rita et al., 2018). 
There are also a number of studies that proved Ambra1 ubiquitylation; it is 
ubiquitinated by RNF2 which is an ubiquitin E3 ligase at Lysine 45 by Lys48-
linked ubiquitin chains to mediate Ambra1 degradation by proteasomes; a 
process that result in autophagy suppression after it has been induced by 
starvation (Xia et al., 2014). A study has summarized the ubiquitylation of 
Ambra1 by Cullin E3 Ubiquitin Ligases during autophagy (Antonioli et al., 2014). 
Moreover; Ambra1 is not only considered as a substrate for ubiquitylation, but 
also it is an essential co-factor in the activity of different E3 ligases (Cianfanelli 
186 
 
et al., 2015). It has been shown that Ambra1 and TRAF6 are essential for the 
ubiquitylation of ULK1 by LYS-63-linked chains during autophagy (Nazio et al., 
2013). This study also shows that Ambra1 may affect the acetylation of 
CDC25A (6.4), as well as a role in PTMs specifically ubiquitination (7.3)  
Western blot analyses (3.2) showed Ambra1 band at ~130KDa; as well as 
different bands in the rAmbra cell lines only. A band is observed at ~150kDa 
which is approximately 20 KDa higher than the Ambra1 band; this can indicate 
different changes to the Ambra1 protein including PTM (Larsen et al., 2006). 
Other bands were observed at ~90 KDa, 50 KDa and 30 KDa which indicates a 
possibility of Ambra1 protein cleavage. A band is observed in the two cell lines 
at ~10 kDa which indicates a possible cross-reactive protein. Indeed the study 
that reported Ambra1 cleavage by Caspases and Calpains showed an N-
terminal (~60 kDa=Ambra1 plus myc-tag) and a C-terminal (~100 kDa) cleavage 
products by western blot analysis (Pagliarini et al., 2012). Another possible 
explanation to the multiple bands on western blot analysis is Ambra1 transcript 
variants, which are identified by Uniprot to be at least 6 variants for this protein. 
Transcript variants can be generated due to alternative splicing of an mRNA. If 
the epitope that the antibody recognizes is shared between the proteins, then 
multiple bands will be observed (Ghosh et al., 2014) 
Differential expression and PTM studies on these protein samples were started. 
The visual comparison of the well separated proteins on gels for rAmbra and 
rBgal indicated that there is not much difference in the proteomic profile at least 
for the few runs that were successful. However; this arm required a lot of 
optimization and 2D gel electrophoresis was extensively repeated to reach the 
point where visual separated proteins can be clearly and reproducibly seen on 
the gels. Reproducibility of protein separation was not achievable and hence; 
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further analysis of these gels either by mass spectrometry or PTM using 2D 
western blotting were not feasible.  
2DE technique is deemed to be one of the leading powers in the expansion of 
proteomics and protein studies (Magdeldin et al., 2014). Despite the wide use of 
2DE for proteomics experiments, there are few limitations of protein separation 
by this technique. These limitations include poor reproducibility of separation, 
inability to detect low abundant proteins, and moreover; a protein pH has to be 
between 3 and 10 also a protein size has to be between 10 and 150 KDa to be 
identified by 2DE, and finally streaking of spots and poor membrane resolutions 
which result in poor protein separation (Chandramouli and Qian, 2009; 
Magdeldin et al., 2014). Spot streaking and poor separation was the main 
limitation of our work, other limitations included poor reproducibility. 
Metabolomics studies were initiated and the initial runs showed nearly no 
difference in the metabolome between rAmbra and rBgal. However; repeating 
the same steps on a larger scale did not perform the same and this protocol 
was repeated to identify possible technical errors. A last attempt was  designing 
a control experiment. A 20 amino acid standard solution was prepared and 
different dilutions were extracted in methanol and underwent derivatization 
using MSTFA reagent. However the separation of these amino acids was not 
achievable and the blanks showed a lot of noise and contamination on the 
columns and hence; metabolomics studies were discontinued.  
There can be many reasons during different steps of extraction, derivatization 
and detection behind the poor quality results of metabolomics. The choice of the 
quenching reagent is critical to ensure effective metabolism quenching as well 
as; largely affecting the yield of metabolites, the method used in this study is 
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direct quenching and extraction by cold methanol after a single wash by PBS 
which is reported to be one of the most effective methods that result in minimal 
leakage of intracellular metabolites (Kapoore et al., 2017). 
Derivatization is obviously most effective method to improve the detection 
characteristics of metabolites. It acts by changing an analyte to make it 
detectable in gas chromatography and enable chromatographic separation. 
Derivatization either increases or decreases the volatility of the compound and it 
reduces the absorption of the analyte in the gas chromatography system. The 
two derivatization agents used in this study BSTFA and MSTFA are the most 
widely used derivatization agents; they both act by silylation of active hydrogens 
present in functional groups (Monteiro et al., 2013).  
Regarding detection, GC-MS has advantages of a greater chromatographic 
resolution when compared to LC-MS-based methods (Aretz and Meierhofer, 
2016). Our initial work shows that extraction and derivatization approaches 
used were promising to generate reproducible data. It is more likely that the 
poor results were due to poor separation resulting from column deterioration. 
Results from proteomics and metabolomics indicate that there is not a great 
difference between the profiles of rAmbra and rBgal. However; a 
comprehensive conclusion cannot be made due to poor reproducibility of the 
experiments as well as testing only a fraction of the proteome and metabolome 





















Studying the effect of Ambra1 differential expression has been an attraction for 
many researchers since its discovery in 2007. The first study that reported the 
role of Ambra1 in autophagy used the overexpression and the knockdown of 
Ambra1 to identify its role in autophagy and different cellular processes (Maria 
Fimia et al., 2007). Literature show more studies that utilized overexpression 
and/or knockdown of Ambra1 to assess the roles and study the functions of 
Ambra1, its ability to induce autophagy and inhibit apoptosis as an autophagic 
pro-survival response has been shown by the overexpression and knockdown 
of Ambra1 in fibroblasts (Pagliarini et al., 2012) and, the same role was shown 
in SW620 cells (Gu et al., 2014). In relation to this role the knockdown of 
Ambra1 in A375 melanoma cell lines was used to show that 
Tetrahydrocannabinol (THC) induced autophagy was independent of Ambra1 
(Armstrong et al., 2015). Furthermore; the downregulation of Ambra1 has also 
shown: reduced ability of Beclin1 to interact with Vps34 (Sun, 2016), and an 
increase in basal apoptosis in adult neural stem cells (Yazdankhah et al., 2014). 
There can be far more studies that have performed the same approach to study 
this gene; these ones mentioned are to show that the differential expression of 
Ambra1 is of a great impact on different cellular processes. 
Transcriptome can be defined as the sum of all RNA transcripts produced by an 
organism (Lowe et al., 2017), transcriptome analysis is then the study of the 
transcriptome, of the complete set of RNA transcripts that are produced by the 
genome, under specific circumstances or in a specific cell, using high-
throughput methods. There are two main techniques applied to study 
transcriptomes; microarrays and, RNA-Seq. DNA microarrays are discovery 
type research that can be used as a tool to assess the genetic information or 
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the gene expression by analyzing mRNA complete set produced by the genome 
of a specific organism (Govindarajan et al., 2012). 
Previous experiments carried out in this study did not indicate that the 
overexpression of Ambra1 is of a great value in the A375 melanoma cell lines. 
On the other hand; there was a growing interest in the knockdown of the same 
gene. As mentioned before the proliferation rate of the ShAmb cell lines was 
notably different to all other cell lines, the decreased proliferation rate of the 
ShAmb cell lines was proved by SRB and Incucyte proliferation assays. The 
effect of Ambra1 knockdown on cell proliferation rate in this model is the 
opposite of reported Ambra1 role in normal and primary melanoma cells (3.4). 
In order to study the transcriptome changes related to Ambra1 differential 
expression; a DNA microarray experiment was designed. Unlike the proteomics 
and the metabolomics studies which were limited to the overexpression model, 
the knockdown model was included in the microarray analysis to allow for 
investigating the outcomes of Ambra1 knockdown as well as overexpression. A 










































































































































































































To perform a microarray analysis, RNA was extracted using Trizol reagent 
(2.2.12) from four different passages of each cell line 72 hours after selection 
antibiotic removal. 
6.3.1 RNA quality analysis 
Quality analysis of extracted RNA samples from rAmbra, rBgal, ShAmb and 
ShCon is shown in Figure 6.2. RNA integrity numbers are shown in table 6.1. 
















































































































































































































Table 6.1: RNA integrity numbers for RNA extractions used for 
microarrays data analyses. Table shows 12 RNA integrity numbers for the 
four different cell lines. Highlighted are the samples chosen to be analyzed by 
Microarray gene chip. 
Lane 
number 
1 2 3 4 5 6 7 8 9 10 11 12 
rAmbra 9.8 9.8 9.9 9.8 8.8 9.9 9.8 9.4 7.5 10 9.5 10 
rBgal 9.5 9.7 9.9 9.8 9.9 9.8 9.7 9.5 9.8 - - - 
ShAMB 9.7 9.8 9.1 9.8 8.7 9.9 9.6 9.6 9.3 - - - 
ShCon 9.9 10 10 9.9 10 10 - 10 10 - -- - 
 
6.3.2 Differential expression analysis of the microarray results 
In this arm two datasets were analyzed (Table 6.2) using transcriptome analysis 
suite (2.2.14). In the first dataset rAmbra was compared to the matching control 
rBgal. While in the second dataset ShAmb was compared to its matching 
control ShCon. Three samples of each cell line were analysed using an array 
Type HuGene-2_0-st, Genome Version hg19 (Homo sapiens) annotated: 
HuGene-2_0-st-v1.na36.hg19.transcript.csv. The analysis results (Figure 6.3) 
showed 107 differentially expressed genes in the first dataset where 60 and 47 
genes are up and down regulated respectively, in the second dataset 243 are 
upregulated and 79 are downregulated to give a total of 322 differentially 
expressed genes. 
Table 6.2 datasets analyzed from the Hugene_2.0 microarray for 
comparing Ambra1 effect on transcriptome 
Comparison Group 1 Group 2 Count 1 Count 2 Up Down 
rAmbra vs rBgal rAmbra rBgal 3 3 60 47 





Figure 6.3: analysis results of the differentially expressed genes in two 
different datasets showing up and down regulated genes in each dataset. 
The top dataset is comparing rAmbra vs rBgal. The bottom dataset is 




Principal components analyses (PCA) mapping for the two datasets were 
performed to analyze the samples clustering. The first dataset shows a distinct 
pattern of the rBgal. However; the rAmbra did not show the same clustering 
(Figure 6.4).  On the other hand, the second dataset shows distinct patterns of 
ShAmb and ShCon clustering (Figure 6.5). To demonstrate the effect of Ambra1 
knockdown on the change of transcriptome, a PCA mapping for the four cell 
lines was performed (Figure 6.6). It is clear that ShAmb cells cluster 





Figure 6.4: PCA mapping of the Ambra1 overexpression model microarray 
dataset. Blue dots represent rAmbra and red dots represent rBgal. A distinct 




Figure 6.5: PCA mapping of the Ambra1 knockdown model microarray 
dataset. Red dots represent ShAmb and blue dots represent ShCon. A distinct 




Figure 6.6: Combined PCA Mapping of the overexpression and 
knockdown models microarrays datasets. Blue dots represent rAmbra, red 
dots represent rBgal, purple dots represent ShCon and, green dots represent 









Volcano plots were generated for each dataset to summarize the fold change 
and the ANOVA ebayes method used for performing the analysis (Figure 6.7) 
this plot can be considered to determine the most significant differentially 
expressed genes. However; a corrected p-value which in this case is false 
discovery rate (FDR) can be used instead to determine the significance of each 





































































































































































































































































































Hierarchical clustering Heatmaps were generated to visualize the change in the 
genes expression among the different datasets (Figure 6.8). They were 
generated to visualize the expression of the significantly differentially expressed 
genes in the two datasets. Every row represents a gene expression profile 
across the samples (Rows). Red color refers to upregulated genes; white refers 
to unchanged and blue represents downregulated genes. A clear clustering 
within each group for the two datasets can be observed except for the rAmbra 


































































































































































































































































































Differentially expressed genes were analyzed (2.2.14) and the lists of the 
significantly differentially expressed genes (P<0.05) were arranged according to 
the FDR. The first dataset showed higher values of FDR when comparing the 
differential expression between rAmbra and rBgal which indicates a high rate of 
false discovery. The overexpression of Ambra1 in the rAmbra cells was 
confirmed to be 16.37 folds up-regulated compared to the rBgal matching 
control by this technique. Also N(Alpha)-Acetyltransferase 11 (NAA11) and 
Cadherin13 (CDH13) were shown to be overexpressed within an acceptable 
FDR values A list of the p-value significant differentially expressed genes, the p-
values and the FDR values are listed in table 6.3. 
Table 6.3: Differentially expressed genes comparing rAmbra to rBgal. 
Showing the gene symbol, fold change, p-value and FDR. 
Gene Symbol Fold Change P-val FDR P-val 
Uncharacterized -88.18 1.74E-10 3.34E-06 
Uncharacterized -109.49 2.13E-10 3.34E-06 
Ambra1 16.37 2.72E-10 3.34E-06 
Uncharacterized -108.15 2.77E-10 3.34E-06 
NAA11 4.27 8.47E-07 0.0082 
CDH13 3.06 5.78E-06 0.0465 
 
On the other hand, the second dataset showed a great difference in the gene 
expression profile. Comparing the ShAmbra genome expression to the matched 
control ShCon confirmed the knockdown of Ambra1 in the ShAmb cell line to be 
1.58 folds downregulated compared to the ShCon, and showed that Ambra1 
knockdown led to a significant difference in the expression of 322 genes (p-
value <0.05),  a list of genes with FDR value <0.07 was generated (table 6.4.) It 
is notable that only few genes from this list were downregulated leaving the 




Table 6.4: genes differential expression in the ShAmb cells compared to 
the ShCon cells at a cut of FDR <0.07 showing the gene symbol, fold change, 
P-value and FDR P-value. 
Gene Symbol Fold Change P-val FDR P-val 
SEMA3C 3.74 5.93E-07 0.0079 
ZNF844 4.2 5.95E-07 0.0079 
SEMA3A 3.11 7.65E-07 0.0079 
LINC00440 7.05 8.90E-07 0.0079 
RUNX1-IT1 3.86 1.11E-06 0.0079 
AJAP1 3.94 1.14E-06 0.0079 
TCN1 4.94 1.16E-06 0.0079 
MEOX2 3.02 1.46E-06 0.0079 
GALNT5 3.37 1.47E-06 0.0079 
TFPI2 3.6 2.51E-06 0.0113 
FAT3 4.41 2.58E-06 0.0113 
PLA2G7 8.61 3.33E-06 0.0126 
JAG1 3.39 3.45E-06 0.0126 
CDH19 3.19 3.65E-06 0.0126 
SLC14A1 2.74 4.06E-06 0.0131 
IL24 -2.85 4.44E-06 0.0134 
ACTBL2 5.51 5.24E-06 0.0143 
COL4A1 2.55 5.71E-06 0.0143 
NEK10 3.26 5.75E-06 0.0143 
TP73 2.63 5.91E-06 0.0143 
WNT5A 3.65 7.08E-06 0.0163 
EPHA4 2.83 7.82E-06 0.0167 
LOC105377108 2.35 7.96E-06 0.0167 
Uncharacterized 2.94 9.81E-06 0.0197 
NRP1 3.75 1.02E-05 0.0197 
GLIPR1 4.1 1.06E-05 0.0197 
Uncharacterized 4.1 1.17E-05 0.0209 
FLI1 2.26 1.29E-05 0.0222 
RAB27B 4.05 1.38E-05 0.023 
ADGRF1 3.36 1.48E-05 0.0235 
PAPSS2 2.43 1.51E-05 0.0235 
COL4A2 2.03 1.58E-05 0.0238 
GEM 2.36 1.65E-05 0.0241 
NFE2L3 2.26 1.76E-05 0.0244 
SLITRK6 9.41 1.77E-05 0.0244 
ARNTL2 2.99 2.04E-05 0.0273 
NEBL 2.19 2.24E-05 0.0279 
IL1RL1 2.33 2.25E-05 0.0279 
THSD4 2.42 2.26E-05 0.0279 
USP53 2.58 2.37E-05 0.0285 
SLIT3 2.06 2.54E-05 0.0299 
KYNU 2.95 2.65E-05 0.0299 
LOC105379362 2.97 2.72E-05 0.0299 
STC1 5.47 2.73E-05 0.0299 
CEMIP 3.86 2.99E-05 0.032 
IRF4 -3.57 3.10E-05 0.0322 
SV2C 2.27 3.14E-05 0.0322 
ME3 2.14 3.38E-05 0.0334 
CLMP 2.26 3.79E-05 0.0364 
FZD8; MIR4683 2.21 3.85E-05 0.0364 
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NT5E 2.66 3.92E-05 0.0364 
TGFB1 2.06 4.02E-05 0.0366 
F2RL2 2.7 4.41E-05 0.0394 
C15orf54 2.88 4.64E-05 0.0396 
PRR9 2.76 4.66E-05 0.0396 
PPARG 2.35 4.69E-05 0.0396 
ENC1 2.32 5.28E-05 0.0426 
Uncharacterized -2.33 5.31E-05 0.0426 
KCNIP4-IT1 2.41 5.39E-05 0.0426 
KCNN4 2.56 5.64E-05 0.043 
PGM5P2 2.19 5.66E-05 0.043 
HACL1 2.23 5.71E-05 0.043 
SIRPB1 2.02 6.04E-05 0.0448 
PXDN 3.55 6.42E-05 0.0463 
GPX1 2.55 6.49E-05 0.0463 
CADM4 2.1 6.52E-05 0.0463 
ZNF860 2.01 6.95E-05 0.0481 
FLT1 2.06 6.98E-05 0.0481 
SAMD5 2.73 7.26E-05 0.049 
TRIM58; OR2W3 2.82 7.52E-05 0.0497 
Uncharacterized 2.82 7.86E-05 0.0512 
TGFA 3.54 8.03E-05 0.0512 
GLIS3 3.35 8.07E-05 0.0512 
TLR4 5.99 8.17E-05 0.0512 
LOC105379109 2.56 8.67E-05 0.0536 
MIR548XHG 3.18 9.05E-05 0.0553 
SULF1 5.03 9.23E-05 0.0556 
Uncharacterized 2.41 9.48E-05 0.0561 
FAM135B 2.55 9.55E-05 0.0561 
SLC24A3 3.76 9.68E-05 0.0563 
PTHLH 2.9 9.99E-05 0.0573 
MMP2 2.04 0.0001 0.0592 
ITGA3 2.24 0.0001 0.0592 
SFRP1 2.3 0.0001 0.0592 
PMEPA1 2.45 0.0001 0.064 
DAPK1 -2.01 0.0001 0.0656 
PRDM1 2.88 0.0001 0.0663 
ZNF385A 2.17 0.0001 0.0681 




6.3.3 Differential expression functional analysis of the microarray 
results: 
Functional analysis of the first dataset (rAmbra overexpression) was not 
considered due to the high false discovery rate. The second data set was 
analyzed by submitting the 81 characterized differentially expressed genes to 
STRING protein-protein interaction tool, KEGG pathways tool and Go biological 
process tool (2.215).  
STRING analyses showed that the list of the upregulated genes centers around 
VEGFA on the protein level (Figure 6.9). 
 




Figure: 6.9: STRING analysis of the 81 differentially expressed genes 
resulting from Ambra1 knockdown. The analysis shows that a large number 
of the coded proteins of the differentially expressed genes are linked by 
different interactions and centers on VEGFA. 
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KEGG pathways were used to detect which pathways are related to the Ambra1 
knock-down and the five top pathways are presented in table 6.5. Axon 
guidance, PI3K-AKt, Ras and MAPK pathways were among the top pathways 
affected by the knock down of Ambra1. 
Table 6.5: KEGG pathway showing top five pathways affected by Ambra1 
knockdown. 





hsa04360 Axon guidance 12 173 0.0001
5 
hsa05200 Pathways in cancer 18 515 0.0018 
hsa04060 Cytokine-cytokine 
receptor interaction 
12 263 0.0024 
hsa04151 PI3K-Akt signaling 
pathway 
14 348 0.0024 












GO biological process was used to detect the top biological processes affected 
by Ambra1 knock-down (Table 6.6). On top of this list is angiogenesis which 
support STRING analysis results that the knockdown of Ambra1 largely affects 
VEGFA. The list also includes axon guidance, as well as MAPK activation 
Table 6.6: GO biological processes showing top biological processes 
affected by Ambra1 knockdown. 





GO:0048843~negative regulation of axon extension 





GO:0071560~cellular response to transforming 








































6.3.4 Western blot analysis to confirm differential genes 
overexpression 
To confirm the effect of Ambra1 gene knockdown on the protein level of 
differentially expressed analysis; two key candidates were selected to confirm 
their over expression by western blots analysis, Wnt5a and FLT1 (VEGFR-1) 
(2.2.4). Wnt5a western blot analysis (Figure 6.10) showed a band for Wnt5a 
at~50 KDa in the ShAmb cell lines only. These results confirmed significant 
Wnt5a overexpression in the ShAmb cell lines. Statistical analysis was 
performed by comparing normalized band intensities to normalized adjusted 
volumes of total proteins loaded. Wnt5a western blots were performed by 
chemiluminescence using a HRP-conjugated secondary antibody. The FLT1 
western blots were unsuccessfully performed using the traditional HRP-
conjugated secondary antibody, human protein atlas show that FLT1 
expression in skin is less than WNT5A so we considered a more sensitive 
approach to detect FLT1 and therefore; western blots were performed using a 
fluorescent Alexa fluor448 conjugated secondary antibody. Western analysis of 
FLT1 was performed (Figure 6.11), a band was observed in the ShAmb cell 
lines only for FLT1 at~100 KDa. Bands were normalized against adjusted 
volume of protein loaded. Results were statistically significant for FLT1 







Figure 6.10: Western blot analysis of WNT5A from Ambra1 knockdown 
model. (A) Lanes 2 to 4 and 5t o 7 are replicates of two ShAmb biological 
extracts from different passages and, lanes 9 to 11 and 12 to 14 are replicates 
of two ShCon biological extracts from different passages. A band for Wnt5a is 
observed at ~50 KDa after 9 seconds exposure for ShAmb cell lines which 
cannot be observed for the ShCon. (B) Normalized band intensities against 
adjusted volumes of total proteins loaded. Statistics: Mann-whitney U-test 











Figure 6.11: Western blot analysis of FLT1 from Ambra1 knockdown 
model. (A) Lanes (2 and 3) and (4 and 5) are replicates of two ShAmb 
biological extracts from different passages and, lanes (7 and 8) and (9 and 10) 
are replicates of two ShCon biological extracts from different passages. A band 
for FLT1 is observed at ~100 KDa for ShAmb cell lines which cannot be 
observed for the ShCon. (B) Normalized band intensities against adjusted 
volumes of total proteins loaded. Statistics: Mann-whitney U-test significant Bar 







FLT1 and WNT5A differential expression data generated by the microarrays 
and the western blots as a result of the knockdown of Ambra1 were compared 
(Table 6.7), the microarray data showed that WNT5a was 3.65 folds 
overexpressed on the transcription level and western blot analysis showed that 
it is 5.2 folds overexpressed on the protein level. Both microarrays and western 
blot analysis showed FLT1 to be about 2 folds upregulated. 
Table 6.7: FLT1 and WNT5A microarrays and western blot analyses 
differential expression fold change as a result of Ambra1 knockdown.  
Gene/protein name Gene upregulation fold 
change detected by 
Microarray 
Protein upregulation 
fold change detected by 
Western blot 
FLT1 2.06 (p-value 6.98E-05) 2.021 (p-value: 0.043) 




6.3.5 Further analyses 
It was important to further analyze the data generated from Ambra1 differential 
expression to allow investigating roles of the differentially expressed genes and 
clustering them into groups that can help understand the mechanisms by which 
Ambra1 can affect different cellular processes. 
6.3.5.1 Analyses of differentially expressed genes that may affect cell 
cycle 
NAA11 is differentially expressed as a result of Ambra1 overexpression, and 
was found to be of a specific importance in cell proliferation, it can affect the 
activity of cyclin dependent kinases. To understand its interaction with different 
cell cycle components a STRING analysis of NAA11 was performed (Figure 
6.12), the analysis show that it can interact directly and indirectly with cell cycle 
components like CDC25A and CDC25B. 
In relation to cell cycle, there is also TRIM63 that was found to be differentially 
expressed in this study, a STRING protein analysis was performed to 
demonstrate the link between TRIM63 and different cell cycle components 











































































































































































































Figure 6.13 STRING protein analysis of TRIM63. Analysis show TRIM63 can 




6.3.5.2 Analyses of differentially expressed genes that may affect 
angiogenesis 
STRING protein analysis performed in figure 6.9 for the whole set of the 
proteins that are encoded by different genes affected by Ambra1 knockdown 
show that many of these proteins center on VEGF-A, in order to study and 
demonstrate this effect, selected genes that may affect angiogenesis (Table 
6.8) were analyzed using the STRING tool (Figure 6.14). Analysis shows that at 
least 21 of the differentially expressed genes can directly and/or indirectly affect 
VEGF-A including VEGFR-1 (FLT1) and VEGFR-2 (KDR). 
Table 6.8: VEGF related genes differential expression in the Knockdown 
model 
Gene name Folds overexpression in 
ShAmb cells 
FDR P-val 
SEMA3C 3.74 0.0079 
WNT5A 3.65 0.0163 
TGFB1 2.06 0.0366 
FLT1 2.06 0.0481 
TGFA 3.54 0.0512 
JAG1 3.39 0.0126 
ITGA3 2.24 0.0592 
SEMA3A 3.11 0.0079 
EPHA4 2.83 0.0167 
PRDM1 2.88 0.0663 
PPARG 2.35 0.0396 
IL1RL1 2.33 0.0279 
TLR4 5.33 0.0512 
PTHLH 2.9 0.0573 
MMP2 2.04 0.0592 
NT5E 2.66 0.0364 
FLI1 2.26 0.0222 
IL24 -2.85 0.0134 
STC1 5.47 0.0299 
NRP1 3.75 0.0197 





Figure 6.14: string analysis of selected differentially expressed genes. 
Analysis shows a network of interaction that directly affects VEGF-A resulting 




6.3.5.3 Analyses of differentially expressed genes that may affect 
melanoma cell proliferation 
Microarray differential expression data was analyzed to search for key genes 
that can affect the proliferation of melanoma, key melanoma related genes were 
identified and are listed in table 6.9 
Table 6.9: melanoma progression related genes identified to be 
differentially expressed upon Ambra1 knockdown. The table compares 
ShAmb. Vs. ShCon and it includes the gene name, gene symbol, fold change, 
P-value and FDR. 












BANCR -3.46 0.0149 0.5095 
growth hormone receptor GHR 
 
-2.04 0.0036 0.2977 
RAB17, member RAS 
oncogene family 
RAB17 -2.03 0.0031 0.2801 
RAB38, member RAS 
oncogene family 
RAB38 -2 0.0153 0.5109 





Ras association (RalGDS/AF-6) 
domain family member 3 
RASSF3 -2.06 0.0007 0.1407 
secreted frizzled-related protein 
1 
SFRP1 2.3 0.0001 0.0592 
insulin like growth factor binding 
protein 5 
IGFBP5 5.27 0.002 0.2287 





Microarray studies require careful planning and development of analysis 
strategies. However, to be most effective it requires a design of a study to 
answer well-defined questions (Simon et al., 2002). The clear question of this 
study was what are the effects of Ambra1 differential expression on 
transcriptomic regulation? Questions also included: What are the possible 
mechanisms by which Ambra1 can regulate cell proliferation other than its 
reported activity on c-Myc? And how can Ambra1 knockdown inhibit melanoma 
cells proliferation? 
To answer these questions, microarrays studies were designed to utilize the 
A375 cell lines that differentially express Ambra1 (rAmbra and ShAmb) and 
compare the effect of altering Ambra1 levels to a matching control. The 
Affymetrix Gene Chip Human Gene 2.0 ST Array used in this study includes 
more than 53,000 probe sets offering a highly comprehensive expression 
analysis of the entire genome. Also the characterization of the cell lines used in 
this study (chapter 3) contributed to design an effective microarray analysis, as 
RNA extractions were performed after 72 hours of seeding the cells with no 
antibiotic selection, this step was crucial to allow for most of the population of 
each cell line to be expressing Ambra1 at the desired level. Lastly, four 
replicates of each cell line were submitted to the array analysis as having 
replicates for each RNA specimen permits discarding bad arrays (Simon et al., 
2002). 
Differential expression of Ambra1 in this study shows a great alteration in 
pathways that are related to cell proliferation and cancer prognosis, reviewing 
the role of Ambra1 in cancer shows that it is not fully clear and two views 
predominate. The first is that Ambra1 acts as a tumor suppressor gene as it 
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decreases cell proliferation (1.6.5 and 3.4), also Ambra1 deficient mice have a 
higher rate of tumorigenesis compared to the controls (Cianfanelli et al., 2015).  
Secondly there is evidence that Ambra1 over expression in cancer is favorable 
to the tumor in different ways. However, evidence largely relates this effect to 
autophagy. A study has related the role of Ambra in the cross talk between 
autophagy and apoptosis to its pro survival role in SW620 colorectal cancer cell 
line, as it contributes to shifting the cells towards autophagy and survival rather 
than apoptosis (Gu et al., 2014), another has shown that the overexpression of 
Ambra1 is significantly correlated with lymph node metastasis and poor survival 
rate of the patients in cholangiocarcinoma (Nitta et al., 2014). 
Data showing levels of Ambra1 expression in cancer cells and its role in 
tumorigenesis is limited. However; some studies have reported Ambra1 
overexpression in the late stages of a variety of cancers. For example: Ambra1 
is expressed in ~63.9% of pancreatic ductal adenocarcinoma. However; the 
exact levels of Ambra1 were not measured neither were related to prognosis of 
this cancer (Ko et al., 2013), “perineural invasion” a negative prognostic factor 
for cancer therapy is associated with Ambra1 overexpression in prostate 
cancer, gastric adenocarcinoma (Qu et al., 2017) and cholangiocarcinoma 
(Nitta et al., 2014; Sun, 2016). More recently a meta-analysis clearly related 
Ambra1 up regulation to tumorigenesis and progression of breast cancer using 
data from 25 microarrays datasets that included 2460 breast cancer samples 
(He et al., 2018). Also a recent study suggest a role of Ambra1 in cancer cell 
resistance to therapy by showing that higher levels of Ambra1 are associated 
with resistance of breast cancer cells to the most currently used breast cancer 
treatment  Epirubicin  (Sun et al., 2018). The underlying mechanism of how 
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Ambra1 can make such a difference in the treatment of cancer remains 
unknown.  
On the other hand, a recent study reported that Ambra1/Loricrin loss in stage I 
melanomas indicates worse prognosis independent of Breslow depth (Ellis et 
al., 2019), levels of Ambra1 reported in that study are in the epidermis 
surrounding tumors and not in the tumor itself. But this gives indications that 
Ambra1 loss is favorable for tumor in early stages. The role of Ambra1 in cell 
proliferation and cancer can be explained by different effects of the highlighted 
gene in different cancer stages from initiation to progression and metastasis. 
Generally it seems that Ambra1 loss is favored to tumor development. However; 
its overexpression in a well-developed cancer can contribute to cancer 
survivability and treatment resistance, this role also appear to be parallel to the 
role of autophagy in cancer (1.5). However, Ambra1 is also reported to have 
roles in differentiation, apoptosis, and development in addition to its roles 
mentioned above (1.6), and more research is required to investigate its role in 
cell proliferation and cancer and if its role in cancer is related to its well defined 
role in autophagy.. 
FDR is an essential statistical tool in “omics” due to the large number of data 
points and only adjusted P-values are really considered significant. After 
adjusting the P-values using FDR to account for multiple correction testing there 
were few significant genes differentially regulated when comparing the rAmbra 
cell line to its control showing that either Ambra1 overexpression in this cell line 
model is not of a great effect on the transcriptome or, that Ambra1 is already 
expressed to a level which exerts its maximum effect in this malignant cell line. 
Ambra1 was confirmed to be upregulated in the rAmbra cells, also the two 
significantly upregulated genes in this dataset that lie in an acceptable FDR 
225 
 
value CDH13 and NAA11 are of specific importance. CDH13 is well reported to 
be down regulated in the malignant melanoma. Loss of this specific gene is 
reported to have a role in metastasis and the expression of this gene in a 
different melanoma model reduces the tumor invasiveness (Kuphal et al., 
2009), a study has shown that tumor growth was diminished after subcutaneous 
injection of CDH13 positive melanoma cells compared with CDH13 negative 
cells in nude mice (Bosserhoff et al., 2014) the same study has reported that 
the decreased cell proliferation was due to induced apoptosis in the CDH13 
positive model, this effect was found to be mediated by the inhibition of AKT 
signaling as well as, antiapoptotic molecules like BCL-2 and BCL-x . 
Considering this data supports the evidence that Ambra1 is a tumor suppressor 
gene. The relationship between the loss of Ambra1 and developing a worse 
metastatic cancer (Ellis et al., 2019) can be partially explained by our findings 
that Ambra1 may promote CDH13 expression leading to AKT 
hypophosphorylation and downregulation of the antiapoptotic molecules BCL‐2, 
BCL‐x and Clusterin. 
NAA11 is proposed to be an alternative catalytic subunit of the N-terminal 
acetyltransferase A (NatA) complex.1 and it displays an alpha (N-terminal) 
acetyltransferase activity. NAA11 can acetyl different components of the cell 
cycle and its acetylation of CDC25A can modulate the extent of Cdc25A 
ubiquitination, diminish its phosphatase activity and disrupts cell cycle (Lozada 
et al., 2016).  Literature lacks enough data about the role of NAA11 or its 
expression. One study has limited the expression of NAA11 to placenta and 
testis assuming that they did not find any of the tissue reported expression of 
NAA11 in previous studies (Pang et al., 2011). In contrast, another study 
reported that NAA11 was among the top 20 genes with the most altered RNA 
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expression levels in vitiligo patients, which indicates that NAA11 expression can 
well be extended in melanocytes (Reimann et al., 2014). STRING protein 
network shows a direct interaction between NAA11 and cyclin dependent 
kinases through the acetylation of CDC25A in homo-sapiens and CDC25B in 
Bos-Taurus. The interaction with CDC25B is reported in homo-sapiens to take 
place indirectly through MAPK14 (Figure 6.12) which is a key activator of cyclin 
dependent kinases (Lammer et al., 1998) CDC25A is overexpressed in different 
types of cancer, its function as stated by UniProt is “Tyrosine protein 
phosphatase which functions as a dosage-dependent inducer of mitotic 
progression. Directly dephosphorylates CDK1 and stimulates its kinase activity. 
Also dephosphorylates CDK2 in complex with cyclin E, in vitro”. Similarly, 
CDC25B directly dephosphorylates CDK1 and stimulates its kinase activity, it is 
also an inducer of mitotic progression. Data generated by this study suggests 
Ambra1 functions to upregulate NAA11 which suggests that Ambra1 may have 
a role in cell proliferation by disrupting cell cycle as a result of the CDC25A 
acetylation by NAA11. Confirmatory experiments should be carried on to 
investigate the expression of NAA11 in skin, its role and function in acetylation 
of the cyclin dependent kinases and the degree of expression in melanoma, 
also to prove this novel role of Ambra1, levels of NAA11 and ubiquitination of 
CDC25A should be monitored upon Ambra1 overexpression in normal cells. 
To add to the suggested Ambra1 effect on cyclin dependent kinases, this study 
suggests Ambra1 functions to inhibit TRIM63 (Appendix 2), which is an 
oncogene that is overexpressed in melanoma and was described as a signature 
gene in an analysis that used expression profiles for 240 tumor samples from 
eight cancer types and 63 melanoma cell lines (Rambow et al., 2015). TRIM63 
which is an E3 ubiquitin ligase can interact with members of the CDK and MAP 
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cascades like CDC20, CDC23, CDC27 and FZR1 (Figure 6.13) Ambra1 
knockdown results in the downregulation of TRIM63 which may suggest a role 
of Ambra1 in cell proliferation by decreasing the expression of  this oncogene. 
However, this finding to be valid a confirmatory experiment is required as the 
false discovery rate of TRIM63 downregulation is relatively high (P-value 
0.0009, FDR 0.158). 
Results from studying the effect of Ambra1 on differentially expressed genes 
that can affect cell cycle components in this study, show that Ambra1 may 
functions to disrupt of cell cycle and subsequently inhibit cell proliferation. 
As mentioned before the knockdown of Ambra1 appears to be highly 
unfavorable to the cancer model used in this study, and result in a significant 
decrease in cell proliferation, results from this study suggest that in a well-
developed metastatic cancer Ambra1 is essential for the survival and 
proliferation of Cancer cells (3.4). 
Analyzing the second dataset (ShAmb vs ShCon) showed more wide ranging 
effect on the transcriptome as a result of Ambra1 knockdown. Functional 
analysis of these genes gives more insight about Ambra1 different roles in 
cellular functions and molecular pathways. Perhaps one of the strongest 
findings is that Ambra1 knock-down appears to alter the expression levels of 
angiogenesis related genes. There is differential expression in 8 genes 
(COL4A2, FLT1, FZD8, JAG1, MMP2, MEOX2, NRP1 and TGFA) that are 
involved in angiogenesis biological process, and 20 genes that encode proteins 
which interact with VEGF-A (Figure 6.14), these genes and their fold change in 
the ShAmb cell lines compared to the ShCon are shown in table 6.8, which 
shows that all angiogenesis related genes were found to be overexpressed in 
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the ShAmb cell lines but IL24. It is important to mention that both vascular 
endothelial growth factor receptors VEGFR-1 (FLT1) and VEGFR-2 (KDR) are 
up-regulated as a result of Ambra1 knockdown, suggesting that AMBRA1 
functions to inhibit their expression. FLT1 levels were confirmed to be higher in 
the ShAmb cell lines by western blot analysis (Figure 6.11). Although KDR up 
regulation has an FDR value of 0.11 (Appendix 2), it will be of a specific 
importance to study KDR levels as a result of Ambra1 inhibition, as if Ambra1 
can be proven to inhibit the two VEGF receptors as well as all the previously 
mentioned angiogenesis related genes, it will prove a novel role of Ambra1 in 
regulating angiogenesis. 
Tumor growth and metastasis largely depend on angiogenesis, angiogenic 
activators play an important part in the growth and spread of tumors (Nishida et 
al., 2006). VEGF is defined as one of the major therapeutic targets in 
melanoma. Studies have shown that there is a direct correlation between the 
levels of VEGF and the progression of melanoma. Moreover; VEGF is at 
highest levels in the malignant phase of many tumors (Carmeliet, 2005). The 
primary functions of VEGF-A are to promote blood vessel dilation and 
permeability and to induce new blood vessel formation. In one particular study 
that measured the levels of expression of cancer related genes in primary oral 
melanoma patients; VEGF was more expressed in the melanocytes of 70% of 
melanoma patients and this study proved an inverse correlation between VEGF 
levels and overall survival (Simonetti et al., 2015). VEGF-A  is overexpressed 
by the vast majority of tumors studied, and circulating levels of VEGF-A are 
elevated in many patients with cancer. 
This finding is of a great importance as if Ambra1 can function to decrease 
angiogenesis in both healthy and primary cancer cells, then this will support the 
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evidence that it is a tumor suppressor gene. It can also give a possible 
explanation to the finding that Ambra1 loss in epidermis surrounding melanoma 
stage I is related to worse prognosis, it may be well due to increased 
angiogenesis which leads to more aggressive tumor formation. It is of a specific 
importance to monitor Ambra1 and VEGFs levels during tumorigenesis and 
metastasis to prove this suggestion. However, this finding does not explain why 
the proliferation rate is decreased upon the knockdown of Ambra1, if Ambra1 
can function to inhibit angiogenesis, then decreasing Ambra1 levels should 
result in increased angiogenesis, and therefore increased proliferation and 
malignancy, but results in this study show that cell proliferation is decreased 
upon Ambra1 inhibition despite increased levels of angiogenesis related genes. 
Interestingly on the list of angiogenesis related genes, there are few 
differentially expressed genes that are reported to be involved in cancer cell 
proliferation. Perhaps one of the most important genes on the list is WNT5A 
which is a member of the WNT family that signals through both the canonical 
and non-canonical WNT pathways. The role of WNT5A in cancer remains under 
investigation (Asem et al., 2016). WNT5A signaling was strongly correlated to 
melanoma invasion of metastatic melanoma, and its expression in human 
melanoma biopsies directly correlated to increasing tumor grade (Weeraratna et 
al., 2002). WNT5A is most often associated with non-canonical Wnt signalling 
(McDonald and Silver, 2009). 
This study shows that Ambra1 may function to inhibit WNT5A, which can add to 
the evidence that Ambra1 can act as a tumor suppressor gene. The finding that 
Ambra1 knockdown result in increased WNT5A levels was confirmed by 
western blot analysis (Figure 6.10).  
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Two angiogenesis regulators semaphorin-3A (SEMA3A) and semaphorin-3c 
(SEMA3C) are also found to be overexpressed in ShAmb cells, which suggest 
Ambra1 functions to inhibit SEMA3A, and SEMA3C. SEMA3A is potential 
inhibitors of tumorigenesis and angiogenesis in mice melanoma models 
(Chakraborty et al., 2012) its overexpression can dramatically decrease tumor 
vascularization and promote apoptosis, this effect was shown to be mediated 
though neuropillin1 (NRP1) receptors which are also up-regulated as a result of 
Ambra1 knock-down. Surprisingly, however, SEMA3A is reported to be 
secreted by tumor cells and has major functions in regulating the tumor 
microenvironment (Capparuccia and Tamagnone, 2009). On the other hand, the 
full length SEMA3C protein can directly inhibit VEGF-A and decrease 
metastasis (Mumblat et al., 2015), and in an analysis that compared the 
microarray data from 31 primary melanomas to 52 metastatic melanomas 
SEMA3C was among the top down regulated genes in metastatic melanoma 
(Qiu et al., 2015). Not only SEMA3C and SEMA3A but also other semaphorins 
like SEMA5A and SEMA3B were differentially expressed in the ShAmb 
(Appendix 2). A summary of the role of these different semaphorins in cancer is 
shown in table 6.10.  
Table 6.10: differentially expressed semaphorins as a result of Ambra1 
knock-down showing the fold change, the role of each gene in cancer and the 
references 
Gene name Fold change Role in cancer Reference 
SEMA3A 3.11 Inhibits angiogenesis and 
tumorigenesis 
Chakraborty et al., 
2012 
SEMA3C 3.74 Decrease metastasis Mumblat et al., 2015 
SEMA3B 2.44 Tumor suppressor  Neufeld et al., 2012 
SEMA5A -2.38 Angiogenesis inducer Neufeld et al., 2012 
 
Semaphorins signaling has been reported to be involved in regulating cell 
adhesion and motility, and tumor progression (Capparuccia and Tamagnone, 
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2009). While individual semaphorins on the list of the differentially expressed 
genes appear to have a negative effect on angiogenesis, the end result of 
semaphorins activation is not necessarily inhibiting tumorigenesis, semaphorins 
dysregulation has been linked to tumor progression (Neufeld et al., 2012). 
Moreover, semaphorins seems essential for the cross talk between cancer cells 
and may play a role in the metastasis process (Capparuccia and Tamagnone, 
2009). Semaphorins are also involved in semaphorin-plexin signaling pathway, 
which is reported to be involved in axon guidance and regulating the 
morphology and motility in many different cell types (Alto and Terman, 2017). 
Data generated in this study suggests that Ambra1 functions to inhibit NRP1 as 
well as PLXNA2, which is a co-receptor for SEMA3A and is involved in a 
complex with neuropillins (Capparuccia and Tamagnone, 2009). 
Results from this study suggest that Ambra1 may function to alter the 
expression of different semaphorins, while it is hard to assess the net outcome 
of the differentially expressed semaphorins, it gives an indication that Ambra1 
may be a regulator of this pathway and that it may be a new mechanism by 
which Ambra1 can exert an effect on cell motility and cancer progression. 
Moreover, axon guidance was among the top pathways identified by KEGG 
pathways and the top biological processes identified by GO to be affected by 
the knock-down of Ambra1. The suggested role of Ambra1 in this signaling 
pathway reported in this study can be supported by the finding of six different 
components of this pathway to be differentially expressed as a result of Ambra1 
knockdown: SEMA3A, SEMA3B, SEMA3C, SEMA5A, NRP1 and PLXNA2. 
Further analysis of the Ambra1 knockdown dataset was performed to find key 
melanoma cell proliferation regulators that can explain the decreased cellular 
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proliferation in the ShAmb. Few genes were identified that are of known role in 
melanoma progression (Table 6.10). 
On top of the list sits the BRAF-activated non-protein coding RNA (BANCR) 
which appeared to be down regulated as a result of Ambra1 knockdown. 
BANCR is upregulated in different types of melanoma and can interacts with 
chemokine CXCL11 to promote melanoma cell migration. It can also activate 
ERK1/2 and JNK MAPK pathway to promote proliferation (Hulstaert et al., 
2017), (Li et al., 2014). The second identified gene was growth hormone 
receptor (GHR), data suggests that Ambra1 function to increase the expression 
of this gene. GHR is well known to be an oncogene in many cancers including 
melanoma. GHR role in melanoma is well established to activate different 
pathways in the melanoma progression like ERK1/2, STAT1, STAT3, STAT5, 
AKT and mTOR. The knock-down of GHR in four melanoma cell lines affected 
the growth and the progression of the tumor cells (Basu et al., 2017).  
Three genes from the RAS family appeared to be down-regulated: RAB17, 
RAB38 and RASSF3. RAB27B appeared to be upregulated. RAB17 has been 
linked to melanocyte pigmentation (Beaumont et al., 2011). There is not enough 
data about its role in melanoma. However; the human protein atlas reports that 
7 out of 11 melanoma patients have this gene overexpressed. RAB38 mRNA 
was found to be overexpressed in 80-90% of melanoma patients. It is the only 
RAB that shows a predominant expression in melanocytes and is related to 
melanosomal transport and docking (Jäger et al., 2000). The last down-
regulated RAS member is RASSF3 which is known to be expressed in 
melanoma. But if it acts as a tumor suppressor or as an oncogene remains 
unclear (van der Weyden and Adams, 2007). RASSF3 can interact with PP2CA, 
the latter is proven to be an Ambra1 binding partner (Cianfanelli et al., 2015). 
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The only up-regulated gene in the RAS family is RAB27B which role has been 
shown to regulate the movement of melanosomes and suggested to maintain 
the dendritic extensions in melanocytes (Chen et al., 2002). This study suggests 
Ambr1 function to inhibit SFRP1 which is known to interact with the WNT-
frizzled signalling pathway. It is suggested that SFRPs can bind different WNTs 
and massively affect their activity. Data from this study suggests Ambra1 
function to inhibit SFRP1 expression, which is the only protein form the frizzled-
related proteins family that shows a tumor suppressor activity and its over 
expression can be beneficial to treat malignancies (Vincent and Postovit, 2017). 
This study also suggests Ambra1 function to inhibit IGFBP5. This gene is of a 
particular importance and is proven to be a tumor suppressor gene. The over 
expression of IGFBP5 in a study that used the same melanoma cell lines A375 
showed significant inhibition of cancer cell proliferation, invasion and migration 
in vitro. The capability of this gene to exert this effect was related to the 
reduction of the phosphorylation of IGF1R, ERK1/2, and p38-MAPK kinases, 
and decreasing the expression of HIF1α and its target genes (Wang et al., 
2015). Results suggest that Ambra function to inhibit INHBA expression, which 
is known to be one of the TGF-β superfamily. It is strongly related to different 
cell signaling pathways involved in cell cycle arrest, cell differentiation and cell 
development, it shows a cytokine activity and is also involved in MAPK 
pathways (Singh et al., 2018).  
Differential expression of these key genes mentioned above can give a possible 
explanation to how the decreased melanoma cell proliferation can be mediated 
by the knockdown of Ambra1 in a late stage cancer, it appears that the 
knockdown of Ambra1 results in a dysregulation of the RAS/RAF/MAPK as well 
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as PI3K/AKT/mTOR pathways, which are known to be key driver pathways in 
melanoma (1.4). 
The list of the differentially expressed genes also suggests that Ambra1 
functions to inhibit TGFβ1 and INHBA as mentioned before. What is surprising 
is that Ambra1 overexpression also resulted in the up-regulation of INHBA 
(Appendix 1). This means that apparently altering Ambra1 levels either by over-
expression or knocking-down may result in the overexpression of components 
of the TGF-β superfamily, if this finding can be confirmed then it will identify a 
novel role of Ambra1 in cell proliferation as well as, differentiation and migration 
that can be mediated by this pathway. 
In conclusion, results from this study show that Ambra1 role as a tumor 
suppressor gene may well be extended beyond its effect on c-Myc and can be a 
result of Ambra1 effect on angiogenesis related genes and WNT signaling. 
Combining results in this study with what is already known about Ambra1 show 
that its role in melanoma can indeed be parallel to the role of autophagy, this 
study suggests that Ambra1 loss is required for tumorigenesis and malignancy 
and adds to the evidence that Ambra1 is a tumor suppressor gene, but in late 
stage cancer its expression can help the malignant cells to survive. Despite the 
parallel roles of autophagy and Ambra1 in cancer, it is still unknown if Ambra1 
mediates its effects on tumors by its role in autophagy or by a distinct 
mechanism. Results from this study suggest that this role can be mediated by 
pathways other than autophagy.  
This study suggests that Ambra1 is essential for melanoma cell proliferation and 
its knock-down results in decreased cell proliferation in-vitro. It also suggest that 
Ambra1 is a potential interactor with hall mark cell biological processes and 
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signaling pathways like angiogenesis, Cyclin dependent kinases, semaphoring-



































7.1 prelude to final discussion 
Ambra1 is defined as an important component of the autophagy machinery. 
Upon autophagic stimuli Ambra1 activates beclin1, an event which is followed 
by a cascade of interactions that allow autophagy to take place. Since its 
discovery in 2007 as an autophagy regulator by Beclin1 activation and as a 
regulator of development of the nervous system (Maria Fimia et al., 2007) 
Ambra1 has been extensively studied. It is becoming clear that a range of 
different cellular processes that can be linked to this protein and it appears to 
play a role in a number of cancers. However, most of Ambra1’s identified roles 
are still focused on autophagy with few other reports on its roles in other cellular 
processes. The aim of this project was to explore this, initially by looking at its 
role in cellular proliferation but as the project progressed this broadened out. 
Understanding the complex relationship between genotype and phenotype is 
largely a fundamental goal of molecular research. The systems-based approach 
is dependent on the detection and precise quantification of the molecular 
diversity of the cell at the levels of the genome, transcriptome, proteome and 
interactome (Figure 7.1) (Bludau and Aebersold, 2020). This study attempted to 
study Ambra1 using every “omic” level except genomics. RNA microarrays were 
performed to study the change of the transcriptome resulting from Ambra1 
differential expression.  A number of proteomic approaches were used to study 
the proteome and interactome level. Of these the yeast two hybrid based 
approach was most successful and identified potentially novel Ambra1 binding 
partners. A summary of novel roles and pathways that involve Ambra1 in A375 




Figure 7.1: The generation of functional diversity at different molecular 
levels. In contrast to the ‘one gene, one protein, one function’ paradigm, cellular 
complexity arises from many mechanisms that expand molecular diversity 
beyond that encoded by the protein-coding genome. These mechanisms 
include an increase in coding potential using alternative transcription start sites 
as well as 5′ capping, alternative splicing, alternative polyadenylation and RNA 
editing at the co-transcriptional or post-transcriptional level. The diversity of 
proteins is further increased using alternative start and stop codons during 
translation. A high degree of diversification is introduced by post-translational 
modifications, which include covalent cleavages and covalent modifications 
(such as phosphorylation (P)). Finally, proteins can interact with each other to 
form multiple distinct functional units that can potentially perform various 
downstream functions. Although recent technological advances provide 
headway towards fully characterizing the transcriptome, proteome and 
interactome and their relationships in any given state, the assessment of their 
functional impact and the phenotype is a challenge that still remains to be fully 







































































































































































7.2 Ambra1 role in cell proliferation 
7.2.1 Ambra1 role in melanoma cells proliferation rate 
As discussed in the introduction chapter, Ambra1 has been linked with a role in 
cell proliferation. In normal cells Ambra1 loss is associated with non-developed 
hyper-proliferative cells (Benato et al., 2013) and,  also associated with higher 
mRNA levels of cyclins A and B (Cianfanelli et al., 2015). In early stage 
melanoma the loss of Ambra1 is associated with higher risk tumors (3.4) 
In this study we report that in metastatic A375 melanoma cells the 
overexpression of Ambra1 did not appear to significantly affect the 
transcriptome, proteome nor metabolome of the A375 cell lines. Growth curve 
analyses showed that Ambra1 overexpression appears to have no effect on the 
proliferation rate in an environment where nutrition is not limited. However, 
knockdown of Ambra1 resulted in decreased cell proliferation, this was shown 
by both SRB assays and Incucyte live cell imaging. A simple explanation is that 
the blockage of autophagy by Ambra1 knockdown is essential and that 
melanoma cells need the autophagy machinery to avoid apoptosis and cell 
death (Sun, 2016). However, the transcriptional analysis of the Ambra1 
knockdown suggests that Ambra1 has a much wider role across a range of 
cellular processes that are affected by its loss.  Are the transcriptional changes 
directly attributable to the loss of Ambra1 or as a result of defective autophagy? 




7.2.2 Ambra1 interacts with cell cycle components 
There is a relationship between autophagy and cell cycle that has been well 
reported and reviewed in literature (Mathiassen et al., 2017). The mechanism 
by which Ambra1 can affect cell cycle components has been reported to be 
through interaction with C-Myc and PP2CA in a study that demonstrated 
elevated levels of Cyclins A and B upon Ambra1 depletion (Cianfanelli et al., 
2015). 
This study provides a possible link between Ambra1 and cell cycle components. 
It appears that Ambra1 can alter the expression of the N-terminal 
acetyltransferase, NAA11, which is an alternative catalytic subunit of the N-
terminal acetyltransferase A (NatA) complex1; NAA11 can modulate the extent 
of CdC25A ubiquitination, diminish its phosphatase activity and disrupts cell 
cycle (Lozada et al., 2016). This study suggests that activation of Ambra1 can 
inhibit CDC25A by promoting its acetylation by NAA11. It also show that 
Ambra1 may function to inhibit TRIM63; a protein that can interact with 
members of the CDK and MAP cascades like CDC20, CDC23, CDC27 and 
FZR1 (Rambow et al., 2015). Also in relation to cell proliferation, AGO3 was 
among the proteins identified to interact with Ambra1 by the Y2H approach, this 
protein is reported to have a role in stem cell proliferation and also in regulating 
gene expression. Moreover, AGO3 shows a slicer activity. Can it be an Ambra1 
slicer? Answering this question can be done by the Knock-down of AGO3 and 
testing the resulting effect on the levels and activity of Ambra1. 
Future studies can also include exploring the role of Ambra1 on cell cycle via 
CDC25A by NAA11; this can be done by monitoring the degree of CDC25A 
ubiquitination at Ambra1 and NAA11 different levels. 
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Confirmatory experiments to prove the alteration in the expression of TRIM63 
upon Ambra1 differential expression is also essential to prove that Ambra1 can 




7.2.3 Ambra role in embryogenesis 
At the discovery of Ambra1 in 2007, its role in embryogenesis was reported; its 
loss was accompanied by unbalanced cell proliferation (Maria Fimia et al., 
2007). In this study an interaction between Ambra1 and protein Argonaute-3 
was found using Y2H. The protein Arganaute3 is reported to be essential in 
human embryogenesis specifically regulating stem cell proliferation (Hu et al., 
2012). The finding of such an interaction correlates with Ambra1 role reported in 
embryogenesis and, suggests that this role can be mediated by AGO3 which is 
reported to have an RNA slicer activity and an ability to regulate gene 
expression. It will be important to confirm this interaction and monitor the effect 
of AMBRA1/AGO3 interactions during embryogenesis; and it would be 






7.3 Ambra1 novel protein binding partners in this and other 
recent studies 
Ambra binding partners that are already reported in literature are listed in the 
introduction (1.6.1). Recently a group in Harvard used affinity-purification mass 
spectrometry to profile protein interactions in human cells and systematically 
analyze interactions for all accessible human proteins at proteome scale (Huttlin 
et al., 2015). Searching this database, the BioPlex network, also reported 
additional Ambra1 novel binding partners (Figure 7.3). It is notable that 
ANKRD9 is on the list of the interactors as well as ASB8 which bears an ankyrin 
repeat domain as this study has also found interactions with ankyrin repeat 
proteins including ANKRD7 and ANK3. Enrichment analysis of these 
interactions (Figure 7.4) shows that these genes are centered on PTMs like 
ubiquitination and PI3K activity. Ambra1 has also been reported to be an 
essential co-factor in the activity of different E3 ligases (Cianfanelli et al., 2015). 
A combined string protein network analysis of Ambra1 identified protein binding 
partners reported in literature along with results from this study and BioPlex 
data (Appendix 3) was performed to explore possible overlapping interactions 
with the data from this study (Figure 7.5). Figure 7.5(A) shows a string analysis 
of the previously known interactors with those identified within this study, with 
the red arrows indicating interactions this study identified in Chapter 4. Figure 
7.5 (B) shows a string analysis using the data from the Bioplex database. Figure 
7.5(C) shows the string analysis for the combined set of proteins from (a) and 
(B), again with red arrows noting new interactions from this study. What is clear 
is the combined data identifies overlapping between Ambra1 different binding 
partners. For example, this identified an overlap between two identified binding 
partners in this study (ANK3 and TMED7) and, DYNLL2 which was identified to 
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be an Ambra1 binding partner by both BioPlex database and co-
immunoprecipitation (Di Bartolomeo et al., 2010). Moreover, an enrichment 
analysis of Combined Ambra1 identified protein binding partners shows an 
increasing pattern of networks of proteins that regulate PTMs (Figure 7.6). 
Importantly, this also provides additional confidence that the interactions 
identified in Chapter 4 are genuine and biologically meaningful. 
 





Category Color Hits Nodes Hits Nodes Adjusted p-value 
post-translational protein 
modification 
 7 21 343 14543 3.80e-7 
1-phosphatidylinositol-3-
kinase regulator activity 
 3 21 14 14543 1.78e-6 
protein ubiquitination  7 21 438 14543 2.01e-6 
regulation of PDI3-kinase 
activity 
 3 21 17 14543 3.14e-6 
PDI3-kinase complex  3 21 20 14543 5.01e-6 
 
Figure 7.4: Gene ontology enrichment analysis of BioPlex Ambra1 binding 
partners 
 







































































































































































































































































































































































































































































































Figure 7.6: Gene ontology biological process enrichment analysis of 
Ambra1 binding partners. The list of protein entries is combined from 
literature, BioPlex and our results. 
This study report seven novel Ambra1 binding partners (4.4.1). This not only 
show new interactions of Ambra1 protein, but suggests that Ambra1 is involved 
in a range of different cellular pathways and that its role is not limited to 
autophagy. Identified cellular pathways using this technique appear to show a 
novel role of Ambra1 in protein trafficking as most interactors identified have 
roles that are related to protein transport. 
Despite elimination of false positives by a two tier screening process in the 
yeast two hybrid assay confirmation of these interactions by either directed two 
hybrid assays or co-immunoprecipitations is essential.  
 A potential novel role of Ambra1 in SNARE mediated protein transport has 
been identified in this study. Identified binding partners show that Ambra1 is 
extensively involved in protein trafficking, this role can extend to endless 
numbers of cellular processes and functions, studying individual interactions 
between Ambra1 and these proteins involved in cellular transport and the effect 
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of these interactions on different cellular processes will probably identify a 
whole set of Ambra1 effects and highlight the role of this core protein that 
extends well behind autophagy. 
This study also shows that Ambra1 interacts with ANKRD7 and ANK3. 
Combining this study results with BioPlex data which identify that Ambra1 
interacts with two other proteins that bear ankyrin repeat domains (ANKRD9 
and ASB8) confirm that Ambra1 is likely to be an ankyrin repeat domain binding 
partner. These interactions are potentially a novel functional role for Ambra1 
across a range of different cellular processes. Studying the interaction between 
Ambra1 and different ankyrin repeat domain proteins could provide a new 
branch of Ambra1 research. 
String analysis shows that the number of edges which represent proteins 
interactions in the combined string network analysis of Ambra1 and PP2CA 
binding partners identified in this study with Ambra1 binding partners reported in 
literature and Ambra1 binding partners identified by BioPlex ( (Figure 7.5 C) is 
more than the sum of the edges from string network analysis of Ambra1 and 
PP2CA binding partners identified in this study and Ambra1 binding partners 
reported in literature (Figure 7.5 A), and the edges from string network analysis 
of Ambra1 binding partners identified by BioPlex (Figure 7.5 B). which means 
that combining novel results from this study with literature and other databases 
like BioPlex broadens Ambra1 identified network and leads to exploring more 
novel roles of this protein, the analysis also shows that DYNLL2 which is 
identified by (Di Bartolomeo et al., 2010) as well as, BioPlex to be an Ambra1 
binding partner can mediate the interaction of Ambra1 with two of identified 
binding partners in this study, ANK3 and TMED7. The analysis shows that 
DYNLL2 can also mediate the interaction of Ambra1 with PP2CA. It is 
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interesting that in the PP2CA Y2H control experiment SHANK2 was identified 
as a novel PP2CA binding partner, which is another DYNLL2 interactor, 
DYNLL2 is involved in cellular cargo trafficking as well as Macroautophagy 
(Uniprot) and this analysis adds up to the novel identified role of Ambra1 in 
protein trafficking. Ambra1 is reported to regulate mammalian autophagy by its 
interaction with the dynein motor complex (Di Bartolomeo et al., 2010). 
However, that study focused on DYNLL1 interaction with Ambra1 and the role 
of this complex in regulating autophagy, they have shown that Ambra1 also 
interacts with DYNLL2 to regulate autophagy but, their results reported the 
effect of Ambra1/DYNLL2 in autophagy regulation to be less than that of 
Ambra1/DYNLL1. The combined string network analysis performed in this study 
shows ANK3 and TMED7 to be interactors of Ambra1 (novel results) and 
DYNLL2 (from string analysis), these finding highlight AMBRA1/DYNLL2 
complex importance, perhaps not in autophagy regulation as reported by Di 
Bartolomeo and colleagues but in protein trafficking during autophagy and other 
cellular processes.  
Results from different enrichment analyses show that Ambra1 networks play 
important roles in different types of PTMS and specifically; ubiquitination. It 
would be interesting to study the ability of Ambra1 to modify other proteins by 
ubiquitination. Although Ambra1 is reported to be involved in ULK1 
ubiquitylation by LYS-63-linked chains during autophagy (Nazio et al., 2013), 
these results suggests a deeper role of Ambra1 in the ubiquitination of other 
cellular proteins. Ambra1’s role could be explored by the co-expression of 
tagged Ubiquitin in different Ambra1 overexpression/knockdown models for the 
isolation and identification of ubiquitinated proteins. 
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7.4 Ambra1 role in different cellular processes 
7.4.1Ambra1 role in angiogenesis 
Angiogenesis is simply the formation of new blood vessels and, is a hall mark of 
tumors metastasis.it is a process that involves migration, growth, and 
differentiation of endothelial cells (Nishida et al., 2006). Melanomas show high 
levels of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3. Studies have shown that 
there is a direct correlation between the levels of VEGF and the progression of 
melanoma. Moreover, VEGF is at highest levels in the malignant phase of many 
tumors (Carmeliet, 2005).  Anti-VEGF monoclonal antibody Bevacizumab is 
used to treat different types of cancer, but it failed to be validated for melanoma 
treatment after it was tested in clinical trials and used in combination with 
Temozolomide (TMZ). However; ongoing clinical trials are testing the same anti-
VEGF in combination with chemotherapy (Domingues et al., 2018). 
This study demonstrates a novel role of Ambra1 in angiogenesis. Ambra1 
knock-down in melanoma cell lines may result in an increase in a number of 
proteins associated with angiogenesis including; COL4A2, VEGF-R1 (FLT1), 
VEGF-R2 (KDR) FZD8, JAG1, MMP2, MEOX2, NRP1, TGFA, SEMA3C, 
WNT5A , TGFB1, ITGA3, SEMA3A, EPHA4, PRDM1 ,PPARG , IL1RL1 ,TLR4, 
PTHLH, MMP2, NT5E, FLI1, IL24, STC1, NRP1 and, KCNN4. The over-
expression of VEGFR-1 was confirmed by western blot.  The findings in this 
study support the finding that Ambra1 loss in early stage tumors is associated 





7.4.2 Ambra role in Wnt signaling 
The Wnt family of proteins is involved in the regulation of cell proliferation, cell 
motility, cell polarity, organogenesis, cell fate and stem cells renewals (Logan 
and Nusse, 2004). WNT5A is a member of the Wnt family that signals through 
both the canonical and non-canonical Wnt pathways but, it is most often 
associated with non-canonical Wnt signaling (McDonald and Silver, 2009). The 
role of WNT5A in cancer remains under investigation (Asem et al., 2016). 
Frizzled receptors (FZDs) are transmembrane receptors that serve as receptors 
for the WNT ligands. FZDs play crucial roles in regulating cell polarity, 
embryonic development, cell proliferation, formation of neural synapses (Zeng 
et al., 2018) 
Our results indicate a role for Ambra1 in regulating canonical Wnt signaling via 
FZD8 and non-canonical Wnt signaling via WNT5A. This study shows that 
Ambra1 may function to inhibit WNT5A. This was shown by RNA microarrays of 
the Ambra1 knockdown cell line and confirmed by western blot to monitor the 
protein levels of WNT5A. Results have shown a significant increase in WNT5A 
gene expression/protein upon the knockdown of Ambra1. We have also shown 
by RNA microarray that the knockdown of Ambra1 significantly increases the 
expression of FZD8 frizzled receptor. Moreover; we have identified ANK3; a 
regulator of Wnt signaling (Durak et al., 2015) to be an Ambra1 binding partner. 
This example demonstrates the advantage of “multi-omic” approach taken in 
this study. 
It may be of interest to study the regulation of cell cycle by Ambra1 through 
WNT signaling, monitoring the level of destruction of the β-catenin complex 
upon Ambra1 activation may give a new insight about the role of Ambra1 in cell 
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proliferation. ANK3 could also be blocked or down regulated to better 




7.4.3 Ambra1 role in axon guidance 
Axon guidance can be defined as the rules by which the neuronal axons grow to 
reach their target and establish appropriate connections, a process which is 
essential during the development of the nervous system. Semaphorins are one 
of the major soluble proteins that can affect this pathway by binding to their 
receptor proteins which are known as plexins (Alto and Terman, 2017). The first 
study that identified Ambra1 protein stated that Ambra1 plays an essential role 
in developing the nervous system during embryogenesis. They have shown 
high levels of Ambra1 in neuroepithelium, spinal cord, dorsal root ganglia, 
neural retina and encephalic vesicles (Fimia et al., 2007). 
This study reports a novel role of Ambra1 in the regulation of axon guidance 
signaling by changing the expression profile of hall mark genes in this pathway. 
Axon guidance was among the top pathways affected by Ambra1 knockdown 
and genes from this pathway were differentially expressed and, include: 
SEMA3A, SEMA3B, SEMA3C, SEMA5A, NRP1 and PLXNA2. Moreover, ANK3 
is also involved in axon guidance specifically in axon segment initiation (Durak 
et al., 2015) 
Monitoring axon guidance as well as; ANK3 levels in different Ambra1 
expression levels can be a direct step towards identifying the mechanism by 






7.4.5 Ambra1 role in RAS signaling pathway 
RAS signaling pathway have been reviewed in the introduction chapter and it is 
a major pathway in cellular growth. Ambra1 has previously linked to this 
pathway through its ability to enhance the degradation of C-Myc (Cianfanelli et 
al., 2015).  
This study reports a novel role of Ambra1 in this signaling pathway. The knock-
down of Ambra1 appear to result in the down regulation of BANCR, GHR, 
RAB17, RAB38 and RASSF3 and also, the up-regulation of RAB27B, SFRP1, 
IGFBP5, and INHBA. All these genes are regulators of the RAS signaling in 
melanoma. It is also important that we have identified an interaction between 
Ambra1 and ANKRD7, the latter is an effector of the small RAB GTPases 




7.4.6 Ambra1 role in (TGF-β) signaling pathways 
TGF-β receptor plays an important role in tissue homeostasis. It is also a trans-
membrane receptor and it is a serine/threonine kinase. This pathway signaling 
end result is arresting cell cycle and promoting cell entry to G0 (Massagué et 
al., 2000). 
This study suggests that Ambra1 can be part of TGF-β signaling pathways. 
Results obtained by transcriptomics show that altering the expression of 
Ambra1 whether by overexpression or knockdown result in a change in the 
expression of TGF-β superfamily components including INHBA and TGFβ1. 
The FDR obtained from Ambra1 overexpression effect on these components is 
relatively high but,  obtaining the same differential expression of these 
components within a significant FDR value upon Ambra1 knockdown is a strong 
evidence that Ambra1 is related to the TGF- β signaling pathways. 
Future studies of Ambra1 role in TGF-β signaling pathway is of a great interest, 
it can open a new window on how Ambra1 is involved in hall mark cell signaling 
pathways. Assays to identify motifs of Ambra1 that can interact with these 
family members and carrying out assays to identify these interactions as well 
as; monitoring the levels of Ambra1 effect on this pathway will help identify a 




7.5 Limitations of the study 
This study could have reported more novel roles of the highlighted protein 
Ambra1 but, this was not possible due to some limitations that are listed below: 
 Technical limitations: The GC-MS analysis was performed by a different 
team. 
 Financial limitations: complete 2D-E gels analyses were considered 
during this study but was not performed due to financial limitations 
 Time limitations: this study was suddenly stopped due to the situation of 
the COVID-19 pandemic that broke out in UK in March 2020, the main 
effect on this study is that it would have been possible to isolate and 




7.6 final remarks 
This study has also demonstrated that the role of Ambra1 role extends beyond 
autophagy and may be pivotal in a range of cellular processes. We also 
demonstrate that taking a multi-omics approach is a good way to identify 
networks of gene/proteins involved in cellular processes, despite the fact that 
some strands of the research were not fully realized. The findings indicate that 
Ambra1 could play a key role in metastasis in malignant melanomas, treatments 
targeting Ambra1 in metastatic melanoma may be of importance in driving the 
development of future. This role was shown only in melanoma A375 derived cell 
lines and may not be universal. However, it adds to the evidence that show that 
Ambra1 loss appears to upregulate metastatic genes/proteins and is associated 

















Appendix 1: full list of differentially expressed genes resulting 
from Ambra1 overexpression (P<0.05) 
Gene Symbol Fold Change P-val FDR P-val 
AMBRA1 16.37 2.72E-10 3.34E-06 
NAA11 4.27 8.47E-07 0.0082 
CDH13 3.06 5.78E-06 0.0465 
MIR548AN -2.55 3.07E-05 0.1853 
TFPI2 3.26 3.93E-05 0.2096 
NRG1 2.57 4.77E-05 0.2096 
FAT3 2.24 6.88E-05 0.2389 
CYGB -2.59 6.94E-05 0.2389 
PDE3A 2.66 0.0001 0.3703 
NPR2 2.34 0.0001 0.3836 
MIR3689D2 3.09 0.0002 0.3836 
NOX4 2.9 0.0002 0.3836 
CEMIP 2.29 0.0002 0.3882 
FAM105A 3.49 0.0002 0.3882 
TLR4 2.85 0.0002 0.4051 
ABCB5 -2.43 0.0003 0.4322 
SLC24A5 -2.54 0.0003 0.4495 
FAM167B -2.32 0.0005 0.6231 
PPARGC1A -2.34 0.0006 0.626 
PLA2G7 4.7 0.0009 0.626 
LINC00707 3.26 0.0009 0.626 
GALNT5 2.13 0.001 0.641 
AXL 2.05 0.0011 0.641 
LINC01602 -2.15 0.0011 0.641 
NOV -2.6 0.0011 0.641 
LHFPL3-AS1 -2.8 0.0012 0.6596 
LOC105376382 2.16 0.0012 0.6596 
P2RX7 -2.61 0.0013 0.6928 
TAC1 3.15 0.0015 0.7253 
MIR3689A 2.56 0.0018 0.7253 
XYLT1 -2.28 0.0019 0.7253 
HELLPAR -2.09 0.0022 0.7568 
MT1A 3.24 0.0023 0.7568 
CLMP 2.39 0.0027 0.7641 
MIR4486 -2.2 0.0028 0.7641 
BEST1 -2.45 0.003 0.7641 
MIR3689E 2.64 0.0032 0.7641 
INHBA 3.41 0.0032 0.7641 
MIR3689B 2.79 0.0038 0.7641 
SBF1P1 2.02 0.0038 0.7641 
PRICKLE4; TOMM6 -2.3 0.0047 0.7641 
ACAN -2.01 0.0049 0.7641 
SULF1 2.2 0.0062 0.7641 
SNRPN; IPW -2.07 0.0063 0.7641 
MIR3189 -3.46 0.0071 0.7641 
RUNX1-IT1 5.3 0.0073 0.7641 
CNTN3 2.65 0.0079 0.7641 
FOXR2 2.65 0.0093 0.7641 
LOC105374524 2.49 0.0093 0.7641 
PPIP5K1 -3.18 0.0094 0.7641 
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LINC00383 5.32 0.0102 0.7641 
TRAV8-6 -2.11 0.0108 0.7641 
MPV17L 2.41 0.0126 0.7641 
PWAR6 -2.06 0.0138 0.7641 
PDZD2 2.99 0.0144 0.7641 
OR2M3 2.08 0.0153 0.7652 
MIR4518 -2.14 0.0158 0.7652 
IGHV3OR16-12 -2.08 0.0181 0.7737 
GRAMD1B 3.52 0.0183 0.7737 
MRGPRX3 3.9 0.0206 0.7767 
GOLGA2P6; MTPAP -2.04 0.0219 0.7783 
TNFRSF14 -2.57 0.0221 0.7783 
TGFA 2.04 0.0243 0.7858 
SLC24A3 2.18 0.025 0.7876 
RTL1 3.88 0.0293 0.8061 
STK32A -2.02 0.0336 0.8086 
PRDM7 -2.51 0.0339 0.8086 
LINC00597 -2.41 0.0381 0.8185 
CXCL8 2.94 0.0406 0.8243 
NID1 3.02 0.0446 0.8251 




Appendix 2: full list of differentially expressed genes resulting 
from Ambra1 Knockdown (P<0.05) 
Gene Symbol Fold Change P-val FDR 
P-val 
SEMA3C 3.74 5.93E-07 0.0079 
ZNF844 4.2 5.95E-07 0.0079 
SEMA3A 3.11 7.65E-07 0.0079 
LINC00440 7.05 8.90E-07 0.0079 
RUNX1-IT1 3.86 1.11E-06 0.0079 
AJAP1 3.94 1.14E-06 0.0079 
TCN1 4.94 1.16E-06 0.0079 
MEOX2 3.02 1.46E-06 0.0079 
GALNT5 3.37 1.47E-06 0.0079 
TFPI2 3.6 2.51E-06 0.0113 
FAT3 4.41 2.58E-06 0.0113 
PLA2G7 8.61 3.33E-06 0.0126 
JAG1 3.39 3.45E-06 0.0126 
CDH19 3.19 3.65E-06 0.0126 
SLC14A1 2.74 4.06E-06 0.0131 
IL24 -2.85 4.44E-06 0.0134 
ACTBL2 5.51 5.24E-06 0.0143 
COL4A1 2.55 5.71E-06 0.0143 
NEK10 3.26 5.75E-06 0.0143 
TP73 2.63 5.91E-06 0.0143 
WNT5A 3.65 7.08E-06 0.0163 
EPHA4 2.83 7.82E-06 0.0167 
LOC105377108 2.35 7.96E-06 0.0167 
NRP1 3.75 1.02E-05 0.0197 
GLIPR1 4.1 1.06E-05 0.0197 
FLI1 2.26 1.29E-05 0.0222 
RAB27B 4.05 1.38E-05 0.023 
ADGRF1 3.36 1.48E-05 0.0235 
PAPSS2 2.43 1.51E-05 0.0235 
COL4A2 2.03 1.58E-05 0.0238 
GEM 2.36 1.65E-05 0.0241 
NFE2L3 2.26 1.76E-05 0.0244 
SLITRK6 9.41 1.77E-05 0.0244 
ARNTL2 2.99 2.04E-05 0.0273 
NEBL 2.19 2.24E-05 0.0279 
IL1RL1 2.33 2.25E-05 0.0279 
THSD4 2.42 2.26E-05 0.0279 
USP53 2.58 2.37E-05 0.0285 
SLIT3 2.06 2.54E-05 0.0299 
KYNU 2.95 2.65E-05 0.0299 
LOC105379362 2.97 2.72E-05 0.0299 
STC1 5.47 2.73E-05 0.0299 
CEMIP 3.86 2.99E-05 0.032 
IRF4 -3.57 3.10E-05 0.0322 
SV2C 2.27 3.14E-05 0.0322 
ME3 2.14 3.38E-05 0.0334 
CLMP 2.26 3.79E-05 0.0364 
FZD8; MIR4683 2.21 3.85E-05 0.0364 
NT5E 2.66 3.92E-05 0.0364 
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TGFB1 2.06 4.02E-05 0.0366 
F2RL2 2.7 4.41E-05 0.0394 
C15orf54 2.88 4.64E-05 0.0396 
PRR9 2.76 4.66E-05 0.0396 
PPARG 2.35 4.69E-05 0.0396 
ENC1 2.32 5.28E-05 0.0426 
KCNIP4-IT1 2.41 5.39E-05 0.0426 
KCNN4 2.56 5.64E-05 0.043 
PGM5P2 2.19 5.66E-05 0.043 
HACL1 2.23 5.71E-05 0.043 
SIRPB1 2.02 6.04E-05 0.0448 
PXDN 3.55 6.42E-05 0.0463 
GPX1 2.55 6.49E-05 0.0463 
CADM4 2.1 6.52E-05 0.0463 
ZNF860 2.01 6.95E-05 0.0481 
FLT1 2.06 6.98E-05 0.0481 
SAMD5 2.73 7.26E-05 0.049 
TRIM58; OR2W3 2.82 7.52E-05 0.0497 
TGFA 3.54 8.03E-05 0.0512 
GLIS3 3.35 8.07E-05 0.0512 
TLR4 5.99 8.17E-05 0.0512 
LOC105379109 2.56 8.67E-05 0.0536 
MIR548XHG 3.18 9.05E-05 0.0553 
SULF1 5.03 9.23E-05 0.0556 
FAM135B 2.55 9.55E-05 0.0561 
SLC24A3 3.76 9.68E-05 0.0563 
PTHLH 2.9 9.99E-05 0.0573 
MMP2 2.04 0.0001 0.0592 
ITGA3 2.24 0.0001 0.0592 
SFRP1 2.3 0.0001 0.0592 
PMEPA1 2.45 0.0001 0.064 
DAPK1 -2.01 0.0001 0.0656 
PRDM1 2.88 0.0001 0.0663 
ZNF385A 2.17 0.0001 0.0681 
FDCSP 6.4 0.0001 0.0697 
MIR432 4.06 0.0001 0.0724 
ANPEP 2.21 0.0002 0.073 
EFEMP1 2.92 0.0002 0.073 
FAM20C 2.23 0.0002 0.073 
HSPA2 -2.4 0.0002 0.0748 
ZC4H2 2.32 0.0002 0.0748 
LOC105375451 2.2 0.0002 0.075 
PARM1 2.57 0.0002 0.0787 
MET 2.22 0.0002 0.0809 
CHAC1 -2.77 0.0002 0.083 
MUC13 2.98 0.0002 0.083 
MAB21L1; MIR548F5 2.67 0.0002 0.083 
PLXNA2 2.11 0.0002 0.083 
LOC105376382 3.24 0.0002 0.0857 
MYO10 -2.22 0.0002 0.0857 
MIR708 2.02 0.0002 0.0857 
DEPDC7 2.57 0.0002 0.0857 
FAM105A 5.69 0.0002 0.0857 
SCML1 -2.43 0.0003 0.0884 
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ESM1 3.53 0.0003 0.0884 
LINC01433 -2.08 0.0003 0.0885 
PTGS2 2.74 0.0003 0.091 
LAMA1 -2.4 0.0003 0.091 
MGAM2 2.03 0.0003 0.091 
TSHZ3 2.12 0.0003 0.0919 
SNORD114-28 3.37 0.0003 0.0925 
GRAMD1B 2.33 0.0003 0.0946 
CADPS 2.46 0.0003 0.0994 
SLIT2 3.35 0.0003 0.0994 
SEL1L3 2.49 0.0004 0.1016 
COL9A3 2.11 0.0004 0.1083 
IKZF2 2.7 0.0004 0.1083 
RTL1 5 0.0004 0.1105 
LCTL 3.89 0.0004 0.1116 
BCAR3 2.01 0.0004 0.1166 
TGFA-IT1 3.58 0.0004 0.1167 
PLAUR 2.4 0.0004 0.1167 
KDR 2.41 0.0004 0.1171 
ELL2 2.55 0.0005 0.1191 
FLRT2 2.19 0.0005 0.1191 
OSBPL10 2.02 0.0005 0.1192 
EPHB1 2.04 0.0005 0.1198 
PXYLP1 2.22 0.0005 0.1203 
TENM4 2.77 0.0005 0.1241 
CDYL2 2.17 0.0005 0.1293 
CYGB -2.31 0.0005 0.13 
LHFPL3-AS1 -3.93 0.0006 0.1319 
GRAMD1B 3.93 0.0006 0.1319 
DTNA 2.07 0.0006 0.1319 
XYLT1 -2.57 0.0006 0.1319 
IL37 3.93 0.0006 0.1327 
ASTN1 2.16 0.0006 0.1327 
CLU; MIR6843 2.44 0.0006 0.1332 
MIR433 3.19 0.0006 0.1336 
ZNF704 -2.35 0.0006 0.1336 
LOC105374003 2.4 0.0007 0.1406 
RASSF3 -2.06 0.0007 0.1407 
SLAMF9 3.23 0.0007 0.1422 
FLRT3 2.54 0.0007 0.1422 
FAM19A3 3.96 0.0007 0.1477 
SPATS1 -2.4 0.0007 0.1477 
MYOZ2 2.02 0.0008 0.1485 
SH3PXD2A 2.29 0.0008 0.1504 
MIR127 3.83 0.0008 0.1504 
GALM -2.26 0.0009 0.1578 
MIR136 5.48 0.0009 0.1578 
TRIM63 -3.92 0.0009 0.158 
CXCL8 4.12 0.0009 0.1598 
KIAA0040 2 0.0009 0.1605 
TMEM171 2.24 0.001 0.1613 
LOC100506257 2.05 0.001 0.1613 
KDELC1 2.66 0.001 0.1716 
P2RX7 -2.09 0.0011 0.1732 
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PDE8B 2.12 0.0011 0.1773 
LOC105376617 2.14 0.0011 0.1788 
TIAM2 2.65 0.0011 0.1788 
ABI3BP 3.41 0.0012 0.1788 
PDE5A 2.27 0.0012 0.1828 
SPP1 -2.6 0.0012 0.1831 
DKK1 2.42 0.0012 0.1836 
MRGPRX3 2.13 0.0013 0.1849 
LOC105369559 2.7 0.0013 0.1873 
SYTL5 2.18 0.0013 0.1897 
INHBA 5.57 0.0014 0.19 
NRG1 4.49 0.0014 0.19 
SULT1B1 6.44 0.0014 0.1923 
LOC102724542 2.23 0.0014 0.1927 
LINC00410 -2.18 0.0017 0.209 
STRIP2 -2.01 0.0017 0.213 
ANKH 2.31 0.0018 0.2152 
TAC1 2.45 0.0018 0.2163 
KCNE4 2.03 0.0018 0.2183 
ERO1B 2.2 0.0019 0.2209 
MIR548O2 -2 0.0019 0.2209 
IGFBP5 5.27 0.002 0.2287 
BIRC3 4.81 0.0021 0.2287 
PRDM7 -3.26 0.0021 0.2321 
Mar-02 2.02 0.0022 0.2332 
ZP4 2.22 0.0023 0.2408 
XAGE3 -2.89 0.0024 0.2494 
DCT -2.61 0.0024 0.2509 
EHF 3.24 0.0027 0.2643 
VGF -2.25 0.0028 0.2669 
SRPX2 2.17 0.0028 0.2671 
RUNX1T1 2.93 0.0029 0.2706 
TMEM47 3.56 0.0029 0.2714 
MGAM2 3.11 0.003 0.2761 
RAB17 -2.03 0.0031 0.2801 
CA14 -2.53 0.0034 0.2883 
KIAA1644 2.08 0.0035 0.2919 
SERPINB7 2.04 0.0035 0.2934 
SNORD70 2.12 0.0036 0.296 
CACNA2D3 2.48 0.0036 0.2977 
LINC01186 2.3 0.0036 0.2977 
GHR -2.04 0.0036 0.2977 
SSX2B; SSX2 2.44 0.0037 0.2977 
SSX2B; SSX2 2.44 0.0037 0.2977 
MIR431 6.62 0.0038 0.3037 
GPM6B -2.88 0.0039 0.3069 
LOC105376425 -2.78 0.0039 0.3069 
SEMA5A -2.38 0.0043 0.3232 
KRTAP2-3 3.27 0.0046 0.3328 
LRIG3 2.16 0.0053 0.3506 
TXNIP -2.12 0.0056 0.3551 
SNORD1B -2.24 0.0062 0.3686 
GMCL1 -2.01 0.0063 0.3699 
KCNN2 -2.85 0.0063 0.3705 
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TDRD7 -2.06 0.0063 0.3707 
RORB 2.22 0.0065 0.3749 
PCDH7 -2.47 0.0069 0.3839 
MIR4500 2.46 0.0074 0.3986 
TTYH2 -2.49 0.0074 0.3986 
LOC105372845; 
LOC105378172 
-2.08 0.0075 0.3987 
CTLA4 2.41 0.0081 0.4106 
ACPP 3.07 0.0082 0.4112 
NID1 2.17 0.0083 0.4144 
GABRG3 2.32 0.0083 0.4147 
BEST1 -2.07 0.009 0.4297 
VAT1L 4.18 0.0092 0.4346 
DPYD 2.12 0.0097 0.4426 
FAM21C -2.24 0.01 0.4442 
CXCL14 6.23 0.0102 0.4477 
MIR221 2.64 0.0102 0.4482 
LOC105377747; 
LOC105379684 
-2.58 0.0102 0.4484 
CASC21 2.12 0.012 0.4724 
ALS2CR12 -2.44 0.0121 0.4751 
SERTAD4 2.02 0.0124 0.4757 
HAPLN1 2.54 0.0125 0.4772 
CCL2 3.4 0.013 0.4834 
TRPM1 -2.95 0.0133 0.486 
FGF14 2.02 0.0135 0.4892 
BANCR -3.46 0.0149 0.5095 
RAB38 -2 0.0153 0.5109 
CDH13 2.28 0.0154 0.512 
SNORD115-45 -2.04 0.0156 0.5146 
MAP3K14 2.29 0.0159 0.517 
IL7R 3.29 0.0168 0.5238 
CHRNA6 -3.45 0.0169 0.5239 
MIR548X 3.03 0.0179 0.5309 
LINC01372 -2.01 0.0184 0.5365 
DIRC3-AS1 4.83 0.0188 0.5394 
B3GALT2 2.29 0.0191 0.5434 
PLA1A -2.97 0.0193 0.5458 
TBC1D7 -3.29 0.0201 0.5538 
NF2 2.58 0.0203 0.5538 
LINC00383 3.68 0.0204 0.5538 
MIR544A 2.23 0.0205 0.5548 
SLC24A5 -3.04 0.0211 0.5586 
NAV3 -2.33 0.0214 0.5592 
CAPN3 -3.87 0.0216 0.5596 
ADAM19 2.41 0.022 0.5619 
MGAM2 2.21 0.0221 0.5627 
LOC105373730 -2.03 0.0234 0.5683 
COL12A1 2.39 0.0249 0.5775 
CTGF 2.77 0.0254 0.58 
MIR873 2.42 0.0309 0.599 
PLEKHH1 -2.29 0.0313 0.6009 
LCE1F 2.16 0.0318 0.6024 
TNFRSF12A 2.95 0.0336 0.6117 
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PKNOX2 -2.15 0.0337 0.6121 
MIR222 2.97 0.035 0.6144 
GNG11 2.07 0.0378 0.6266 
LOC105376694 2.06 0.0381 0.6266 
LINC00707 4.49 0.0397 0.6327 
LINC01419 2.78 0.0397 0.6327 
SEMA3B 2.44 0.0399 0.6336 
GYG2 -2.29 0.0416 0.6379 




Appendix 3: Ambra binding partners identified in this study, by 
BioPlex data bases and reported in literature. 
Ambra1 binding partner Reference 
ANK3 This study 
ANKRD7 This study 
AGO3 This study 
STX7 This study 
TMED7 This study 
DSTN This study 
DDB1 Antonioli et al., 2014 
TRIM32 Rienzo et al., 2019 
TRAF6 Nazio et al., 2013 
DLC1 Di Bartolomeo et al., 2010 
BECN1 Fimia et al., 2007 
BCL2 Strappazzon et al., 2011 
LC3 Strappazzon et al., 2015 
PP2CA Cianfanelli et al., 2015 
SPSB2 BioPlexHCT_1_0 
RAB40C BioPlexHCT_1_0 




RFPL4B BioPlex_3_0, BioPlexHCT_1_0 




SOCS3 BioPlex_3_0, BioPlexHCT_1_0 
RAB40A BioPlexHCT_1_0 
HPS1 BioPlex_3_0, BioPlexHCT_1_0 
SOCS1 BioPlex_3_0 
SPSB4 BioPlex_3_0, BioPlexHCT_1_0 
PPP4C BioPlex_3_0 




TEX19 BioPlex_3_0, BioPlexHCT_1_0 
S100P BioPlex_3_0 
ASB8 BioPlex_3_0, BioPlexHCT_1_0 
PRAMEF17 BioPlexHCT_1_0 
PPP4R1L BioPlex_3_0 
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